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Cardiovascular disease is a prevalent cause of death in the world. Cell transplantation therapy 
has recently been developed as an alternative therapy for cardiovascular disease. However, 
current studies employing the use of undifferentiated bone marrow stem cells have resulted in 
variable clinical outcomes with modest efficacies. Differentiating primitive adult bone 
marrow stem cells into a stable and committed cardiac (-like) phenotype ex vivo prior to 
transplantation into an injured myocardium may be more effective for the treatment of 
cardiovascular disease.  
Fibrosis and ventricular remodeling following a myocardial infarction begins with elevated 
extracellular matrix (ECM) deposition, which stiffens the myocardium and inadvertently 
contributes to ventricular dysfunction. Notwithstanding, ECMs reportedly influence critical 
cellular processes such as survival, proliferation and differentiation in many cell types via the 
engagement of specific integrins. However, it is not well understood if ECMs exert a 
significant influence on the proliferation and cardiac transdifferentiation of primitive 
mesenchymal stem cells. Additionally, the effect/s of myocardial fibrosis and post-infarct 
remodeling on stem cell differentiation in vivo is not well studied.  
This project has 2 specific objectives:  
1. To explore the role/s of extracellular matrices and their integrin partners on the cell 
fate and development of CLCs vs, MSCs in vitro and in vivo and 
2. To compare the relative therapeutic efficacies of the 2 cell types 
Adult human bone marrow mesenchymal stem cells (MSCs) can differentiate into 
cardiomyocyte-like cells (CLCs) with the concomitant use of collagen V extracellular 
matrices and a simple non-toxic culture medium in vitro. Importantly, this distinct cardiac-
like phenotype is stable in prolonged cultures. In contrast, MSCs exhibited a spontaneous but 
transient expression of cardiac-specific proteins.  
 
Objective 1: 
Cell-ECM interactions are mediated via the engagement of integrins, which in turn activates a 
cascade of downstream intracellular signaling events that lead to the expression of multiple 
proteins among other biological processes. CLCs demonstrated preferential interaction with 
specific collagen subtypes. Specifically, Collagen -V, but not collagen -I, promoted the 
cellular adhesion and cardiac differentiation of MSC-derived CLCs. More remarkably, 
collagen V matrices promoted the large-scale production of CLCs that was valuable for 
subsequent transplantation therapies. Initial cellular adhesion to collagen V but not collagen I, 
was dependent on the 21 integrin but independent of the v3 and v integrins. However, 
inhibition of v3 integrin, but not 21 integrin reduced gene expression levels of troponin T, 
sarcomeric -actin and RyR2 in CLCs cultured on collagen V ECM. Importantly, the 
engraftment of CLCs within close proximity of collagen V-expressing myofibers promoted 
their integration into the cardiac syncytium. More remarkably, CLCs demonstrated distinct 
striations that were indistinguishable from host cardiomyocytes in collagen V-enriched areas 
in the infarcted myocardium, while CLCs that engrafted in collagen I-enriched areas in the 
infarct borders did not. Thus, collagens -I and -V may play pivotal roles in the cell fate 
development of CLCs in vivo, although it remains to be elucidated if the colocalization of 
CLCs with the collagen V-enriched, endomysial-lined myofibers correlates with a specific 
interaction between the endogenous ECM and the transplanted cells, that is reminiscent of 
their affinity in vitro. It is also unclear if the localization of CLCs in the interstitial tissues 
enriched in collagens -I and -III prevented their integration into the host myofibrillar 
architecture. Notwithstanding, significant improvements in cardiac function were observed in 
rats administered with low-dose CLC therapy despite low incidences of cell integration in the 
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host myocardium. However, it is highly unlikely that such remarkable benefits were attributed 
to myocyte replacement. Instead, the introduction of an exogenous supply of viable cells may 
possibly improve cardiac function by modulating the ECM architecture in vivo to retain a 
certain degree of pliancy in the post-infarcted myocardium, thus reducing overall tissue 
stiffness in the compromised myocardium. Hence, CLCs may facilitate functional recovery 
by preserving tissue compliance in the peri-infarct borders, which in turn sustains the 
contractile efficiency for long-term functional recovery in the infarcted myocardium.  
Objective 2: 
CLC-therapy was more effective when administered in higher doses as demonstrated by 
increasingly evident improvements in cardiac function. Additionally, high- dose CLC therapy 
resulted in enhanced cell integration with the host myocardium. Notwithstanding similar 
trends in functional improvements observed in both low- and high-dose cell therapy groups, 
the high-dose therapy groups were relatively better reflections of the direct cellular effects of 
cell- transplantation on the infarcted myocardium. Correspondingly, cell-treated rats exhibited 
smaller cardiac volumes and LV internal diameters. Cell therapy generally improves the 
injured myocardium by restraining progressive wall thinning and ventricular dilatation. Thus, 
cell-therapy alleviated adverse remodeling effects, possibly by sustaining myocardial tissue 
compliance. However, CLCs were more effective than MSCs in improving cardiac function 
as CLC-treated rats demonstrated persistently superior systolic activities with respect to 
control and in particular, MSC-treated rats. Echocardiography assessments showed that high-
dose CLC-therapy mediated a significant 9.9 ± 12.1% improvement in LV fractional 
shortening (FS) as compared to a decrease of 14.4 ± 13.6% in control rats (p<0.001 vs. 
control). Similarly, CLC-treated rats showed a 7.14 ± 8.39 % improvement in ejection 
fraction as compared a deterioration of -11.3 ± 11.4 % in control rats (p< 0.001). In contrast, 
MSC -therapy appeared only to prevent further deterioration in LVFS (LVFS = -0.1 ± 
10.1%) and EF (LVEF = -0.76 ± 7.1 %); p< 0.005 vs. control, p< 0.05 vs. CLC-treated rats. 
Additionally, only CLC-treated rats (-13.8 ± 23.9%) demonstrated a significant improvement 
in the heart rate- independent myocardial performance index with respect to control rats (10.2 
± 18.3%). More remarkably, PV catheterization shows that CLC-therapy restores myocardial 
systolic performance as end-systolic pressure-volume relationships (2.10 ± 0.889mmHg/l) in 
CLC-treated rats reverted to baseline levels (all pairwise comparisons, p < 0.05). MSC-treated 
rats consistently exhibited significant cardiac relief with respect to control rats. These 
functional improvements may be attributed to possible cardioprotective paracrine-mediated 
effects, as the MSC-treated myocardium persistently demonstrated enhanced angiogenesis in 
the infarcted myocardium with respect to sham-operated control myocardium. In contrast, 
engrafted CLCs exhibited mature cross-striated fibers in vivo that aligned with and were 
indistinguishable from native cardiac myofibers in the myocardium. This further translated 
into a superior regional and global contractility to that in MSC-treated rats. A significant 
increase in neoangiogenesis in regions proximal to the sites of cell engraftment relative to 
control myocardium indicates that CLCs may also confer a paracrine-mediated 
cardioprotective influence on the compromised myocardium in vivo. Thus, CLCs may confer 
cardiac relief via distinct myogenic and non-myogenic repair mechanisms. These coexistent 
mechanisms may bring about a synergistic improvement in cardiac function, which may 
further explain CLCs‟ exceptional recovery of contractile performance in the infarcted 
myocardium. To date, most clinical studies have employed the use of undifferentiated bone 
marrow stem cell therapy with variable outcomes and modest efficacies. This study shows 
that the pre-differentiation of MSCs into a stable and committed cardiac lineage prior to 
transplantation is a more effective and efficacious treatment for cardiovascular disease.  
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Chapter One: Introduction 
Cardiovascular Disease (CVD) is a leading cause of death in the world. Current trends 
in epidemiology and rising incidences of diabetes and obesity among others indicate 
that CVD will continue to remain widespread. Transcending geographical and 
socioeconomic boundaries and gender differences, CVD was estimated to afflict 80.7 
million people in the United States in 2005
1
. In that year, CVD also accounted for an 
estimated 17.5 million deaths, and is representative of 30% of all global deaths. Of 
these mortalities, 7.6 million were due to heart attack and 5.7 million were attributed 




1.1 Atherosclerosis  
Atherosclerosis is a form of arteriosclerosis and is a condition in which patchy fatty 
deposits or atherosclerotic plaques develop within the walls of arteries, leading to 
reduced or blocked blood flow. Atherosclerosis is caused by repeated injury to the 
arterial wall and many factors such as high blood pressure, smoke, diabetes and high 
cholesterol levels in the blood contribute to this injury. Atherosclerosis is one of the 
leading causes of illness and death in America as well as most other developed 
countries. Approximately 16 million people have atherosclerotic heart disease in 
2005
3
. Clinical manifestations of artherosclerosis vary and depend on the location of 
the affected artery and whether it is gradually constricted or occluded. Complications 
of artherosclerosis include angina, heart attack, abnormal heart rhythms and heart 
failure. 
  2 
 
1.2 Ischemic Cardiomyopathy 
Coronary artery disease or ischemic heart disease is the most common underlying 
cause of heart failure. An acute myocardial infarction (AMI) is the consequence of a 
sudden and complete occlusion of a coronary artery that supplies blood to the 
myocardium. This leads to a significant amount of cardiomyocyte death within the 
myocardium. Resuscitation of cardiomyocytes is not possible if blood supply is not 
restored within minutes. This decreases the bulk of functional cardiomyocytes and 
leads to decreased cardiac contractility and an irreversible dilatation of the ventricular 
chambers, as the left ventricle undergoes pathological remodeling or enlargement. 
1.3 Cardiovascular Heart Failure 
Heart failure is a multisystem disorder that is characterized by aberrant cardiac, 
skeletal muscle, renal dysfunction and complex neurohormonal changes
4
. Heart 
failure can result from systolic dysfunction or diastolic dysfunction. Heart failure due 
to systolic dysfunction can be seen in two thirds of patient population and is caused 
primarily by ischemic heart disease. Patients with this type of dysfunction 
demonstrate a left ventricular ejection fraction (EF) < 30%. Heart failure resulting 
from diastolic dysfunction on the other hand is observed in the remaining one third of 
the patient population and is generally brought about by hypertension, ventricular 
hypertrophy and possibly diabetes. 
1.3.1 Myocardial systolic dysfunction 
Systolic dysfunction can be simplistically described as failure of the heart to pump 
blood into the circulation. This may be attributed to impairment or loss of cardiac 
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myocytes and/or their molecular components. In congenital diseases such as 
Duchenne muscular dystrophy, the molecular structure of individual myocytes is 
affected. Myocytes and their components can be damaged by inflammation, as in the 
case of myocarditis
5
. However, the most common mechanism of damage is ischemia 
causing infarction and scar formation. After a myocardial infarction, dead myocytes 
are replaced by scar tissues that affect the function of the myocardium.  
Myocardial systolic dysfunction is characterized by a decrease in ejection fraction as 
the strength of ventricular contractions is attenuated and generates an inadequate 
stroke volume. This results in an inadequate cardiac output. Ventricular end-diastolic 
pressures and volumes are correspondingly increased as the ventricle is inadequately 
emptied. This pressure is in turn transmitted to the atrium, whereupon increased 
pressure on the left side of the heart is transmitted to the pulmonary vasculature in left 
heart failure. The resultant hydrostatic pressure favors extravasation of fluid into the 
lung parenchyma, leading to pulmonary edema
6
.  On the other hand, increased 
pressure on the right side of the heart is transmitted to the systemic venous circulation 
and systemic capillary beds in right heart failure. This in turn leads to fluid 
extravasation into the tissues of target organs and results in peripheral edema
6
. 
1.3.2 Myocardial diastolic dysfunction 
Heart failure caused by diastolic dysfunction is generally described as the failure of 
the ventricle to relax adequately. This generally denotes a stiffer myocardium that 
leads to inadequate filling of the ventricle, and further results in an inadequate stroke 
volume. Impaired chamber relaxation also results in elevated end-diastolic pressures 
and the end result is identical to the case of systolic dysfunction (i.e. pulmonary 
edema in left heart failure and/or peripheral edema in right heart failure). 
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1.3.3 Ventricular Remodeling 
Cardiac contractility is often impaired following a myocardial infarction. 
Neurohormonal activation leads to regional hypertrophy of the infarct zone in a 
process known as remodeling. In ventricular remodeling and dysfunction, the 
geometric shape of the ventricle is altered and becomes more spherical and dilated
7
. 
This geometric alteration adversely affects hemodynamic function and increases the 
risk of ventricular arrhythmias so that sudden cardiac death is seen in 40% to 60% of 
persons with systolic dysfunction
8. These aberrant physiological effects are associated 
with ventricular remodeling and involves neurohormonal release which affect the 
structure and metabolism of the heart, increases hypertrophy, and ultimately leads to 
chamber dilatation via adverse alterations in preload, afterload, stretch, wall stress, 
interstitial collagen deposits and other direct inflammatory and apoptotic effects
9
. 
Adverse consequences of remodeling include increased wall tension, increased 




1.4 Cardiac myofibrillogenesis 
In order to develop efficient therapies for cardiovascular disease, it is important to 
understand the basic physiology of muscle development. Myofibrillogenesis 
essentially involves the ordered integration of actin,
 
myosin and other accessory 
proteins into sarcomeres, the basic functional units responsible for contraction in 
mature striated
 
muscle. The incorporation of actin and myosin proteins at episodic 




specific and dynamic interactions with 
other cytoskeletal components
10-12. The initial assembly of myofibrils, Z bodies 
composed of -actinin, the N-terminus of titin, nebulin, and telethonin contribute to 
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. Likewise, M-band proteins such as
 
myomesin, M 
protein and the C-terminus of titin play a significant role in incorporating the myosin 
thick
 




Importantly, the coincident association of the 
giant protein titin (3–4 MDa) with thick and thin filaments as well as its persistent 
localization to nascent
 
Z and M bands strongly indicates that titin is of central 
importance for the coordinated assembly
 
of the key elements of sarcomeres during 
early myofibrillogenesis
13, 21, 22, 26, 27
.  
 
There are currently two models of sarcomerogenesis. Both models are similar
 
in that 
structural proteins are essential for the assembly
 
and incorporation of actin and 
myosin into mature myofibrils. In the first, thin and thick filaments
 
assemble 
independently on stress fiber-like structures during early myofibrillogenesis.
 
These 
stress fibre-like structures further develop into nonstriated myofibrils, which progress
 





. Adjacent strands of thin and thick filaments are initially aligned at the 
cell borders and subsequently throughout the cytoplasm during the transition from
 
nonstriated to striated myofibrils.
 
Thus, the earliest precursors of mature thin and 
thick filaments are formed independently
 
within the myoplasm of developing muscle 





The second model describes three distinct structures during myocyte development: (i) 
premyofibrils
28
, (ii) nascent myofibrils and (iii) mature myofibrils. Premyofibrils 
contain transitory
 
arrays of I-Z-I complexes consisting of sarcomeric actin occupying
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primitive I bands that are attached to precursors of Z disks,
 
termed Z bodies, that are 
enriched in -actinin and interact with miniature A bands composed of nonmuscle 
myosin II. These primitive premyofibrils
 
develop into nascent myofibrils, which 
further differentiates into mature myofibrils
 
with the simultaneous replacement of 




. In this model therefore, the precursors 
of thick and thin myofilaments are formed along the same
 
structures and develops 
concurrently into mature sarcomeres. 
1.5 Novel therapy 
Organ transplantation or orthotopic heart transplant is the gold standard of treatment 
for heart failure, but remains impractical in reality due to a severe shortage of donor 
organs. Successful treatment of cardiovascular disease is therefore restricted in many 
situations by the lack of suitable autologous tissue to restore injured cardiac muscle or 
tissue.  
There is a pressing need to develop innovative and alternative therapies that may 
replace irreversibly damaged heart tissue. The emergence of new drugs and 
innovative devices have improved the quality of life for many patients diagnosed with 
heart failure, however these do not necessarily prolong life expectancy or decrease 
mortality and morbidity. End-stage heart failure eventually becomes refractory to 
current treatments.  
Current treatments for loss or failure of cardiovascular function include organ 
transplantation, surgical reconstruction, mechanical assistance via the use of synthetic 
devices, or the administration of drugs and other metabolic products. Although 
routinely used, these treatments are not without constraints or complications. Most of 
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these modalities do not replace existing damaged areas of the heart but rather work 
towards enhancing the viable areas in the heart that are still functional. To date, the 
only other therapy that addresses the underlying problem of extensive cardiomyocyte 
loss in AMI is cardiac cell transplantation. Recent discoveries in the past decade have 
led to the revelation that various stem/progenitor cells may regenerate the 
myocardium. These have ignited an explosive implementation of numerous clinical 
trials. Most of these studies however have reported variable outcomes and modest 
efficacies. 
1.5.1 Stem cells 
1.5.1.1 Embryonic stem cells  
Human embryonic stem (ES) cells are totipotent and are distinguished by their ability 
to proliferate in their primitive state while retaining their ability to differentiate into a 
myriad of cell types arising from all 3 germ layers (See Figure 1). Derived from the 
inner cell mass (ICM) of pre-implantation or peri-implantation embryos in the 
blastocyst stage, these cells remain in their native state only when cultured on a feeder 
layer of mitotically inactivated mouse embryonic fibroblasts
30, 31
. The use of 
xenosupport systems has raised concerns of possible inter-species pathogen infection 
that may prove problematic in downstream clinical applications. However, original 
concerns surrounding the use of such a system have been quelled with the 
development of serum-free support systems and human feeder layers.  
Differentiation may be induced upon removal from feeder layers
30, 31
. Most ES cell 
lines will spontaneously differentiate into a vast array of cell lineages upon the 
formation of an embryoid body. This includes spontaneously beating cells, which 
have since been determined to be cells belonging to a cardiomyogenic lineage.  
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Figure 1. Embryonic stem cells are totipotent and can differentiate into various cell 
types. 
 
ES cell-derived embryoid bodies have been reported to develop into early-stage 
cardiomyocytes that recapitulate the ontogeny of cardiomyogenesis by sequential 
expression of cardiac-specific transcription factors and sarcomeric proteins
30, 31
. 
Messenger RNAs encoding cardiac transcription factors, GATA-4 and Nkx2.5 are 
expressed in EBs before messenger RNAs encoding the atrial natriuretic
 
factor 





exchanger, and phospholamban. Sarcomeric proteins
 
are also expressed in the following order: titin (Z disk), -actinin, myomesin, titin (M 
band), MHC, -actin, cardiac troponin T and M protein30, 31. Myofibrillogenesis and 
organization into sarcomeric structures are subsequently observed that accompany 
cardiac-like excitability and contractility with nodal, atrial, and ventricular 
characteristics. The nascent myofibrils in these terminally differentiated cells are
 
sparse and irregularly organized, although parallel bundles of myofibrils demonstrate 
evidence of
 
A and I bands that are characteristic of sarcomeric structures
32
. 
Additionally, these mature cells reportedly express intercalated disks, fascia adherens, 
desmosomes and functional gap junctions. This ES-derived cardiomyocytes are 
capable of being electrically coupled with the host myocardium upon their 
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engraftment in the compromised myocardium
32, 33
. Furthermore, they form stable 
intracardiac grafts for 7 to 32 weeks following their engraftment in the ventricular 
wall. This in turn led to significantly reduced left ventricular remodeling and 
enhanced cardiac contractile performance in the impaired myocardium. 
1.5.1.2 ES cell stem therapy is not ideal for clinical use 
The derivation of human ES cell lines and the establishment of a cardiomyocyte 
differentiation system are promising for the development of heart regenerative 
therapy. ES cells‟ pluripotent nature marks their main attraction as therapeutic agents. 
However, this same property confers ES cells with a similar propensity for 
tumorigenesis. It was recently reported that as little as 500 mouse or human ES cells 
were sufficient to elicit reproducible tumor formations in vivo 
34, 35
. 
Consistent with a tumor-like phenotype, ES cells express a low level of the human 
leukocyte antigen (HLA) class I molecules and do not express class II molecules. Just 
like cancer cells, cells with a negligible expression of HLA molecules would be able 
to evade the immune system. Thus, ES cells may exhibit immunotolerance following 
engraftment in the myocardium. However, while ES cells may be immunoprivileged 
in their undifferentiated state, it is likely that these cells may express HLA molecules 
upon differentiation. To circumvent this problem, it has been suggested that ES cells 
from a bank of only 150 donors with distinct HLA types be used for therapy
36
. 
However, these 150 cell lines may be inadequate to match the highly variable 
genotypes in a multiracial patient population. Moreover, this „solution‟ was conceived 
on the assumption that each of the 150 cell lines posses the same inherent 
differentiation potential, a concept far from clinical reality.   
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The implantation of undifferentiated ES cells or other inappropriate ES cell-
derivatives may also lead to an inadvertent perturbation of tissue function. Ironically, 
it is ES cells‟ immense plasticity coupled with the fact that there are presently no 
differentiation techniques that would yield a 100% pure population of mature progeny 
that further underscores their limitations as a choice cardiovascular therapeutic agent. 
It is not surprising therefore that ES cells are currently restricted from clinical use for 
their questionable immunogenicity, innate propensity for teratoma formation and 
controversial ethical issues arising from their use.  
1.5.2 Adult stem cells 
Adult stem cells are found in many organs and tissues and may replenish cells that are 
lost during physiological homeostasis. Specific gene expressions are imprinted at the 
fetal stage so that their ability to differentiate is restricted to the tissue in which they 
reside. However, recent discoveries report that adult stem cells retain a high degree of 
developmental plasticity, and can transdifferentiate into brain, gut, lung, liver, 
pancreas, kidney and cardiac cells, when placed under specific conditions in vitro and 
in vivo 
37-44
. This new concept challenges the traditional dogma of adult stem cell 
commitment and presents the impetus for a burgeoning interest in adult stem cell 
therapeutics. The use of adult bone marrow stem cells in cellular transplantation is 
perhaps the most progressive in current cardiovascular research.  
1.5.2.1 Bone marrow stem cells 
There are 2 most common types of stem cells in bone marrow: (i) hematopoietic stem 
cells and (ii) mesenchymal stem cells. These cell types are believed to be ideal for 
myocardial transplantation for their ability to develop into cell types representing 
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various mesodermal lineages. These include smooth muscles, angioblasts and cardiac 
muscle, which are the three major cell constituents in the heart.  
1.5.2.1.1 Hematopoietic stem cells 
Hematopoietic stem cells (HSCs) are multipotent and responsible for reconstituting 
and maintaining all blood lineages. This population of adult stem cells is also 
conferred with natural self-renewing properties. In vitro studies have reported that 
human hematopoietic stem cells possess an inherent regenerative capacity and are 
particularly predisposed to adipocyte and osteoblast differentiation (See Figure 2). 




1.5.2.1.2 Mesenchymal stem cells 
Mesenchymal stem cells (MSCs) encompass a heterogeneous population of 
undifferentiated, lineage-primed cells with differential phenotypic characteristics and 
differentiation propensities. Found in bone marrow, muscle, skin and adipose tissue, 
MSCs may be isolated from bone marrow aspirates in culture as they may adhere 
differentially to the plastic culture dish. These cells can differentiate into muscle, 
fibroblasts, bone, tendon, ligament and adipose tissue
46
 (See Figure 2). Cells 
belonging to mature blood lineages may be removed using specific antibodies to 
hematopoietic markers by fluorescence- or magnetic- activated cell sorting and 
further purified in a Histopaq-Ficoll density gradient, prior to adherence on tissue 
culture plastic surfaces.  This unique property allows for an additional purification 
measure, which enhances the specificity of this isolation method
47-49
. Single cells of 
spindle morphology may be observed 3-4 days after initial plating in a normal growth 
medium. These cells exhibit a high proliferation rate and rapidly expand into colonies 
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of confluent spindle cells by 10-14 days. The cultures consist mostly of 
homogeneously needle-like cells typical of mesenchymal stem cells, although a 
minority population of cells may reflect a polygonal morphology. 
 
Figure 2. Bone marrow stem cells are multipotent and can 
differentiate into cells belonging to various mesodermal lineages.  
 
The MSCs used in cardiac research are mainly from the heterogeneous cell 
population. Several studies have demonstrated that these adult stem cells can 
transdifferentiate into cardiomyocytes and vascular-like structures
37, 50, 51
.   
5-azacytidine is a demethylating agent
52
 reported to induce the transdifferentiation of 
murine bone marrow stem cells into spontaneously beating myocytes
53
. Human MSCs 
have also been reported to exhibit a cardiomyocyte-like phenotype when treated with 
5-azacytidine. These cells reportedly express multiple cardiac specific proteins and 
display distinct ultrastructural and electrophysiological characteristics that resemble 
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native cardiomyocytes
54, 55
. However, this phenomenon is inefficient and not readily 
reproducible. Moreover, 5-azacytidine may induce a random demethylation of non-
specific genes that may in turn elicit toxic and adverse consequences on a systemic 
basis. Thus, its clinical application has been cast with doubts. 
On the other hand, butyric acid inhibits histone deacetylases, thus favoring histones in 
an acetylated state in the cell
56.  Acetylated histones can neutralize electrostatic 
interactions and thus have a lower affinity for DNA than non-acetylated histones. 
Transcription factors are thus unable to access regions where non-acetylated histones 
are tightly associated with DNA (i.e. heterochromatin). Therefore, butyric acid may 
enhance the transcriptional activity at promoters that are otherwise usually silenced or 
downregulated due to histone deacetylase activity. However, like 5-azacytidine, 
butyric acid has a random mode of action and may lead to undesirable complications 
on a systemic basis in downstream clinical applications.    
Milieu-dependent differentiation forms the basis for undifferentiated bone marrow 
stem cell therapy. It is believed that these multipotent stem cells undergo site-directed 
differentiation to become resident cells of the recipient organ, specifically 
cardiomyocytes and endothelial cells in regenerating myocardium. However, there is 
growing evidence that cardiac transdifferentiation may be a rare and inefficient 
process in MSCs.  
1.5.3  Bone marrow stem cell-transplantation therapy 
Bone marrow stem cell transplantation was originally conceived as a means to 
repopulate and regenerate the non-viable areas of the infarcted myocardium to 
compensate for the extensive loss in cardiomyocytes following a myocardial 
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infarction. Moreover, bone marrow stem cells present as an attractive modality from 
the perspective of autologous cardiovascular therapeutics. 
The rationale for engrafting cardiomyocytes onto a compromised myocardium is 
intuitive and has prompted the initiative for subsequent “proof-of-concept” 
experimentation. Early success in these preclinical investigations formed the impetus 
for the explosive, albeit premature initiation of numerous clinical trials in the last 
decade. To date, there are more than 1000 patients receiving undifferentiated bone 
marrow stem cell therapy in clinical trials. However, most of these studies have 
reported mixed outcomes and modest efficacies
57, 58
.  
Bone marrow-derived cardiac transdifferentiation is inefficient and rare, but 
existent
59
. This inefficient process may be attributed to the heterogeneous 
subpopulations in the bone marrow and ironically further confounded by the 
multipotent plasticity of stem cell precursors in the bone marrow. Breitback et al 
recently reported the presence of encapsulated deposits containing calcifications 
and/or ossifications following cell transplantation in a murine myocardial infarction 
model
60
. These findings highlight the disturbing possibility of extended bone 
formation in vivo following undifferentiated bone marrow stem cell therapy. To 
significantly enhance clinical outcomes, it may be safer and more efficient to engineer 
primitive bone marrow stem cells in such a way that they may play a more active role 
in recovering the overall contractile performance in the infarcted myocardium. This 
may be achieved if undifferentiated bone marrow stem cells were first committed to a 
stable and distinct cardiac lineage ex vivo prior to actual transplantation therapy.  
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1.6 Skeletal myoblasts 
Skeletal myoblasts are resident mononucleated progenitor cells within the skeletal 
muscle that unlike cardiac muscle possess the ability to regenerate upon injury. 
Animal studies have shown that grafted myoblasts form myotubes in the myocardium 
and eventually develop into distinct myofibers with contractile properties
61
. However, 




One of the earliest reports described the implantation of autologous skeletal myoblasts 
into the postinfarction scar during a coronary bypass. Menasche et al measured 
contraction and viability in the grafted scar. A mean of 871 x 10
6
 autologous 
myoblasts were injected into the scar during bypass grafting. There was improvement 
in contraction and viability in the cell-implanted scars at an average follow-up of 10.9 
months. However, 4 of the 10 patients suffered from sustained ventricular tachycardia 
(VT) that was resistant to treatment with amiodarone and beta-blockers and was 
managed with automated defibrillator implantation, while 4 of 5 patients suffered 
from atrial fibrillation or VT
63-65
. However, most episodes of arrhythmias were 
clinically well tolerated and did not result in mortality. Nonetheless, the reasons for 
arrhythmia following myoblast transplantation are multifactorial and may be 
attributed to: 
(i) A lack of gap junctions between transplanted myoblasts and resident 
cardiomyocytes,  
(ii) A difference in the action potential of the 2 cell types,  
(iii) An inhomogeneous distribution of gap junctions in skeletal muscle as 
compared to cardiac muscle,  
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(iv) A differential expression of ion channel isotypes between skeletal muscle cells 
and cardiomyocytes and  
(v) The release of inflammatory mediators after needle puncture66.  
Myoblast transplantation is also plagued with problems of survival of donor cells 
post-transplantation
67
. It has been shown in animals that up to 90% of grafted cells die 
within the first 1-2 days after transplantation
68, 69
 so that total myoblast survival is 
approximately <1% in humans. This poor cell survival has been attributed to 
inflammatory changes at the site of implantation, which has been attributed to the 
result of trauma due to needle puncture, immune-mediated rejection of myoblasts, or 
release of immune modulators as a result of myoblast cell death
70
. Furthermore, a 
recent randomized trial conducted by Menasche et al did not show any significant 
benefit in patients with ischemic cardiomyopathy
62
. Efforts are underway to 
genetically modify skeletal myoblasts to enhance their therapeutic efficacy. The 
future of skeletal myoblast as a cardiovascular treatment modality remains to be 
elucidated.  
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1.7 Clinical trials in BM stem cell transplantation for treatment of 
MI 
1.7.1 Clinical outcomes 
Interest in bone-marrow stem cell- mediated cardiac regeneration began in 2001 with 
Orlic et al‟s observation of induced cardiac repair in murine myocardial infarcts 
following the introduction of Lin- cKit+ bone marrow cells in the compromised 
myocardium
71
. These mice demonstrated significant functional recovery within 9 
days of transplantation via the de novo regeneration of cardiomyocytes and blood 
vessels. Orlic‟s newly acquired knowledge then embraced a new concept that directly 
challenges the traditionally accepted developmental paradigm of adult stem cell 
commitment, as bone marrow cells were able to generate new cardiomyocytes, 
smooth muscle cells and endothelial cells
72-77
. This has inspired numerous 
nonrandomized phase I clinical trials that test the feasibility and safety of autologous 
cell transplantation. The results of the first clinical trial
78
 were published 1 year after 
Orlic et al‟s discovery71 and almost 1000 patients have received similar treatments to 
date. Table 1 summarizes the outcomes of the 4 major clinical trials
79-86
.  
1.7.1.1 Bone marrow transfer to enhance ST-elevation infarct regeneration (BOOST) 
The BOOST trial was a randomized controlled trial, which recruited 60 patients 
diagnosed with an ST-elevation myocardial infarction with subsequent reperfusion
87
. 
Patients were randomized into a conventional therapy group vs. a conventional 
therapy combined with intracoronary transfer of autologous bone marrow cells 
approximately 5 days following percutaneous coronary intervention. Cardiac function 
was assessed via magnetic resonance imaging (MRI) and post transplantation 
assessments show smaller infarct sizes, and no significant difference between scar 
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tissue remodeling following cell transplantation therapy. More importantly, the 
initially promising results at 6 months post therapy was not sustained in a longer 
follow-up study at 18 months post-therapy, as there are no significant differences in 
LV contractile performance between the 2 treatment groups. This in turn raises 
concerns that transplantation of bone marrow cells may only bring about a transient 
recovery of myocardial function but not permanent cardiac repair.  
1.7.1.2 Autologous Stem Cell Transplantation in Acute Myocardial Infarction 
(ASTAMI) 
This trial recruited 100 patients into the study, of which 47 patients underwent 
intracoronary injection of BM cells 6 days after an ST elevated myocardial infarction. 
In a similar experimental design to the BOOST trial, cardiac function was assessed 
with single photon emission computed tomography (SPECT) echocardiography and 
MRI. As in the BOOST trials, transplantation of bone marrow cells did not 
significantly affect LV myocardial function, infarct size or scar tissue remodeling.  
1.7.1.3 LEUVEN-AMI 
The LEUVEN-AMI trial conducted by Janssens et al was a double-blind randomized, 
placebo-controlled study involving 67 patients
84
. Bone marrow cell transplantation 
was conducted the day after successful percutaneous coronary intervention for 
STEMI. Functional recovery of cardiac function following transplantation of BM 
included a significant reduction in infarct size and an enhanced recovery of regional 
systolic activities. However, there were no significant differences in cardiac function 
4 months post-therapy. 
1.7.1.4 Reinfusion of Enriched Progenitor cells and Infarct Remodeling in Acute 
Myocardial Infarction (REPAIR-AMI) 
To date, this randomized, double-blind and placebo-controlled trial is currently the 
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largest trial involving bone marrow stem cell transplantation in the world. BM cells 
were transplanted 3-7 days following successful percutaneous coronary interventions 
in patients with STEMI. Stem cell transplantation led to an increase of 2.5% in EF 4 
months post therapy. This trial highlighted the fact that timing of cell transplantation 
may be important in mediating myocardial improvement, as BM cells administered 
from days 5-7 led to an increase of approximately 5.1% EF, whereas there no 
observable recovery of cardiac performance with BM cell treatment up to 4 days after 
reperfusion.  
1.7.2 Problems encountered 
Current clinical trials have shown that bone marrow stem cell transplantation for the 
treatment of heart failure is feasible and relatively safe. However, early benefits in 
cardiac function have been overshadowed by consistent trends showing only a modest 
recovery of cardiac function in patients at longer follow-ups. These cast doubts on 
bone marrow stem cells as ideal candidates for the treatment of heart failure as these 
undifferentiated bone marrow stem cells appear only to confer temporary recovery of 
myocardial function but not permanent cardiac repair. However, the source, number 
and type of cells, mode and time of cell application and other details of design differ 
between trials and this makes comparisons difficult. The critical problem is that there 
is currently no mechanistic explanation for the clinical data. The initial results were 
interpreted in terms of transdifferentiation of BMC to myocytes and vessels, as in the 
animal models, but alternative angiogenic and paracrine hypotheses have also been 
proposed. For example, in angiogenesis, endothelial cell precursors would 
differentiate into blood vessels in vivo. This enhances myocardial perfusion, which in 
turn keeps the remaining myocytes alive. In the paracrine hypothesis, it is believed 
that the exogenous cells produce certain anti-apoptotic factors that can prevent cell 
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death and/or stimulate stemness of other cells
72, 73, 76, 88
. 
Several other key concerns of BM stem cell transplantation in the clinical setting that 
remain to be addressed in the clinical setting include the longevity of intracardiac 
grafts, (engrafted) cell propensity for cardiac transdifferentiation, integration with 
host myocardium, (engrafted) cell response to physiological and pathological stimuli, 
possible tumorigenesis at the site of transplant and asynchronus contractions leading 
to arrhythmias. Current phase I trials provide an insight into how BM stem cells may 
contribute towards improving cardiac function. However, the long-term benefits of 
BM stem cell transplantation remain less conclusive than those established in 
preclinical studies.  
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Table 1. Clinical outcomes of current major trials on cardiac regeneration for 
treatment of acute myocardial infarction 
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1.8 Extracellular matrices 
The intimate and dynamic relationship between stem cells and their niches is 
invaluable to the design of cardiovascular therapeutics but is not fully understood. 
However, it is known that extracellular matrices (ECM) constitute a major part of 
stem cell niches. These niches sustain the stem cell pool within each tissue or organ 
by maintaining a tight balance of self-renewal, proliferation and differentiation.  
Collagen, proteoglycan, glycoaminoglycans and glycoproteins are among the primary 
constituents of the ECM. ECM collectively performs diverse physiological functions 
and is elementary to maintaining the structural integrity of tissues and organs. 
Cardiomyocytes in the healthy myocardium usually adhere to a collagen-based ECM 
that is adequately compliant to external and internal physical forces to facilitate 
cardiac contractility. This presents the „cue‟ for many cells, and influences many 
physiological functions such as morphology, protein expression and organization, 
proliferation, repair, senescence as well as differentiation, via the engagement of 
relevant cell surface receptors and subsequent downstream signaling events. These 
surface receptors include laminin receptors and syndecans, matrix metalloproteinases 
and integrins.  
Extracellular matrices may also provide a means to manipulate differentiation of stem 
cells into well-defined lineages in vitro, by introducing ECM molecules into the 
culture milieu. In addition, cell-ECM interactions may promote the proliferation of 
these adult stem cells while simultaneously retaining their differentiation potential. 
Although adult mesenchymal stem cells (MSCs) are amenable to in vitro 
manipulation, they progressively lose their proliferative potential and multipotent 
nature with continuous passages in culture. One way to harness stem cells into well-
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defined lineages in vitro would be to introduce ECM substrates within the culture 
milieu.  
1.8.1 Collagens 
Collagen fibrils and proteoglycans are the most ubiquitous component of the ECM 
and are present in all connective tissues. Collagens are homo- or hetero- trimeric 
proteins assembled from type-specific- chains. The basic structure of collagen sees 
α - chains are wound around one another in a coil-coiled conformation to form a triple 
helix of collagenous domains.  
The collagen family is a large heterogeneous class of proteins, which contain a 
myriad of other protein-binding domains, in addition to the collagenous domain. 
Collagens are also known to form supramolecular structures with other collagens 
and/or other components of the ECM. Depending on their ability to form organized 
fibers, collagens can be classified into fibrillar and non-fibrillar collagens
90-92
. The 
fibrillar collagens are a rather homogeneous group comprising of collagens type –I, -
II, -III, -V and –XI. These collagens are characterized by a single collagenous domain 
and form fibrils, fibers via intermolecular interactions and are ultimately organized 




Collagen type I is the most dominant form of collagen in the vertebrate body 
including the heart. Collagen type I typically acts in concert with other collagens and 
proteoglycans to confer tissues with optimal tensile strength and structural integrity. 
Upon cellular interactions, collagen type I elicits vital biological functions such as 
survival, motility and proliferation among other cellular events. The type I collagen 
fibrils comprises of a core of collagen type V fibrils encapsulated by polymerized 
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collagen types I and III fibrils
94, 95
. The ubiquitous collagens types I-III confers 
mechanical strength onto the collagen fibril, while the core collagens contribute 
towards overall fibril morphology and thus tissue- specificity. Importantly, these 
collagens serve as both a structural scaffold and attachment sites for other ECM 
constituents and cell surface receptors such as integrins.  
The overexpression of collagen type I is common observation among a variety of 
fibrotic disorders. These disorders arise from a defective regulation of collagen 
synthesis rather than mutation in the collagen structure. Following a myocardial 
infarction, beating cardiomyocytes are replaced by a scar tissue that is infinitely stiffer 
and less elastic than the normal myocardium. Elevated collagen deposition replaces 
functional contractile cardiomyocytes in the scar areas of the infarcted myocardium 
and correlates with a corresponding decrease in myocardial tissue compliance. Just as 
a scar-like rigidity inhibits spontaneous beating, so the collagen-based domains in the 
scar may be responsible for the low frequencies of marrow-derived cardiac myogenic 
transdifferentiation in vivo.  
1.8.2 Integrins and Integrin- mediated Cell Signaling 
1.8.2.1 Integrins 
Integrins are a major class of ECM receptor molecules with critical roles in cellular 
differentiation and tissue development. The binding of distinct - and - subunits 
induces integrin clustering at focal point on the cell membrane. This leads to the 
formation of macromolecular signaling complexes defined as focal adhesions, which 
trigger a cascade of downstream intracellular signaling events. Thus, integrins 
essentially translate exogenous signals released from a cell‟s microenvironment into 
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intracellular signaling events to regulate and influence subsequent cell fate and 
function.  
 
Figure 3. Known -integrin heterodimers. 
 
To date, there are 24 identified human - and 9 -subunits96. Established - and - 
integrin dimers are presented in Figure 3. Integrin activation occurs via positive 
allosteric modulation of the receptor. Upon ligand binding, integrins undergo 
conformational changes, which increase ligand affinity. However, integrin activation 
can also be accomplished via an upregulation of relevant integrin expression levels 
and/ or induced clustering at focal adhesion points on the cell surface, which leads to 
enhanced integrin avidity
97-99
.   
  26 
1.8.2.2 Focal Adhesions 
 Focal adhesions act as intracellular sites of signal transduction and form a dynamic 
„bridge‟ between the ECM and the cytoskeleton and influence adhesion-dependent 
cellular events such as survival, proliferation (via MAPK activation) and 
differentiation. Ligand-occupied integrins connect to the actin cytoskeleton and 
participate in its reorganization, thereby coupling integrin receptors to the actomyosin 
apparatus that is responsible for cellular contractility, while sequestering a myriad of 
signaling molecules at a focal point (Figure 4).  
The engagement of integrin receptors activates critical a cascade of intracellular 
signaling events which influence cell survival and proliferation
100-102
. Additionally, 
integrin-stimulated signaling pathways have also been implicated in the 
differentiation of stem cells. Notably, integrin-mediated pathways reportedly play 
significant roles in the transdifferentiation of ES cells into the neuroectodermal and 
mesodermal lineages
103
. They may also be responsible for the differentiation of bone 
marrow stromal precursors into functional osteoblasts
104
. For instance, laminin is 
known to direct the osteogenic differentiation in vitro
105
.    
Integrins that bind to the interstitial collagens include the 11, 21 101 111 and 
v3 integrins
106, 107
. Of these integrins heterodimers, the 21 and the v3 integrins 
have been implicated in diverse physiological and pathological conditions. Several 
reports have described 11 to inhibit collagen synthesis, and 21 to be a positive 
regulator of collagen gene expression although they may function more as a 









Figure 4. Schematic illustration of a focal adhesion complex following integrin receptor clustering at a focal point on the cell surface.   
Following ligand binding, distinct a/b subunits undergo receptor heterodimerization, which in turn leads to clustering at point of ligand 
engagement. This further recruits cytosolic proteins to the site of clustering and subsequent formation of an intracellular macromolecular 
signaling complex that further engages the cytoskeletal structure in the cell and activates critical cellular processes such as survival, 
proliferation (activation of Ras/MAP Kinase pathways) and differentiation. Thus, integrins act as the physical and dynamic link between the 
ECM and the cytoskeleton. 
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The v3 integrin is an indiscriminate receptor with multiple specificities to a diverse 
array of ligands including fibrinogen, fibronectin, thrombospondin and bone 
sialoproteins among others. The principal binding motif for v3 interaction is the 
Arg-Gly-Asp (RGD) sequence
110
. Some ECM molecules such as collagens and 
laminins possess intrinsic RGD sequences that are exposed upon allosteric 
conformational changes following receptor binding. Notwithstanding, it is important 
to highlight that the v3 integrin binds denatured but not native collagen. The v3 
integrins have been implicated in participating in collagen- mediated processes 
including remodeling of the collagen matrix
111-114
.  
1.9 Cardiac Tissue Engineering 
The main disadvantage of cell-based transplantation therapies for the treatment of 
cardiovascular disease is that only a limited number of cells being delivered to the 
myocardium at any one time. However, this may be circumvented by efforts in tissue 
engineering, in which cells were concentrated in a hydrogel-based and patch-like 
heart tissue construct to replace irreversibly damaged portions of the heart.  
Collagen type I is the most ubiquitous collagen in the human body. It is readily 
available commercially and has been the most studied matrix for tissue engineering. 
Zimmermann et al demonstrated the feasibility of collagen-based scaffold for tissue 
engineering of an artificial cardiac tissue construct. They further demonstrated that 
collagen matrix supported mechanical load that enabled development of 
spontaneously contracting heart tissue constructs. These collagen-based cardiac 
constructs were mechanically robust yet ﬂexible and was quickly vascularized after 
implantation
115
. Radisic M and colleagues have also successfully seeded preformed 
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collagen sponges/foam with neonatal rat heart cells suspended in Matrigel while 
stimulating them electrically for extended time
116
m while Simpson and colleagues 
observed that neonatal rat cardiac myocytes aligned with the collagen to adopt a 
tissue-like organization
117
 when a scraper was used to remove a part of the coated 
surface of culture dishes pre-coated with freshly neutralized collagen type I. This led 
to the generation of cardiac muscle constructs with improved cardiac tissue 
morphology, contractile function, and molecular marker expression when compared 
with non-stimulated cultures. Therefore, the underlying substrate of extracellular 
matrix (ECM) plays an important role in cell growth and differentiation. 
Commercially available ECMs substrates can be acquired as a puriﬁed powder to 
form tissue construct with enhanced interaction and adhesion of stem cells.  
Tissue engineered cardiac construct is an emerging field with real potential to benefit 
a large number of patients with cardiovascular disease. Understanding the complex 
interactions between the stem cells and their underlying collagen substrate will be 
crucial in developing this into a clinical relevant application.  
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1.10 Significance of study 
Plasticity of mesenchymal stem cells may present an added advantage for cell 
therapy. However, like their embryonic counterparts, this may inadvertently lead to 
tumorigenesis or transdifferentiation into undesirable cell types following 
transplantation therapy in the injured myocardium. Recent findings have indicated 
current undifferentiated bone marrow stem cell therapies mediate their improvements 
via non-myogenic mechanisms, while actual marrow-derived cardiac 
transdifferentiation in vivo is inefficient and rare
59
. Thus, it may be a safer and more 
efficacious to commit these undifferentiated stem cells to a stable cardiac-like lineage 
in vitro before transplantation into infarcted myocardium. This study reports that adult 
human bone marrow mesenchymal stem cells (MSCs) can be differentiated into 
cardiomyocyte-like cells (CLCs) via the simultaneous use of a non-toxic myogenic 
induction medium (MDM) and collagen V matrix. This preclinical investigation aims 
to develop a more effective cell-based therapy for the treatment of heart failure. 
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1.11 Specific Aims 
This study aims to establish a large-scale production of cardiomyocyte-like cells by 
exploring stem cell commitment via milieu-dependent cardiac transdifferentiation of 
human mesenchymal stem cells. Specifically, this study explores  
(1) The effect of extracellular matrices like fibronectin, collagen, laminin, gelatin 
and vitronectin, on the proliferation and cardiomyogenic differentiation  
(2) Functional contribution of the newly established human cardiomyocyte-like 
cells  
(3) Investigate the dose-dependent effect of cardiomyocyte-like cells in the 
systolic and diastolic performance of post-infarcted myocardium. 
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Chapter Two: Materials and Methods 
2.1 Recruitment of patients  
Forty-five patients who were scheduled open-heart surgery were recruited into the 
study. The study was approved by the Institutional Review Board of the Singapore 
General Hospital. Informed consent was obtained from recruited patients.  
2.1.1 Isolation and Cell culture 
Cell suspensions were isolated from the sternum of patients undergoing open-heart 
surgery. Approximately 0.5 -2 ml of bone marrow aspirates were collected in a sterile 
tube containing 17IU/ml lithium heparin using a 23-gauge needle. The aspirates were 
subsequently depleted of mature blood lineages by using specific antibodies against 
CD3, CD14, CD19, CD38, CD66b and Glycophorin-A (Stem Cell Technologies, 
Vancouver, Canada) and further purified by centrifugation in a 1.077 g/ml 
Histopaque-Ficoll (Sigma, St. Louis, MO) density gradient. The enriched cell fraction 
was collected from the interphase and subsequently transferred onto tissue culture 
flasks in basal medium for 9-11 days to yield plastic adherent MSCs. The basal 
medium, designated NGM, comprises of Dulbecco‟s modified Eagle‟s medium-low 
glucose ([DMEM-LG] GIBCO; Grand Island, NY) supplemented with 10% fetal 
bovine serum (Hyclone, Logan, UT) and 1% penicillin-streptomycin. Media was 
changed every 3-4 days thereafter. Subconfluent cells were harvested by 
trypsinization in 0.25% Trypsin-EDTA (Sigma) 14-21 days after initial plating and 
further expanded as BM-MSCs in basal medium or differentiated towards 
cardiomyocyte-like cells in a myogenic differentiation medium (MDM). All primary 
cell cultures were maintained at 37 in 5% CO2 in air.  
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2.2 Isolation and culture of neonatal rat cardiomyocytes 
Cardiomyocytes were isolated from neonatal rats using a cardiomyocyte-isolation kit 
(Worthington Biochemical Corporation). The cardiomyocytes were subsequently 
cultured in the presence of arabinosylcytosine (Ara-C) to inhibit the growth of 
fibroblast in the primary cultures. Cardiomyocyte cultures were maintained in NGM 
at 37 in 5% CO2 in air, and medium was changed every 3-4 days.  
2.3 Flow Cytometry 
Cells were stained with a selection of specific anti-human antibodies. A comparative 
histogram analyses was performed using the mean fluorescence intensities of MSCs 
and CLCs. Early passage cells (passage 4-6) were trypsinized, washed with 5% BSA 
and 1% fetal bovine serum in PBS and subsequently stained with a panel of the 
following fluorescence- conjugated anti-human antibodies and the corresponding IgG 
isotype controls for 2 hours at 4°C: FITC-conjugated CD34, CD90, CD106 and 
integrin v3 (Chemicon), PE-conjugated CD31, CD44, CD45 and APC-conjugated 
KDR (R&D Systems), CD105 and VEGF Receptor 2 (VEGFR2). Unconjugated 
mouse anti-human antibodies to TIE2 (USBiological), 21 (Chemicon), 2 (Santa 
Cruz), v (Research Diagnostics Inc), 1 (Chemicon) and 3 integrins (Cell Signaling 
Technology) were detected using an allophycocyanin-conjugated rat anti-mouse 
secondary antibodies (all BD Biosciences, unless otherwise stated). FACS was 
performed using FACSDiva (BD Biosciences) and analyzed with FlowJo software. 
2.4 Gene expression profiling via RT-PCR analyses 
BM-MSCs were cultured separately in the basal or myogenic development medium 
for 7 and 14 days. The expression of specific cardiomyogenic markers was assessed 
by RT-PCR on mRNAs extracted from the respective cell types on Days 7 and 14. 
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BM-MSCs were also proliferated on uncoated, collagen -I and -V extracellular 
matrices for 14 days, whereupon mRNAs were subsequently extracted and probed for 
gene expression of cardiac-specific markers.  
Total RNA was extracted using TRIzol
 
reagent (Invitrogen Life Technologies, Inc), 
and RNA was precipitated with isopropanol. One microgram of RNA, extracted from 
the respective cells, was reversed transcribed using 500ng oligo-dT and the 
SuperScript® III First-Strand Synthesis System for RT-PCR (oligo-dT primers and 
reverse transcription kits both from Invitrogen Life Technologies, Inc). Control 
reactions were carried out in the absence of:  
i. Superscript III reverse transcriptase (Invitrogen Life Technologies, Inc.) to 
control for genomic DNA contamination and  
ii. cDNA (template) to control for primer specificity.  
iii. PCR amplification was carried out on 200ng of cDNA in a Biometra thermal 
cycler, using Taq polymerase (Promega Corp.)  Cycling parameters are 
described as follows: 95C for 2 minutes; 40 cycles of Denaturation at 95C 
for 1 minute, 60C for 30 seconds and 72C for 1 minute; 72C for 7 minutes.  
Nested PCR was employed to detect the presence of transcripts expressed in low 
abundance. These transcripts include GATA4, csx/nkx2.5, atrial natriuretic factor, 
brain natriuretic peptide, cardiac troponin t, - myosin light chain 2a, and the - and 
- myosin heavy chains.  The thermal cycling profile is described as follows:  
i. Primary PCR: 95C for 2 minutes; 35 cycles of 95C for 1 minute, 58C for 
30 seconds and 72C for 1 minute; 72C for 7 minutes.  
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ii. Secondary PCR: 95C for 2 minutes; 40 cycles of 95C for 1 minute, 60C for 
30 seconds and 72C for 1 minute; 72C for 7 minutes.   
2.5 Cell proliferation assays 
Individual wells were coated overnight with various ECM substrates, according to the 
manufacturer‟s recommendations. Early passage (Passage numbers 1-4) BM-MSCs 
were cultured in DMEM or a myogenic development medium (MDM) and 
proliferated on Collagen I, III, IV, V, gelatin, fibronectin, laminin, poly-L-lysine and 
vitronectin matrices, at a seeding density of 1000 cells per well. BM-MSC and MSC-
derived CLC proliferation were monitored over 11 days, and a total cell count was 
obtained with the use of a hemocytometer at days 1, 3, 5, 7, 9 and 11. The assay was 
repeated 3 times with 5 replicates per respective treatment. 
Gene expression profiling of cells expanded on competing collagen I:V substratum.  
CLCs were cultured on tissue culture plastic surfaces pre-coated with competing 
collagens I:V substrata in the respective ratios of 5:0, 1:4, 2:3, 3:2, 4:1 and 0:5, 
overnight at 4°C. All samples were made up to a final concentration of 10mg/cm2. 
Cells were trypsinized upon attaining 90% confluency, and re-seeded on freshly 
coated surfaces with consistent collagens I:V ratios. Cells were harvested on the 14th 
day of culture and total RNA was extracted from the cell samples as described for 
subsequent gene expression profiling.  
2.6 Integrin inhibition assays 
Neutralizing antibodies were used to inhibit the v (Millipore) and 1 integrin 
subunits as well as 21 and v3 heterodimers on CLCs (All antibodies were 
purchased from Chemicon unless otherwise stated). To determine the effect of 
functional integrin inhibition on initial cellular adhesion on collagen- ECM, CLCs 
  36 
were harvested and allowed to recover overnight on low-adhesion TC plates. 
Subsequently, CLCs were cultured with neutralizing antibodies towards 21, v3, 
v and 1 integrins for 1 hr on ice. These treated cells were then seeded on the 
respective uncoated surfaces and collagens -I and -V substrata. A total cell count was 
obtained the following day.  
0.4 x 10
6
 CLCs were typsinized and incubated with 1mg/ml, 5mg/ ml, 10 mg/ml, 
25mg/ml or 50 mg/ml of the respective neutralizing antibodies for 2 hours on ice in a 
final volume of 400mL to investigate the effects of dosage-dependence on gene 
expression. Control samples included treatment with 10ug/ml IgG isotype antibodies 
and untreated CLCs. Treated CLCs were subsequently plated on collagen V surfaces. 
One thousand treated CLCs/200uL were plated 96 wells plates pre-coated with 
collagen V with 5 replicates per treatment. A total cell count was obtained the 
following day to compare the effects of integrin blocking on initial cell adhesion. At 
the same time, the remaining (treated) cells were allowed to grow till approximately 
90% confluency on tissue culture flasks pre-coated with collagen V ECM, thereafter 
CLCs were trypsinized and the inhibition assay repeated 7 days after the first 
inhibition, before cells were re-plated on fresh collagen V-coated surfaces. CLCs 
were harvested on the 14 days following initial neutralization, and pellets were 
collected for gene expression profiling.   
2.7 Indirect Immunofluorescence Microscopy 
2.7.1 Detection of collagen-coated tissue culture coverslips 
Tissue culture coverslips (Electron Microscopy Sciences) were coated with 10ug/cm2 
Collagen I and Collagen V (Sigma Aldrich Pte. Ltd), and their presence detected with 
the use of specific antibodies. The coverslips were incubated with anti-Collagen I, 
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anti-Collagen V and the control mouse IgG antibodies respectively, overnight at 4C. 
After washing three times with PBST for 5 minutes each time, the cells were 
incubated with Alexa Fluor 555-conjugated secondary antibodies in 0.1% bovine 
serum albumin in PBS buffer for 1 h at room temperature, and subsequently mounted 
with 70% Glycerol in PBS. Immunofluorescence microscopy was performed with a 
Zeiss Axiovert 200M microscope. 
2.7.2 Detection of cardiac myofibrillar proteins 
CLCs were cultured on round glass coverslips (Electron Microscopy Science) at a 
seeding density of 5000 cells per (24-) well for 14 days in the myogenic development 
medium, MDM. The cells were first washed in a phosphate buffered saline containing 
0.025% Tween 20 (PBST) and fixed in 4% paraformaldehyde and permeabilized with 
0.1% Triton X-100 for 10 min each time, at room temperature. The cells were then 
washed in 5% bovine serum albumin for 1 hour to block nonspecific binding. The 
permeabilized cells were incubated overnight at 4C with primary or control IgG 
antibodies in 0.1% bovine serum albumin. After washing three times with PBST for 5 
minutes each time, the cells were incubated with Alexa Fluor 488-conjugated 
secondary antibodies in 0.1% bovine serum albumin in PBS buffer for 1 h at room 
temperature. Nuclei were stained with DAPI; cells were washed and subsequently 
mounted with prolong Gold. Immunofluorescence microscopy was performed with a 
Zeiss Axiovert 200M microscope equipped with 40x and 63x oil immersion lens.  
2.7.3 Cardiac-specific promoter-driven EGFP reporter assay 
The -myosin heavy chain promoter driven construct was a generous gift from 
Professor Loren J. Field (The Indiana University School of Medicine), while the 
myosin light chain 2v promoter driven EGFP plasmid was kind donation by Dr. 
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Jennifer Moore (Department of Physiology, The McKnight Brain Institute). The 
265bp fragment of the  myosin heavy chain promoter (kindly provided by Professor 
Giuseppe Inesi at the School of Medicine, University of Maryland), was subcloned 
into the pEGFP-2 (Clontech) using BamHI/EcoRI restriction sites. All constructs 
were verified with restriction digestion and sequencing analysis. The promoter-less 
plasmid was transfected as a control. All plasmids were transiently transfected into 
MSC-derived cardiomyocyte-like cells with Fugene6 (Roche). Subsequently, the 
transfected CLCs were selected with 25ug/ml G418 for 2 weeks to a month. 
Neomycine-resistant clones were subsequently analyzed for the presence of green 
fluorescence under a Zeiss Axiovert 200M confocal microscope at 40x magnification. 
2.8 Golgi Disruption 
Cells were trypsinized and replated on coverslips in 24-well plates at a seeding 
density of 10k cells per well. Cells were incubated with 500nM sodium monensin for 
an hour at room temperature before washing with ice-cold PBS and fixing with ice-
cold 4% paraformaldehyde. Treated cells were subsequently stained sequentially for 
the cardiac MHC and human Golgin97 and visualized under a Zeiss Axiovert 200M 
microscope at 20-40x magnification. 
2.9 Cell-labeling and detection 
For the low-dose cell therapies, MSCs and CLCs were incubated with 10uM BrdU 
(Roche Applied Sciences) at 37C for 48 hours. Subsequently, cells were washed 
thoroughly with PBS for 15 minutes, and resuspended in a final concentration of 1 
million cells/ 250 mL. This volume compensates for dead space. For the high-dose 
cell therapies, CLCs were incubated with 1uM Vybrant CellTracker CM-DiI at 37C 
for 48 hours, while MSCs were trypsinzed and incuated with 10uM Vybrant CFDA-
SE at 37C for 15 minutes. CM-DiI labeled CLCs were excited at 546nm using a 
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Helium-Xenon lam and emission was acquired at 615-665nm. CFDA-labeled MSCs 
on the other hand were verified with an anti-fluorescein AlexaFluor 488-conjugate 
antibody which was excited at 492nm using a Helium-Xenon lamp. Emission for 
CFDA fluorescence was acquired at 500-530nm. All fluorescence were detected with 
a Zeiss Axiovert 200M fluorescence microscope and visualized with Metamorph 
version 6.2 software.  
2.10 Rat myocardial infarction models 
A rat model of myocardial infarction was developed in female Wistar rats weighing 
200-250g in body weight. Animals were anesthetized with a ketamine (100mg/ml)/ 
valium (5mg/ml) cocktail at a dose of 0.1ml per 100g body weight via intramuscular 
administration. A left thoracotomy was performed while the rats were intubated 
through intratracheal ventilation at a tidal volume of 2.5 mL (85 cycles/min). The left 
anterior descending (LAD) coronary artery was identified and permanently suture-
ligated with a 7-0 polypropylene snare. One week post infarction, the rats were 
subjected to an ultrasound echocardiography assessment prior to another thoracotomy 
before 1 million BrdU-labled cells, 5 million CFDA-labeled MSCs (n=20 rats) or 
CM-DiI labeled CLCs (n=20 rats) or serium-free medium (n=23 rats) were injected 
intramyocardially around the peri-infarct regions of the compromised myocardium. 





 cells per 0.2ml serum free medium (NGM) respectively. Cyclosporine was 
administered daily at a dose of 5mg/kg following cell transplantation. Six weeks post 
LAD-ligation, the rats were subjected to another ultrasound echocardiography 
assessment as well as a real-time in vivo pressure-volume catheterization before hearts 
were explanted. Post-mortem was conducted immediately following death of animals.   
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2.10.1 Ultrasound echocardiography assessments 
All rats were gas anesthetized with 1.5% isoflurane and positioned left lateral 
decubitus on a wooden table. The chests were shaved and cleaned with methylated 
spirit. Transthoracic echocardiographical assessments were performed with a 
commercially available ultrasound system equipped with a 13-MHz linear array 
transducer (i13L) (Vivid 7 GE-Vingmed). Cardiac function was assessed as baseline 
determinations, 1 week post-LAD ligation and 6 weeks post therapy. Recordings were 
made under continuous ECG monitoring by securing the electrodes on the back, Grey 
scale images were recorded in a parasternal short axis view at a depth of 2 cm. M-
mode tracings were recorded from the parasternal short axis view at the papillary 
muscle (mid-LV) level at a speed of 200mm/s. Data was analyzed in the offline 
system (Echopac). LV dimensions were measured from 3 consecutive cardiac cycles 
on the M-mode tracings. LV ejection fraction was calculated using the modified 
Quinones method, while LV fractional shortening was calculated as (LVIDed-
LVIDes)x100%/LVIDed. 
Multiple pairwise comparisons were conducted between rats in the respective 
treatment groups for in vivo assessment of cardiac function. For ultrasound 
echocardiography assessment, normalized changes in respective cardiac parameters 
measured were used as statistical variables and analyzed with Tukey‟s HSD or the 
Games-Howell post-hoc ANOVA analysis for samples with equal and unequal 
variances respectively. 
2.10. 2 In vivo hemodynamic measurements 
Surviving rats were allowed to recover for 6 weeks before being subjected to real-
time pressure volume catheterization. Animals were anesthetized with a ketamine 
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(100mg/ml)/ valium (5mg/ml) cocktail at a dose of 0.1ml per 100g body weight via 
intramuscular administration, and placed supine on a table. A 2-Fr microtip pressure-
volume conductance catheter specially designed for small animals (Millar 
Instruments, Houston, TX) was inserted into the right carotid artery and advanced into 
the left ventricle. The position of the catheter was visualized and guided by ultrasound 
echocardiography. The volume calibration of the conductance system was performed 
according to Pacher et al‟s methodology. At experimental endpoint, 50 uL of 15% 
hypertonic saline was injected intravenously, and the shift of PV relationships parallel 
conductance volume (Vp) was derived using PVAN3.2 (Millar Instruments) to correct 
for cardiac mass volume and interference from baseline interference from the 
immediate peripheral tissues. Preload independent indices were obtained via the 
depression of the inferior vena cave with a sterile cotton swab for 7 seconds. Upon 
completion of all steady state and preload-independent hemodynamic measurements, 
rats were injected intraperitoneally with an overdose application of 70mg/kg of 
sodium pentobarbitals while still subjected to general anesthesia. Hearts were 
perfused with 0.9% saline, explanted and embedded in OCT, frozen in liquid nitrogen 
and stored at -80C. Tissue heart sections were prepared with a cryostat and cut to 
5um.  
2.10.3 Detection of human nuclei 
Explanted hearts were frozen fresh and sectioned to 5m. Cryosections were 
rehydrated in PBS for 10 minutes and post fixed in 4% paraformaldehyde for 15 
minutes before permeabilization with 0.5% Triton X-100 for 30 minute and blocking 
in 5% bovine serum albumin containing 0.25% Triton X-100 (PBSTx). Cells were 
incubated with a specific anti-human nuclei antibody (Millipore) in PBSTx for 4 
hours, washed thrice with PBSTx for 15 minutes at room temperature and incubated 
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with Alexa Fluor 488-conjugated secondary antibodies in PBSTx for 1 hour at room 
temperature. Visualization of nuclei and general tissue sections was performed as 
described in the following section. 
2.10.4 Fluorescence microscopy of frozen tissue sections 
For detection of other cardiac myofibrillar proteins, frozen tissue sections were fixed 
in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 for 10 minutes, and 
blocked in 5% bovine serum albumin (BSA) before overnight incubation with 
primary antibodies against fluorescein, cardiac troponins –I and –T, -actinin, 
MHC, connexin 43, von Willebrand factor, smooth muscle actin, the proliferating 
cell nuclear antigen (PCNA) and collagens –I, -III and –V diluted in 1% BSA at 4C. 
Washing steps were carried out with phosphate buffered saline supplemented with 
0.25% Triton X100. Cells were incubated with Alexa Fluor 488/555/660-conjugated 
secondary antibodies in 0.1% bovine serum albumin in PBS buffer for 2 hours at 
room temperature. Nuclei were stained with DAPI. Immunofluorescence microscopy 
was performed with a Zeiss Axiovert 200M fluorescence microscope and visualized 
with Metamorph version 6.2 software.  
2.10.5 Microvessel density count 
Following von Willeband factor staining, tissue sections were visualized with 
fluorescence microscopy. Random fields in the locale of cell engraftment in the mid-
anterior section of the infarcted myocardium were selected for vessel counting at 
200x magnification (20x objective lens and 10x ocular lens). A microvessel was 
defined as any immunofluorescent stained endothelial cell, while presence of a lumen 
was not necessarily defined as a microvessel. Microvessel counts were derived from 
an average of 3 areas per stained tissue section. Counts were further taken from 3 
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fields in each selected area. Microvessel density count was expressed as the average 
number of microvessels identified within the 200x fields.  
2.10.6 Statistical analysis 
All statistics were analyzed with SPSS version 13. A one-way ANOVA was used to 
determine statistical significance between groups. Tukey‟s Highly Significant 
Difference (HSD) post-hoc analyses were used to determine statistical significance 
between treatment groups for samples with equal variances, while significance for 
samples with unequal variances was calculated with the Games-Howell post-hoc 
analyses. Homogeneity of variances was tested using the Levenne‟s statistic.     
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Chapter Three: Results 
This project investigated the relative efficacies of undifferentiated human 
mesenchymal stem cells (MSCs) vs. MSC-derived cardiomyocyte-like cells (CLCs) 
as a cell-based therapy for the treatment of chronic heart failure in a rat myocardial 
infarction model. Furthermore, ECM that plays central roles in many vital aspects of 
the electrically active myocardium including cell survival, differentiation, 
proliferation, metabolism and regulation of resident cardiomyocytes, cardiac 
progenitor cells and stem cells were examined. This chapter is sectioned 
systematically into: 
i. Comparative in vitro characterization of sternum-derived mesenchymal stem 
cells (MSCs) vs. MSC-derived cardiomyocyte-like cells (CLCs);  
ii. Examination of physiological roles of extracellular matrices on the cell fate 
and development of CLCs; 
iii. Comparative analyses of the respective therapeutic efficacies of high- and 
low- dose MSC- vs. CLC- therapy via ultrasound echocardiographical 
assessments, real-time in-vivo pressure volume hemodynamic measurements 
and comparative histological assessments.  
iv. Investigation into possible cell-mediated cardiac repair mechanisms in vivo  




Figure 5. Schematic map showing an overview of how the various project objectives and specific aims integrate with one 
another and collectively form the framework of this study. 
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3.1 Isolating Sternum-Derived Mesenchymal Stem Cells 
3.1.1 Isolation of Bone Marrow Mesenchymal Stem Cells (MSCs) 
After informed consent, bone marrow aspirates were obtained from 30 male and 15 
female patients (mean age = 58.9 ± 11.4 years) undergoing open heart surgery. MSCs 
were isolated from bone marrow mononuclear cells via Histopaque-Ficoll density 
gradient centrifugation. Sternum-derived cells isolated via this standard purification 
method were negative for CD31 expression but exhibited low CD34 expression 
levels. Consistent with adult bone marrow mesenchymal stem cell, these cells were 
also positive for CD44, CD90, CD105 and CD106 (Figure 6).  
MSCs were further identified by colony forming units comprising of cells with a 
fibroblastic-like morphology after adhering to tissue culture plastic following 
purification in a standard density gradient. This passage was designated P0. 
Subsequent MSC passages were characterized by a rapid proliferation rate, which 
declined progressively in the mid passages (6-9). The patient-derived bone marrow 
stem cells demonstrated plasticity consistent with mesenchymal stem cells since they 
differentiated into bone and fat (Figure 7) upon induction in specific induction media. 
3.1.2 Patient-derived cells can differentiate into osteoblasts and adipocytes  
The hallmark of bone marrow stem cells is their multipotent plasticity. CD34+ 
CD44+ CD90+ CD105+ and CD106+ bone marrow cells were induced to become 
osteoblasts and adipocytes (Figure 7), and subsequently cardiomyocyte-like cells 
(discussed extensively in later sections) and were established as bone marrow MSCs. 








Figure 6. Patient-derived cells isolated via standard purification techniques demonstrated a low 
expression of CD34, and were positive for CD44, CD90, CD105 and CD106, 40x magnification.  






Figure 7. Patient-derived bone marrow cells can be induced to undergo osteogenic and adipogenic differentiation.  
Cells isolated from the sternum of patients are bone marrow stem cells. Von Kossa stainings in Figure 7A(i) shows mineral deposition (black 
deposits) in these cells upon induction with an osteogenic induction medium, while green fluorescence in Figure 7A(ii) shows positive alkaline 
phosphatase activities in the sternum-derived cells.  Mineral deposition and high alkaline phosphatase activity are characteristic of osteocytes. B. The 
presence of red oil deposits indicates that these cells have been successfully induced to become adipocytes.  Cells were counterstained with 
hematoxylin to visualize the nuclei.  
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3.2 Developing a myogenic development medium  
This project extends from an earlier study, which had reported that MSCs can be 
differentiated into cardiomyocyte-like cells
118
 that expressed multiple cardiac 
myofibrillar proteins and transcription factors.  
RT-PCR showed that the expression profile of such differentiated CLC expressed 
cardiac transcripts consistent with human adult cardiomyocytes. Moreover, cells 
cultures induced with MDM promoted the enhanced expression of cardiac transcripts 
such as Troponin -C and -T throughout 28 days in vitro as compared to other 
differentiation methods using demethylation or acetylation techniques (Figure 8).  
Further characterization studies show that different isolates of MSCs treated with this 
simple and non-toxic myogenic development medium, MDM, showed a stable and 
reproducible expression of many cardiac-specific myofibrillar proteins and 
transcription factors that were consistent with the previously characterized CLCs. 
Furthermore, the cardiomyogenic profile of these CLCs was stable after prolonged 
























Figure 8. Gene expression profile of differentiating mesenchymal stem cells (MSCs) 
following exposure to 5-azacytidine (AZA), butyric acid (BA) or previously developed 
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3.3 In vitro characterization of MSCs and MSC-derived CLCs 
Bone marrow aspirates were isolated from the sternum of 45 patients undergoing 
open- heart surgery. These were subjected to negative selection with specific 
antibodies to cells belonging to the mature blood lineages, and further purified in a 
Histopaque-Ficoll density gradient. Plastic- adherent MSCs were used in subsequent 
studies. In all experiments, MSCs were cultured in MDM to derive cardiomyocyte-
like cells for at least 7 days. Differentiation of early-passage MSCs (passage 0-3) into 
cardiomyocyte-like cells after 2 weeks of culture in MDM was accompanied by a 
change from spindle to stellate morphology (Figure 9). Importantly, MDM had a 
significant effect on cell proliferation from the 5th day in culture, and eventually led 
to a significant 4-fold increase in cell numbers at the end of 11 days (Figure 10). 
CD34 and CD45 are cell surface markers typically associated with hematopoietic cell 
types, while CD31 and CD106 are typical endothelial cell markers. Consistent with 
histological stainings in Figure 6, MSCs did not express any of these cell surface 
proteins but expressed high levels of CD44, CD90 and CD105 as consistent with a 
cells belonging to mesenchymal lineage. MSCs of similar passage number were 
cultured in MDM for 7 and 14 days.  
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Figure 9. Induction of MSCs in MDM coincided with a change in morphology from 





Figure 10. Differential cell proliferation rates in MSCs and CLCs. MDM promoted the 
significant expansion of differentiating MSCs. 









Figure 11. Gene expression profiles of MSCs and CLCs after 7 and 14 days in the 
respective culture media.  
Figure (i) shows the spontaneous expression of several cardiac-specific proteins in MSCs, 
which disappeared after 14 days in culture. In contrast, the expression of the same markers 
was sustained in MDM-treated MSCs after 2 weeks in culture. In addition, Figure (ii) shows 
the expression of additional cardiac markers in vitro after 14 days in MDM. However, the 
expression of the late-stage cardiac myofibrillar protein, Myomesin and the calcium channel, 
Ryanodine Receptor 2 was notably attenuated by the 14th day in culture.  
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Figure 11 shows that freshly isolated human MSCs spontaneously express some 
cardiac-specific proteins such as the cardiac-specific transcription factors GATA4 and 
Nkx2.5, cardiac troponin C and MLC2a as well as the cardiac-specific calcium 
channels IP3R2 and the L-type voltage gated 1c calcium channel. However, the 
expression of these proteins quickly diminished with time and disappeared by the 2nd 
week in culture. In contrast, MSCs differentiated in MDM showed sustained 
expression of these proteins. In addition, MDM also promoted the expression of other 
cardiac-specific proteins such as the cardiac transcription factors, Nkx2.3, Nkx2.8 and 
GATA6 as well as the cardiac myofilament, skeletal muscle  actin. MDM also 
induced expression of the mature cardiac myofibrillar protein cardiac, myomesin and 
the specific calcium channel, ryanodine receptor 2 (See Figure 11).  
Further characterization studies showed that MSC-derived cardiomyocyte-like cells or 
CLCs, expressed functional Nkx2.5 and GATA4. Both transcription factors displayed 
a strong nuclear localization (Figure 12A), which strongly suggests an “activated” 
state that is required to drive the expression of relevant downstream cardiac-specific 
proteins. GATA4 and Nkx2.5 are reportedly required for the lineage development 
preceding the expression of genes such as atrial natriuretic protein (ANP), myosin 
light chain (MLC)-2v, -myosin heavy chain (-MHC), -myosin heavy chain 
(MHC), and connexin 43 that are indicative of distinct maturation stages within the 
developing organ in vivo 
30, 31, 119, 120
. 
These transcription factors interact with other proteins to form a macromolecular 
protein complex that binds to specific sequences in the promoter regions upstream of 
the cardiac myosin heavy chains and the MLC2v mRNA121, 122. However, an 
aberration in any of the proteins forming the transcriptional machinery complex will 
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not drive the expression of any cardiac genes downstream of the promoter, regardless 
of their respective expression levels. Cardiac-specific promoter driven reporter assays 
were used to test for the functionality of these transcription factors responsible for the 
expression of the myosin heavy and light chains. In this assay, the MHC-, MHC- 
and MLC2v- promoters were cloned upstream of a reporter enhanced GFP gene 
(expression vectors were kindly provided by Dr LJ Field, Dr. G. Inesi and Dr. 
Jennifer Moore). Thus, green fluorescence in Figure 12 indicates that the cardiac 
transcription factors driving the expression of myosin heavy and light chains are both 
expressed and functional.  
 




Figure 12. Spatial expression and functional activity of cardiac transcription factors in CLC cultures.  
A. Prevalent nuclear localization of Nkx2.5 and GATA4 in CLC cultures. B. Green fluorescence strongly indicates that 
the transcription machinery, which includes Nkx2.5 and GATA4, driving the expression of the cardiac myosin heavy 
and light chains are expressed and fully functional.   
B 
A 
  57 
CLCs exhibited intense stainings of endothelial cell markers such as the vascular 
endothelial growth factor receptors, VEGFR2 and the smooth muscle -actin, that are 
typically associated with blood vessel formation (Figure 13A). Additionally, CLCs 
also expressed several calcium channels such as SERCA and especially the cardiac-
exclusive voltage gated 1c calcium channel that are critical in muscle contractility 
(Figure 13B).  
CLCs exhibit a distinct cardiac myogenic-like phenotype as they express a multitude 
of cardiac myofibrillar proteins including the cardiac troponins -C and –T, 
tropomodulin, phalloidin actin filaments as well as mature myofibrillar proteins like 
titin and the myosin heavy and light chains. More importantly, the punctate assembly 
of myofibrillar protein aggregates or Z-bodies, especially those of -actinin, into 
well-defined cross striations consistent with sarcomeres strongly suggests a 
developing contractile phenotype (Figure 13C).  Nonetheless, CLCs did not exhibit 
spontaneous beating. This suggested that CLCs while committed to a stable and 
distinct cardiac-like phenotype, they did not achieve terminal differentiation. This in 
turn implies that CLCs may still retain a certain degree of multipotency reminiscent of 
their stem cell origins and these cells may undergo dedifferentiation to develop into 
other mesenchymal-derivatives such as chrondrocytes and osteocytes among others. 
However, dedifferentiation was neither observed in prolonged CLC cultures (up to 11 
passages in vitro) nor in vivo, as fluorescent-labeled CLCs in the treated myocardium 
demonstrated distinct cross striations that were not distinguishable from host 
cardiomyocytes 8 weeks post-transplantation. Nonetheless, future preclinical 
investigations should including tracing the cell fate and development of CLCs in the 
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treated myocardium at 4, 6, 12 and 24 months post-transplantation to establish a 
stable CLC-derived cardiac development in vivo.      
3.3.1 Golgi-Localization of GATA4 and  Myosin Heavy Chain 
GATA4 is an early transcription factor that critically regulates embryonic 
development, cardiomyocyte
 
differentiation and stress responsiveness of the adult 
heart. GATA4 also promotes MSCs to transdifferentiate into a partial cardiac 
myogenic phenotype via an upregulation of the insulin growth factor binding protein 
4
123
. These cells have been observed to exhibit nuclear translocation of GATA4
124
, 
which correlates with -sarcomeric actinin expression during cardiac 
transdifferentiation. Consistent with a developing cardiac phenotype, CLCs but not 
MSCs, demonstrated an increased nuclear localization of GATA4 and 
correspondingly an enhanced cytoplasmic accumulation of MHC. More specifically, 
MDM induced protein transport into the relevant spatial compartments within the cell. 
Moreover, MHC assumed a myofibrillar appearance in the cytoplasm that was 
consistent with a cardiac differentiated state. This further supported MDM-treated 
MSCs differentiation into cardiomyocyte-like cells.  Interestingly however, patient-
derived MSCs and CLCs also exhibited a persistent Golgi-localization of GATA4 and 
 myosin heavy chain (Figure 14-15).  
It has been reported that certain MHC antibodies may recognize the -COP protein 
that is ubiquitous in the Golgi Apparatus
125
. However, the Golgi-retention of MHC 
in particular was consistent with 3 different antibodies to MHC. Moreover, when 
applied to neonatal rat cardiomyocytes, these same antibodies did not illustrate the 
Golgi-retention of MHC. Moreover, MHC took on a parallel swollen appearance 
when the Golgi Apparatus was disrupted with sodium monensin (Figure 16), which 
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further verified a specific interaction between MHC and the Golgi-apparatus. 
However, Figure 15 also shows that the cytoplasmic localization of MHC in CLCs 
was not affected by Golgi disruption with 500nM of monensin. This in turn suggests 
that cytoplasmic trafficking and fibrillogenesis of MHC may be independent of the 
Golgi apparatus.  
The golgi-localization of cytoplasmic proteins, myosin in particular, is not new. 
However, the myosins that associate with the Golgi apparatus are the non-
conventional myosins such as myosin II, which are implicated in vesicular transport 
of secretory proteins or in the maintenance of structural integrity of the Golgi 
Apparatus. It remains to be determined if MHC also played an alternative 
developmental role in maintaining the structural integrity of the Golgi Apparatus or 
the cytoskeletal architecture of the increasingly cardiac-like CLC. 
The golgi-localization of these proteins is recurring phenomenon in patient-derived 
MSCs and MSC-derived CLCs. GATA4 has been implicated in driving the 
expression of MHC. The golgi-localization of both GATA4 and the myosin heavy 
chain implicates the Golgi apparatus in playing an important role in the regulation of 
cardiac differentiation and myofibrillogenesis of MHC in differentiating CLCs. This 
is discussed further in Chapter 4 of this thesis.  
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A. Endothelial markers 
 
 
B. (Cardiac) Calcium channels 
 
 
Figure 13 A-B. CLCs express endothelial marker proteins and several calcium channels that are critical for cell contractility 
including the cardiac-exclusive ryanodine receptor 1/ 2and the voltage gated L-type 1c calcium channels.  
… continued next page 
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C. Cardiac Myofibrillar Proteins 
 
 
Figure 13. Characterization of protein expression in CLCs. 
A. CLCs express endothelial protein markers and may thus possess an inherent propensity for 
endothelial differentiation. B-C: CLCs also express a myriad of cardiac specific myofibrillar 
proteins such as the cardiac troponins, well developed actin filaments, cardiac myosin heavy and 
light chains and titin. C. More importantly, the appearance of well-defined cross-striations, 
especially distinct with -actinin stainings, strongly suggests a developing contractile phenotype. 
All fluorescence were detected with a Zeiss Axiovert 200M fluorescence microscope and 
visualized at 63x magnification (oil immersion lens) with Metamorph version 6.2 software. 






Figure 14. Golgi-localization of GATA4 in MSCs and CLCs.  
(A) shows that GATA4 expression in both undifferentiated MSCs and cardiomyogenic CLCs was predominantly localized to the Golgi 
Apparatus, although CLCs also exhibited an enhanced nuclear localization of the cardiac transcription factor that is strongly indicative of 
an activated cardiac differentiated state. (B) shows the colocalization of the GATA4 transcription factor with a resident trans Golgi network 
(TGN) protein, Golgin 97. This further verifies the spatial expression of GATA4 in the trans-Golgi network. 
A 
B 
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Figure 15 Spatial expression of MHC in MSCs vs. CLCs. 
Immunofluorescence analysis shows the colocalization of the cardiac -myosin heavy chain with human golgin 97 in both 
MSCs and CLCs. This golgi-localization was consistent with 3 different specific antibodies to MHC, and is a persistent 
occurrence in more than 95% of either cell types. There is however increased cytoplasmic localization of MHC in 
MDM-treated MSCs. This spatial expression of MHC in the cytoplasm resembles the cytoplasmic accumulation of Z-
bodies prior to their coalescence into Z-bands in early sarcomeric development. Hence, the Golgi-retention of MHC may 
be a property of the undifferentiated state. Nonetheless, the differentiated cell types (CLCs) still retained a relatively 
intense MHC expression in the golgi apparatus. This may be explained by the fact that MSC-derived CLCs have not yet 
achieved terminal differentiation, despite being committed to a distinct cardiac lineage.  








Figure 16. Cardiac  myosin heavy chain (MHC) takes on a parallel swollen appearance as the Golgi 
Apparatus is dispersed in MSCs and CLCs with 500nM monensin.   
The cytoplasmic localization of  myosin heavy in CLCs was not affected by golgi disruption with 500nM monensin. This in 
turn suggested that cardiac MHC fibrillogenesis may be independent of the Golgi apparatus.  
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3.4 The roles of extracellular matrices on the cell fate and 
development of CLCs 
Heart failure is a debilitating clinical manifestation of an acute myocardial infarction 
(MI) and is typically characterized by active remodeling of the compromised 
myocardium. Fibrosis and ventricular remodeling are inherent pathophysiological 
responses to an acute myocardial infarction and begins with elevated extracellular 
matrix (ECM) deposition
126
.  Subsequent deregulation of matrix synthesis occurs as 
an inadvertent process of (negative) ventricular modeling post-infarction as changes 
to the composition, organization and fibril orientation of the myocardial extracellular 
matrices (ECMs) constitute principal processes in restructuring cardiac geometry 
during active ventricular remodeling. This ultimately „stiffens‟ the myocardium and 
leads to deleterious consequences as an increasingly noncompliant myocardium 
inadvertently exacerbates ventricular dysfunction.  
There is increasing evidence that the myocardial ECMs may be a dynamic link 
between electromechanical function and the macroscopic architecture of the 
myocardium. It is possible that remodeled myocardium may secrete interstitial ECM 
substrates (or other secretory proteins such as inflammatory cytokines, etc) into the 3-
dimensional microenvironment of resident/stem cells in the cardiac syncytium. In 
turn, these myocardial ECMs may influence critical cellular processes such as cell-
survival, proliferation and differentiation via the engagement of specific integrins on 
resident/stem cells in vivo. The interstitial collagens are integral constituents of the 
myocardial ECMs. Specifically, Collagen I and III represent the major components of 
the myocardial ECMs while collagen V is a minor but important collagen subtype that 
regulates matrix assembly and tissue stiffness
127, 128
. It is not well studied if ECMs 
play significant roles in the proliferation and cardiac transdifferentiation of primitive 
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human mesenchymal stem cells (MSCs).  Furthermore, the pathophysiological 
effect/s of myocardial fibrosis and post-infarct ventricular remodeling on stem cell 
survival, engraftment and differentiation in the infarcted myocardium also remains 
poorly understood.  
This section seeks to understand the roles ECM substrate molecules and their 
extracellular matrix ligands in the cellular physiology of MSC-derived 
cardiomyocyte-like cells (CLCs). More specifically, this study aims to identify an 
appropriate extracellular matrix that would 
i. Promote the large-scale expansion of MSC-derived cardiomyocyte-like cells 
in vitro and  
ii. Sustain/ promote a distinct cardiac-like phenotype in vitro and in vivo.  
3.4.1 Collagen V enhances cellular adhesion and proliferation of CLCs 
To test for the effects of extracellular matrices on human mesenchymal stem cells, 
patient-derived MSCs were cultured on various ECM substrata including fibronectin, 
gelatin, laminin, poly-L-lysine, vitronectin and the collagen types I, III, IV and V. As 
is evident in Figures 17-20 and further verified with ANOVA analyses, CLCs 
expanded significantly on collagen V matrix through enhanced initial cell attachment 
and cell survival. In contrast, laminin was among the least supportive substratum for 
cell attachment, p > 0.05 (See Figure 17). This result is consistent with Conget et al‟s 
and Phinney et al‟s findings that laminin matrices do not encourage cell adherence129, 
130
.  
Collagens –I, -III and –V constitute the predominant components of the interstitial 
ECM in the myocardium. CLC-attachment on the collagen extracellular matrices in 
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vitro showed that the number of total cells adhered to pre-coated collagen surfaces 
increased with respect to those cultured on uncoated tissue culture (TC) plastic 
surfaces. CLCs (1.39 ± 0.23 fold) cultured on Collagen I extracellular matrices 
showed a trend towards enhanced initial cellular attachment. However, this did not 
achieve statistical significance. Similarly, collagen III matrix, another major collagen 
subtype found in the heart, did not support a significant adhesion of CLCs and MSCs  
(Figures 17-18). In contrast, CLCs showed preferential interaction with collagen V 
substrate molecules, resulting in a significantly enhanced initial cellular attachment 
(1.97 ± 0.54 fold, p<0.01) (Figures 17-18). 
Collagen V supported the highest attachment of CLCs as compared to those cultured 
on collagens -I (p=0.06) matrices. The simultaneous effect of MDM and collagen V 
extracellular matrices promoted a synergistic increase in CLC proliferation that 
persisted throughout 11 culture days (Figure 19-20), as CLCs expanded a further 8-
fold from a simple culture in MDM on uncoated TC plastic surfaces (Figure 19-20). 
In addition, CLCs cultured on collagen V ECM persistently demonstrated enhanced 
expansive rates (in relation to CLCs cultured on collagen I matrices). As seen in 
Figure 19, this benefit persisted throughout the entire study period, and resulted in a 
29.3 ± 13.5 fold increase (p<0.05) in CLCs expanded on collagen V, as compared to a 
7.4 ± 2.9 fold expansion in CLCs cultured on collagen I matrices on the 11th culture 
day. Collectively, these observations suggest that a significant initial attachment-
dependent survival, which is achieved via CLCs‟ preferential interaction with 
collagen V substrates, is important for subsequent expansion of CLCs on a large 
scale. 
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Figure 17. CLCs were harvested and seeded on tissue culture plastic surfaces pre-coated 
with various ECM substrates.  
These include fibronection, collagens I, III, IV and V, gelatin, Laminin, poly-L-lysine and 
vitronectin. Of the 9 ECM substrates tested, only Collagen V promoted a significantly 
enhanced adherence-dependent cell survival in CLCs with respect to CLCs that were 
expanded on uncoated tissue-plastic surfaces.  
 
 
Figure 18. CLCs demonstrate preferential affinity for collagen V ECM. 
Collagen V, but not collagens -I and -III, promotes a significant attachment off the 
differentiating cells 1 day after cell seeding on surfaces pre-coated with the respective 
collagen ECM. In contrast, MSCs did not demonstrate preferential interactions with Collagen 
V ECM. *p<0.01 vs. MSCs on collagen V. 
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Figure 19. Collagen V ECM promotes enhanced adherent-dependent survival of CLCs.  
CLCs‟ significant initial attachment on collagen V extracellular matrices resulted in 
significant expansions that persisted throughout 11 days. In contrast, CLCs did not proliferate 
significantly on collagen I. Data were normalized to day 3 control that was seeded on 




Figure 20. Large scale expansion of CLCs on collagen V ECM.  
Collagen V was the only 1 of the 9 ECM substrates tested to promote a significant increase in 
expansive rate as compared to CLCs that were expanded on uncoated tissue culture plastic 
surfaces. This benefit was initiated as early as the first day and persisted for 2 weeks in 
cultures.   
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Figure 21. Red fluorescence verified that the tissue culture plastics were indeed 
pre-coated with Collagens -I and -V molecules respectively. 
 
 
Figure 22. Quantitative assessment of cardiac gene expression levels in CLCs expanded 
on collagens -I and -V substrata via densitometry.  
All gene expression levels were normalized to the expression level of the housekeeping gene, 
-actin. CLCs cultured on collagen I matrices exhibited persistently attenuated expression 
levels of several cardiac-specific proteins, while collagen V matrices enhance selective 
cardiac gene expression in cardiomyocyte-like cells. Gene expression of cardiac transcription 
factors and sarcomeric myofilaments, but not ion channels, was upregulated in collagen V 
cultured cells. Densitometric assessments of cardiac gene expression were measured as Mean 
 SD arbituary units normalized to the  actin expression levels in CLCs cultured on 
Collagen I and V ECM respectively. 
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3.4.2 CLCs demonstrated enhanced cardiac differentiation on Collagen V 
matrices 
As shown in Figure 21, red fluorescence verified that the pre-coated surfaces were 
indeed coated with the respective collagen substrate molecules. CLCs cultured on 
collagen V matrices demonstrated enhanced expression levels of the cardiac 
transcription factors, GATA4 and Nkx2.5, as compared to collagen I-cultured CLCs 
(Figure 22). Consistently, downstream gene expression of ryanodine receptor-2 
(RyR2), skeletal muscle α actin, troponin C and troponin T was similarly enhanced in 
CLCs that were expanded on collagen V matrices.  
Images obtained via DNA gel electrophoresis were subjected further to densitometry 
to obtain a quantitative assessment of the relative gene expression levels of the 
respective cardiac-specific markers in CLCs that were expanded on collagen I vs. 
collagen V ECMs (Figure 22). CLC-interaction with collagen I ECMs resulted in the 
attenuated expression of several cardiac specific transcription factors such as GATA4 
and Nkx2.5, the ryanodine receptor 2 (RyR2), which is in turn a cardiac-exclusive 
intracellular calcium channel that releases calcium from the sarcoplasmic reticulum; 
and several myofibrillar proteins including troponins -C and –T, the cardiac -actin 
and the cardiac skeletal  -actin. However, the gene expression of MEF2C, 
connexin43, IP3R2, L-type calcium channel α1c subunit and cardiac α actin remained 
relatively unchanged in relation to the 2 collagen subtypes (Figure 22). The same 
observations were further vindicated in a comparative analysis of gene expression 
profiles of CLCs cultured on competing ratios of collagen I: collagen V substratum 
(Figure 23). 
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Figure 23 shows enhanced expression levels of cardiac-specific proteins with 
increasing CLC-collagen V interaction. Conversely, CLCs demonstrated decreasing 
cardiac expression with increasing CLC- collagen I interaction (Figure 23). Thus, 
collagen V matrices promote and support the distinct cardiac-like gene expression in 
CLCs. More importantly, the expression of these cardiac-specific proteins remained 
stable in prolonged cultures, thus supporting the persistence of a distinct cardiac-like 
phenotype in the differentiating CLCs on Collagen V ECM (Figure 24).  
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Figure 23. Relative cardiac gene expression in CLCs cultured on competing 
Collagen I: collagen V substrata.  
CLCs were expanded on competing collagen I: collagen V substrata with a 
final total collagen concentration of 10ug/cm
2
 in any 1 sample. Data is 
presented to show increasing collagen V concentrations toward the right, and 
increasing collagen I concentrations towards the left. 
 
 
Figure 24. Stable (gene) expression of cardiac specific myofibrillar 
proteins in prolonged CLC cultures. 
 
  74 
3.4.3 Study of relevant integrin signaling 
Cell-ECM interactions activate downstream intracellular signaling processes via the 
heterodimerization of relevant integrin subunits. Cellular interaction with collagens 
reportedly involves the engagement of the 11, 21 and V3 heterodimeric 
integrins 
104
. The human-specific antibody against the 11 integrin heterodimer was 
commercially unavailable at the point of writing and studies investigating the role of 
11 in cellular adhesion on collagen types -I and -V extracellular matrix surfaces 
were thus excluded in this thesis.  
Flow cytometry analysis showed that more CLCs expressed higher levels of the 21 
(50.2  17.2% vs 34.2  23.2% in MSCs) and v3 (56.5  21.4 % vs. 33.1  25.5 % 
in MSCs) integrin at basal levels relative to MSCs (Figure 25), while, the v and 3 
integrin was upregulated in CLCs on collagen –I and –V extracellular matrices Table 
2. In particular, CLC-attachment on collagen -I and especially collagen -V surfaces 
was significantly attenuated upon the functional blocking of the 21, v3 and 1 
integrins (Figure 26B). These observations suggest that cellular attachment of CLCs 
on collagen –I and especially collagen -V surfaces involve the engagement of these 
integrins. As less MSCs express these integrins at basal levels (Figure 18), they do not 
exhibit preferential interaction with collagens I and V extracellular matrices.  
Notably, the v and 1 integrin subunits constituted the majority of integrin family in 
CLCs regardless of matrix surface. CLCs expressed the 1D integrin, which is 
selectively expressed by skeletal and cardiac muscle as well as endogenous levels of 
collagens –I and –V, and it is possible that they may secrete varying levels of the 
respective collagens when cultured on different ECM surfaces (Figure 26A). This 
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may lead to inadvertent variations in endogenous integrin expression as CLCs interact 
with the respective collagen matrix substrates. To circumvent possible confounding 
results, each treatment group was normalized to untreated CLCs cultured on the 
respective surfaces.  A paired t-test was then conducted against the IgG isotype 
control in each ECM group to analyze for significant attenuation in CLC attachment 
on each ECM surface.  
As shown in Figure 26B, CLCs treated with the IgG isotype control did not affect 
cellular attachment on any surface as indicated by an approximately equivalent ratio 
of IgG-treated CLCs to untreated CLCs on the respective surfaces (i.e. IgG-treated 
CLCs on collagen I ECM/ untreated CLCs on collagen I ECM ≈ 1). Initial CLC 
attachment on uncoated tissue culture plastic surfaces involves the engagement of the 
v3 integrin heterodimer and the 1 integrin subunits, since the inhibition of either 
integrin significantly attenuated cellular adhesion.  
Functional inhibition of 21 and 1 integrins on CLCs significantly attenuated initial 
cellular adhesion on collagen I (p<0.005 and p<0.0005 respectively) and collagen V 
(p<0.05 and p=0.06 respectively). Conversely, neutralization of v3 and v integrin 
inhibited adhesion of CLCs on collagen I (p<0.05 and p=0.06 respectively) but not on 
collagen V (p=0.09 and p=0.6 respectively), although functional blocking of the v3 
integrin in CLCs cultured on collagen V ECM trended towards low attachment on 
collagen V substratum with respect to IgG-treated CLCs on the same ECM surface. 
Figure 23B. Similarly, functional neutralization of the v integrin did not affect 
cellular attachment on collagen V surfaces as the number of v integrin- inhibited 
CLCs was approximately equivalent to the number of untreated CLCs). CLC 
adhesion also appeared to be primarily dependent on the 1 integrin subunit, as 
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inhibition of the 1 integrin mediated lower CLC-attachment on all tested surfaces 
(p=0.002 on uncoated surface, p = 0.001 on collagen I, p = 0.06 on collagen V coated 
surfaces). Likewise, inhibition of the 21 integrin heterodimer mediated a 
correspondingly marked decrease in CLC- attachment on collagens -I and -V matrices 
(Figure 26B). This is consistent with current literature that reported that the 21 
integrin heterodimer as an important receptor of triple helical interstitial collagens, 
such as collagens -I and -V.  
Cellular interaction with collagens predominantly involves the engagement of the 
11, 21 and V3 heterodimeric integrins
104
. This study shows that collagen V 
significantly enhanced CLC adhesion as compared to MSCs. This enhanced adhesion 
may possibly be attributed to a larger number of CLCs expressing the 21 and V3 
integrin heterodimers as compared to MSCs.  
With the exception of troponin T expression, functional blocking of the 21 integrin 
failed to have any significant impact on cardiac gene expression in CLCs that were 
cultured on collagen V matrix (Figure 27). In contrast, neutralizing the v3 integrin 
with higher concentrations of the specific function-blocking antibody to the (integrin) 
heterodimer significantly reduced expression of troponin T, skeletal muscle  actin 
and RyR2 expression in CLCs cultured on collagen V matrices (Figure 27). Thus, the 
V3 integrin may be a primary effector of a collagen V-centric response to CLCs in 
cardiac differentiation. However, GATA4 expression in collagen V-expanded CLCs 
remained inert to the functional neutralization of the v3 integrins, even after 
exposure to the highest concentration of v3 neutralizing antibody. This suggests that 
GATA4 expression is independent of 21 and v3 integrin-mediated signaling.  
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It remains to be elucidated if differential integrin signaling was responsible for CLCs‟ 
significantly enhanced adherence and expansion rates when exposed to collagen V 
matrix. More importantly, CLCs cultured on collagen V matrices retained the 
expression of cardiac-specific myofilamental proteins, as these partially cardiac 
differentiated stem cells retained the appearance of nascent Z-body aggregation 
reminiscent of developing cross striations that are in turn characteristic of sarcomeres 
(Figure 28). Therefore, collagen V extracellular matrices support an emergent 
contractile phenotype in the differentiating CLCs.   
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Figure 25. Flow cytometry analysis of integrin expression in MSCs 
and CLCs. 
MSCs and CLCs also express the 21 and v3 integrin heterodimers, 
which reportedly interact with the interstitial collagens, including the 
collagen subtypes -I and -V respectively. CLC expressed higher levels of 
v3 and v3 integrin heterodimers than MSCs. Flow analyses derived 
from 3 independent experiments.   
 
Table 2. Human CLCs express 2, 1, v, 3, 21, and v3 integrins. The gene 
expression levels of the v and 1 integrins were markedly higher in CLCs cultured on 




Collagen I Collagen V 
2 33.3% 37.1% 
v 81.7% 79.2% 
1 81.4% 75.1% 
3 43.6% 38.7% 




Figure 26. Initial cellular-attachment of CLCs on collagen matrices is mediated via engagement of specific integrins.  
A. CLCs expressed the cardiac-specific integrin 1d as well as endogenous levels of collagens I- and V.  
All cell counts were normalized to the total number of untreated CLCs on the respective ECMs to circumvent possible confounding experimental 
variations due to endogenous collagen or integrin expression. B. CLC-attachment on uncoated tissue culture plastic surfaces is mediated via the 
engagement of the v3 and 1 integrins (p<0.05 vs. IgG control in either inhibition), while CLCs interact with collagen substrates via ligation of the 
21 integrin heterodimer (p= 0.026 vs. IgG control on Collagen V ECM, p = 0.001 vs. IgG control on Collagen I ECM). Additionally, CLC-
adhesion on collagen V matrix primarily engages 1 integrins (p=0.06 vs. IgG control), but not the v and v3 integrins (p>0.05 vs. IgG control on 
collagen V ECM). In contrast, CLCs‟ interaction with collagen I substrates involves the v3 (p=0.016 vs. IgG control) and 1 integrins (p<0.001 vs. 
IgG control). CLC attachment on any of the tested surfaces did not demonstrate selective integrin engagement in cell attachment. Data presented here 
is derived from 5 replicates. 
A 
B 




Figure 27. Dose-dependent effect/s of 21 and v3 integrin inhibition on expression 
levels of cardiac-specific proteins in CLCs that were expanded on collagen V 
extracellular matrices.  
Functional integrin blocking neutralized the effect of collagen V on cardiac gene expression 
in cardiomyocyte-like cells when administered in higher doses. In particular, inhibition of the 
v3 but not the 21 integrin heterodimer attenuated expression of troponin T, skeletal  
actin and RyR2 receptor. 
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Figure 28. CLCs expanded on 
collagen V extracellular matrices 
retained expression of several mature 
cardiac myofibrillar proteins.  
More importantly, these cells retained 
the distinct cross-striations that are 
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3.5 In vivo functional studies 
This section reports the findings of a comparative study investigating the respective 
therapeutic efficacies of (i) low- and (ii) high- dose cell therapies employing the use 
of (i) undifferentiated MSCs and (ii) CLCs in a rat myocardial infarction model. The 
full methodology for in vivo functional studies is summarized in Figure 29. As shown 
in Figure 30, the different sample sizes used in echocardiographical assessments and 
examination of PV relationships in the respective cell therapy groups was attributed to 
the high experimental attrition encountered in this survival model. One week after the 
creation of the rat MI model via the ligation of the LAD coronary artery, cell-treated 
rats, MSCs or CLCs were injected around the peri-infarct region of the myocardium 7 





MSCs or CLCs in a final volume of 0.2ml serum free medium. These rats were 
subsequently subjected to another ultrasound echocardiographical assessment as well 
as a real-time in vivo pressure-volume catheterization 6 weeks post-transplantation.  
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Figure 29. Flowchart summarizing experimental methodology for in vivo studies 




Figure 30. Surviving number of rats in the respective cell therapy groups pre- and post transplantation.  
The relatively high attrition observed in post-therapy assessments of pressure-volume relationships was attributed to a 
learning curve associated with unfamiliarity with a relatively novel experimental technique at the point of 
investigation. 





Figure 31. 2-Dimensional (2D) M-mode 
echocardiographical analyses show the disease 
progression of a sham-operated control rat.  
(A) A 2-Dimensional M-Mode echocardiogram of a rat 
myocardium at baseline demonstrates a robust 
contractility characteristic of a healthy rat. (B) 2D M-
mode echocardiographs of a representative media-
injected control rat illustrate a severe thinning of the 
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Figure 31C. Successfully myocardial infarction was created in rats in the respective 
treatment group as shown by significant functional decreases in LV ejection fraction from 
baseline levels post- LAD ligation. 
Table 3. Mean LVEF (%) of rats in the respective treatment groups at baseline, post-
ligation and 8 weeks post-therapy.  
*























































68.24 4.02 61.69 7.85 
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Figure 31 shows a 2-dimensional M-mode echocardiographical analysis of a 
representative rat in the medium-injected control group. Figure 31A depicts the 
healthy myocardium at baseline levels, while Figure 31B shows the myocardium of a 
representative serum-free media injected rat 6 weeks after injecting serum-free 
medium into the peri-infarct zones of the myocardium. Following ligation of the LAD 
coronary artery, control rats demonstrated severely thinned interventricular septa 
(IVS) with respect to baseline. Systolic wall thickening in these rats worsened 
progressively with time, following injection of serum-free media into myocardium, as 
can be seen in Figure 31B. At the same time, Figure 31B also shows that the LV 
internal diameter increased with time, suggesting progressive chamber dilatation in 
the control rat.  
Figure 31C shows that the successful creation of a myocardial infarction in all rats 
before they were randomized into the respective treatment groups as LVEF decreased 
significantly from baseline levels post LAD ligation. Baseline values were not 
significantly different among the different treatment groups. However, post-ligation 
values significantly differed between several groups despite randomization into the 
respective groups and the sonographer and surgeon being blinded to the study (Table 
3). Furthermore, post-ligation and post-therapy values of rats within each treatment 
group were plagued with large variations as reflective of inadvertently variable infarct 
sizes, which are in turn exemplified by the large standard deviations between groups. 
These variations may give rise to large standard errors, which may obscure actual 
functional improvements between treatment groups.   
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Normalized treatment-induced changes in multiple cardiac functions were calculated 
as follows to circumvent possible confounding factors due to the presence of large 




This method of calculation essentially used each rat as its own control and allowed for 
a more meaningful comparison of functional improvements effected by the respective 
therapies. This also eliminated the confounding factor of significantly different 
statistics that was present in the low dose cell therapy group post ligation and which 
may be attributed to the relatively smaller sample sizes in the respective low-dose cell 
therapy groups, as compared to the high dose cell therapy groups. In contrast, 
conventional comparisons between treatment and placebo groups in current clinical 
trials do not normalize measurements in cardiac function to pre-transplantation 
values. However, this approach is only applicable if the post-ligation reference values 
between treatment groups are not statistically different from one another. This was not 
the case in this study as post-ligation EF values were significantly different between 
rats in the respective treatments.  
 
Rats treated with a low-dose of MSCs and CLCs had a mean LVEF of 56.7  21.8% 
and 54.6 18.8% while control rats had a mean LVEF of 24.0  5.9% (Figure 32iv). 
Following normalization to post-ligation values, these translated into (0.76  28.99)% 
and (5.87  21.71)% as control rats deteriorated by (3.34  20.23)%. Rats 
administered with a high dose of CLCs and MSCs showed a mean improvement of 
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(7.14  8.39)% and (-0.76  7.1)% in LVEF respectively while control rats 
deteriorated by (11.3  11.4)%. This is consistent with current literature, which 
reports an improvement of 3 - 7% in LVEF in clinical trials (Table 1). 
Notwithstanding reportedly modest improvements observed in most clinical studies 
(Table 1), marked improvements in LVEF have been described in rare cases. For 
example, LVEF improved to 50.1% from 20.9% in a 32 year old man who had 
suffered end-stage cardiac failure from haemachromatosis secondary to red blood cell 
transfusions and was administered bone marrow stem cell transplantation
131
.  
Consistent with Figure 31A-C, 2D M-mode ultrasound echocardiography showed that 
serum-free media injected control rats injected with an equivalent volume of serum-
free media trended towards a progressive deterioration in cardiac function (Table 4). 
Multiple pairwise ANOVA analyses using Tukey‟s HSD post-hoc statistical analysis 
showed no significant differences between therapy groups. However, this particular 
study showed large experimental variability as shown by the large standard deviations 
reported in Table 4. Nonetheless, CLC-treated rats demonstrated consistent trends in 
smaller internal diameters and improved global cardiac functions such as ejection 
fraction and fractional shortening. 
In contrast, hemodynamic measurements derived from real-time intra-ventricular 
pressure-volume catheterization showed that low-dose cell- therapy mediated 
statistically significant improvements in cardiac functions. Consistently, control rats 
demonstrated severely dilated ventricular chambers as represented by enlarged end-
systolic (188.2  69.8 uL) and end-diastolic volumes (224.1  74.4 uL). In contrast, 
end-systolic volumes were significantly smaller in both MSC-treated (84.1  50.3 uL, 
p<0.01) and CLC-treated rats (71.7  50.8 uL, p<0.005).  Similarly, smaller end-
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diastolic volumes were observed in rats treated with MSCs (148.9 ± 49.1 uL, p<0.05) 
and CLCs (139.1  45.2 uL, p<0.05). These smaller cardiac volumes suggest that cell 
therapy attenuated negative LV remodeling in the cell-treated myocardium. It remains 
to be elucidated if cell-therapy actively or simply acted to prevent the progressive 
thinning of the interventricular septum walls (See Figure 32i-ii). 
Cell-therapy also mediated improvements in global systolic performance. 
Specifically, CLC-treated (56.7  21.8%, p<0.01 vs. control) and MSC-treated (54.6 
  18.8%, p<0.005 vs. control) rats demonstrated enhanced left ventricular ejection 
fraction (LVEF) with respect to control animals (25.0  5.9%). This translated further 
into significantly higher cardiac output in rats administered with CLCs (33073.6  
15018.3 uL/min, p<0.05) and MSCs (31498.8  11162.1 uL/min, p<0.05) 
transplantation, in relation to control animals (18111.2  3353.8 uL/min) that received 
serum-free medium injection (See Figure 32 iv-vi). 
Additionally, cell-therapy significantly enhanced myocardial systolic function as 
shown by the elevated maximum dP/dt levels in CLC- treated (13685.5  3870.7 
mmHg/s, p=0.06) and MSC –treated (12929.8  5547.8 mmHg/s, p=0.1) rats with 
respect to control animals (8316.6  4788.7 mmHg/s). Similarly, diastolic myocardial 
relaxation in rats treated with CLCs (10159.6  2838.5 mmHg, p<0.05) and MSCs 
(11118.1  4744.1 mmHg/s, p<0.01) exhibited significantly enhanced minimum dP/dt 
levels as compared to control animals (5391.2  2913.7 mmHg/s) (See Figure 32 iii).  
However, CLC- (66.5  27.8 mWatts, p<0.05), but not MSC- transplantation (60.5  
44.9 mWatts, p=NS), significantly improved maximal cardiac power relative to 
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serum-free media injected control rats (30.8  8.6 mWatts). Although not statistically 
significant, there was a trend towards considerably lower end-diastolic pressures in 
CLC-treated rats (8.5 ± 2.0 mmHg) as compared to MSC-treated (11.2 ± 9.4 mmHg) 
and control rats  (17.1 ± 27.7 mmHg). On the average, the Tau (Glantz) relaxation 
index in CLC –treated rats (14.9  3.5 msec) was also lower than both MSC- treated 
(17.5  7.0 msec) and control (18.5  3.2 msec) animals. These trends collectively 
suggest that CLC-therapy mediated better relaxation properties within the ventricular 
chambers, in turn mediating better tissue compliance, which ultimately leads to 
enhanced biomechanical efficiencies in the CLC-treated myocardium.  
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Table 4. Ultrasound echocardiography assessment of cell-treated rats. 
Measurements obtained via 2D ultrasound echocardiographical assessments show that CLC-therapy trended towards improvements in cardiac 
function, although these did not achieve statistical significance. In particular, the CLC-treated myocardium demonstrated trends in enhanced 
mid-anterior wall velocities and enhanced global contractility such as ejection fraction and fractional shortening with respect to serum-free 
media injected control animals. In contrast, MSC-treated rats trended towards little or no improvement in cardiac function with respect to 








Analysis of cell-mediated changes in cardiac functions by Ultrasound echocardiography 
assessments (Mean ± SD) 
Medium-injected 
control rats 
n = 10 
MSC-Therapy 
(1 million cells) 
n = 8 
CLC-therapy 
(1 million cells) 
n = 9 
p-value 
% changes in:     
Heart Rate -10.86 ± 8.98 -1.41 ± 13.69 -6.68 ± 11.51 NS 
IVSes 12.86 ± 33.66 14.66 ± 33.38 12.7 ± 18.71 NS 
IVSed 2.60 ± 13.90 6.61 ±17.81 2.68 ± 9.59 NS 
LVIDes 15.36 ± 20.51 16.09 ± 35.44 9.49 ± 20.60 NS 
LVIDed 11.44 ± 12.12 12.23 ± 15.79 10.00 ± 13.18 NS 
Systolic Wall 
Thickening 
98.59 ± 162.3 43.30 ± 86.19 48.88 ± 71.77 NS 
Ejection Fraction -4.43 ± 19.03 0.76 ± 28.99 5.87 ± 21.71 NS 
Fractional Shortening -3.34 ± 20.23 -333.9 ± 502.2 8.51 ± 24.33 NS 
Mid-Anterior Wall 
Velocity 
38.03 ± 176.82 28.18 ± 87.60 53.82 ± 99.87 NS 
  93 
 
Figure 32. Functional improvement in cell transplanted myocardium.  
In vivo pressure-volume catheterization showed that both MSC and CLC transplantation stabilized cardiac geometry by preventing chamber 
dilatation as demonstrated by significantly smaller end-systolic volumes and end-diastolic volumes in relation to control animals that received 
serum-free medium injection. Systolic activity and global contractile function was correspondingly significantly improved in MSC and CLC 
transplanted myocardium as compared to control animals. 
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Figure 33. Efficiency of BrdU-labeling in MSCs and CLCs.  
MSCs and CLCs were labeled with bromodeoxyuridine (BrdU) before cell transplantation.  




Figure 34. Identification of transplanted human stem cells in rat 
myocardium 6 weeks post transplantation.  
Co-localization of anti-BrdU (arrows) and anti-human nuclear (arrows) 
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Figure 35. Engraftment of BrdU-labeled CLCs in the cardiac syncytium in host 
myocardium.  
Immunofluorescent cell tracking showed that the integration of some human cardiomyocyte-
like cells (arrows) within the host myofibrillar architecture, while exhibiting distinct 
sarcomeric cross-striation indistinguishable from native cardiomyocytes. The engrafted 
human cardiomyocyte-like cells were found to connect electrically to the host myofibers 
through connexin43 gap junction proteins (arrowheads).  
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3.5.1 BrdU labeling of cells in the low-dose therapy group 
Cells in the low -dose cell therapy groups were uniformly labeled with 
bromodeoxyuridine (BrdU) nuclear labeling dye before cell transplantation. More 
than 99% of the cells were labeled and there were no significant differences in the 
labeling efficiencies of either cell types. In addition, viability of the BrdU labeled 
MSCs or CLCs was comparable with greater than 95% cell survival (Figure 33). 
3.5.2 Cell fate and development of BrdU labeled cells in vivo 
The identity of transplanted human cells in the infarcted myocardium was vindicated 
by the co-localization of BrdU label and human nuclei staining (Figure 34). These 
cells appeared to demonstrate distinct cross-striations characteristic of sarcomeric 
structures in vivo that were indistinguishable from host cardiomyocytes (Figure 35). 
Furthermore, positive connexin 43 stainings in juxtaposition to the engrafted cells 
indicate the formation of gap junctions between the exogenously administered cells 
and the host myocardium (Figure 35). Taken together, these findings imply that the 
engrafted cells underwent extended cardiac differentiation in vivo to become 
cardiomyocytes that were able to couple electrically with host cardiomyocytes.  
However, immunofluorescence tracking of the transplanted cells showed only a low 
frequency of cellular engraftment in the host myocardium. This may explain the lack 
of significant improvements in regional myocardial contractility in 2D ultrasound 
echocardiography assessments (Table 4). More importantly, the low engraftment rate 
in the cell-treated myocardium is still disproportionate to the significant 
improvements in global cardiac function that was observed in cell-treated rats, as it is 
highly unlikely that such a small population of exogenously supplied cells could 
  97 
regenerate the infarcted myocardium or contribute meaningfully to overall 
contractility.  
Persistent improvements in cardiac function in spite of low incidences of cellular 
integration in the cell-treated myocardium underscore the likelihood of alternative 
non-myogenic and possibly paracrine-induced repair mechanisms in vivo. In 
particular, smaller cardiac volumes in cell-treated rats strongly suggest a significant 
attenuation of (negative) LV remodeling (Figure 32 i-ii) Thus, the cell-treated 
myocardium may prevent the progressive thinning of the ventricular walls by 
modulating matrix architecture, thereby reducing tissue „stiffness‟ in an otherwise 
increasingly non-pliable tissue mass in the peri-infarct borders of a developing „scar‟. 
In so doing, cell therapy may act to sustain tissue compliance in the remaining viable 
tissues within the peri-infarct precincts of the infarcted myocardium, while facilitating 
a synergistic recovery of biomechanical functions via myocyte replacement, and 
sustaining or enhancing overall contractile efficiencies with respect to the untreated 
myocardium.  
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3.5.3 High-Dose Cell Therapy 
It is important to emphasize that notwithstanding the discrepancies in cell integration 
and cell-mediated myogenic repair, CLC- transplantation can contribute to cardiac 
contractile activities via myocyte replacement (See Figure 35). However, direct 
cellular effects of cell-mediated myogenic cardiac repair in vivo could only be 
vindicated with relatively higher frequencies of cellular integration in the 
myocardium. It was believed that high-dose cell-therapy would increase the 
probability of cell engraftment in the myocardium when administered in a higher 
dosage. Specifically, cells were administered in high dosage to determine if CLC-
therapy mediated myogenic replacement/ regeneration. This also allowed for a 
subsequent comparative study investigating the dose-dependent effects of cell-therapy 
on cardiac function. 
3.5.3.1 Fluorescent Labeling of cells in the high-dose therapy groups 
Cytoplasmic fluorescent dyes were used to label MSCs and CLCs for rats in the high-
dose cell therapy groups. MSCs were labeled with CFDA-SE, while CLCs were 
labeled with CM-DiI. More than 99% of either cell types were labeled and no 
significant differences were observed in the respective labeling efficiencies of 
cytoplasmic stain. More importantly, viability of either fluorescence-labeled cell types 
remained high at 92.8 ± 1.5% in CFDA-labeled MSCs and 98.9 ± 0.5% in CM-DiI 
labeled CLCs. The high viability rates indicate that the fluorescence dyes used to 
label the respective cell types did not have adverse cytotoxic effects on either cell 
types and thus would not be responsible for any cell death in vivo following 
transplantation (Figure 30).   
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Low cellular integration in the low-dose cell therapy group may obscure any 
discernible improvements in global contractility via ultrasound echocardiography. 
The respective cell therapy groups were administered in higher doses to gain an 
insight into the mechanistic benefits of cell transplantation in vivo. To determine the 
effects of high-dose cell therapy on cardiac function, 5 million CM-DiI-labeled CLCs 
or CFDA-labeled MSCs (n= 20 rats per therapy group) or 200 uL of serum-free 
medium (n=15 rats) were injected into the infarct border regions of the myocardium 1 
week after ligating the left anterior descending coronary artery of 
immunocompromised rats. Left ventricular (LV) function was analyzed via 
ultrasound echocardiography and pressure-volume (PV) catheterization.   
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3.5.3.2 2D M-mode ultrasound echocardiography assessments and Tissue Doppler 
Imaging of Cardiac Function 
Consistent with previous findings discussed in the low dose groups, statistical 
analyses show that the serum-free media injected control rats demonstrated 
significantly larger LV dimensions during end-systole and end-diastole and 
correspondingly thinner interventricular septum (IVS) at the anterior walls (Figure 
36i-iii). In contrast, cell-treated rats generally exhibited significantly thicker 
interventricular septum and anterior walls (Figure 36 i-vi) and smaller LV diameters 
during contraction. Correspondingly, cell-treated myocardium demonstrated smaller 
LV volumes during end-systole and end-diastole with respect to control rats (Figure 
36 vii-x). There was a trend towards systolic and anterior wall thickening in rats 
treated with high-dose MSC-therapy. However, only CLC-therapy mediated 
statistically significant improvements in systolic (Figure 36iii) and anterior wall 
thickening (Figure 36 vi), which were previously obscured by large standard errors 
due to large experimental variation in the low dose group. This underscores a strong 
possibility that CLC-therapy may confer a more superior restraint on progressive 
ventricular wall thinning and chamber dilatation as compared to MSC-therapy.  
Control rats exhibited significantly larger internal diameters as was characteristic of 
ventricular dilatation (Figure 36 vii-viii). In contrast, cell-treated rats demonstrated 
smaller changes in LVIDes measurements with respect to control rats. Thus, cell-
therapy actively restrained the severe progression of chamber dilatation in cell-treated 
rats. However, a positive change in LVIDes measurements indicates that post-therapy 
LVIDes measurements were larger than post-ligation measurements in MSC-treated 
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rats. This in turn indicates that the MSC-treated myocardium still underwent a fair 
degree of ventricular dilatation (Figure 36 vii-viii) following ligation of the anterior 
descending artery, although not to such severe extents as characteristic of control rats.  
In contrast, CLC-treated myocardium exhibited significantly reduced LV internal 
diameters during end-systole and end-diastole following cell transplantation. This 
shows that chamber dilation was attenuated in CLC-treated rats and treated 
myocardium had undergone positive LV remodeling. Furthermore, Doppler analyses 
showed that LVes volumes remained relatively constant following high-dose CLC 
transplantation (Figure 36 ix-x). Taken together, CLC-mediated changes towards 
thicker walls, smaller diameters and constant volumetric changes strongly suggest that 
the CLC-treated myocardium did not undergo ventricular dilation but instead 
exhibited a more robust contractility during end-systole. Thus, CLC-therapy may play 
active roles in enhancing systolic activities in vivo. More specifically, CLCs may be 
more effective than MSCs in promoting systolic recovery in the compromised 
myocardium. More significantly, the combined effects of smaller LV volumes and 
enhanced contractility in relation to a general preservation of the characteristic 
ellipsoidal cardiac geometry of the heart further translate into enhancement in overall 
contractile efficiencies such as ejection fraction and fractional shortening, in relation 
to the untreated hearts. 
Consistent with M-mode findings, tissue Doppler velocities also showed a significant 
improvement in regional myocardial systolic wall motion in cell-treated rats (Figure 
36 xi). These cell-mediated improvements in regional contractility translated into 
significantly enhanced global contractility, with respect to control rats. However, 
MSC-therapy appeared only to prevent further deterioration in LV ejection fraction 
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and fractional shortening as no discernible changes in global contractility indices were 
observed following high-dose MSC-treatment of infarcted rats (Figure 36 xii-xiii). In 
contrast, CLCs worked actively to enhance global systolic functions, thus leading to 
superior improvements in EF and FS with respect to MSC-treated rats (Figures 36 xii-
xiii). These results are consistent with previous postulations that CLCs may be more 
effective than MSCs in the recovery of systolic activities.  
It is important to note that hemodynamic data obtained via pressure-volume 
cathetheraization are measured at end point thereafter comparisons were made 
between the respective treatment groups. Unlike echocardiography assessments, no 
data points were obtained a week following LAD ligation, and thus improvements 
made with respect to each rat could not be determined. Correspondingly, each rat 
could not be normalized to itself. This also explains the differences between MSC-
mediated improvements via echocardiography assessment and conductance 
catheterization approaches. Notwithstanding, similar trends were observed with the 
data obtained via echocardiography and PV catheterization. 
Ejection fraction is amenable to changes in heart rate that may be affected by external 
factors such as stress and anesthesia etc. In particular, EF may be confounded in 
small, fast-beating rat hearts. Although recordings of echocardiographical data 
acquisition was recorded to circumvent potential confounding effects of anesthesia, 
the conventional clinical indicators of cardiac improvement may not present as good 
indices of actual improvements in contractility in rat hearts which beat at heart rates 
of 400 bpm. ECG tracings in ultrasound assessments showed that heart rate was 
consistent across all treatment groups although hemodynamic measurements obtained 
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with an ultra-sensitive 2F catheter designed specifically for small animals detected 
significant decreased in heart rate in the control rats.  
Heart rate-independent contractility indices were obtained as an alternative to 
conventional clinical indicators of heart function. Consistently, these indices showed 
similar trends. As shown in Figure 36 xiv, either cell-based therapy effected 
significantly improved velocities in circumferential fiber shortening (Vcfc). 
Compared to fractional shortening, the rate-corrected Vcfc offers the advantage of 
being relatively heart rate and preload-independent over a physiological range. 
However, only CLC-treated rats demonstrated significant improvements in the 
myocardial performance index (Tei index), which is in turn a reflection of both global 
systolic and diastolic functions. The advantage of this index includes less dependence 
on heart rate and blood pressure
132
 (Figure 36 xv). It is also independent of influences 
due to geometrical ventricular changes. These HR-independent echocardiography-
derived contractility measures are discussed in greater depth in Chapter 4. Figure 36 
showed that the MSC-treated myocardium persistently exhibited no discernible 
changes in global contractility from the point of LAD ligation. Thus, while high-dose 
MSC therapy prevented further deterioration in overall cardiac performance via active 
restraint of negative LV remodeling effects, MSCs did not appear to contribute 
actively towards contractile activities.   
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Figure 36 i-vi. Ultrasound M-mode assessments show that high-dose cell therapy alleviates (negative) LV remodeling by limiting progressive 
thinning of the interventricular septa and anterior walls. Correspondingly, this resulted in enhanced systolic and anterior wall thickening. However, 
only CLC-therapy achieved statistical significance with respect to control rats. Sytolic wall thickening is a regional contractility measure of the IVS 
wall motion, while anterior wall thickening is a regional contractility measure of the mid-anterior walls, which were affected upon LAD-ligation.  
…continued next page. 






Figure 36 vii-x. Consistent with thicker wall, rats treated with high-dose cell therapy 
demonstrated smaller internal diameters and smaller cardiac volumes as compared to control 
rats.  
 
…continued next page. 
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Figure 36. Ultrasound echocardiography assessments show that cell-based therapy led to significant 
improvements in cardiac function as compared to control rats.  
However, despite significantly enhanced myocardial systolic velocities, MSC-treatment appears only to 
prevent further deterioration in function, while CLC-therapy actively improved global contractility such as 
ejection fraction and fractional shortening, as well as the heart rate- independent contractility indices 
including (xiv) Vcfc (velocities of circumferential fiber shortening) and (xv) the myocardial performance 
index, which is a measure of both systolic and diastolic activities. 
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3.5.3.3 In vivo Hemodynamics via Pressure-Volume Catheterization  
In vivo hemodynamic measurements obtained with pressure-volume catheterization 
coincided with ultrasound echocardiographical assessments. A 2F catheter specially 
designed for rats was inserted into the right carotid artery and advanced into the left 
ventricle to obtain steady-state hemodynamic measurements in real time. Load-
independent contractility indices were obtained via the occlusion of the inferior vana 
cavae (Table 5). The rightward shift of the pressure-volume loops in Figure 32 shows 
that cardiac volumes were significantly increased from baseline levels following a 
myocardial infarction. This trend was consistent in all infarcted control rats. PV 
relationships show that cell-based therapies led to significantly smaller volumes. 
These observations are consistent with regional 2D M-mode measurements depicting 
smaller LVID (LV dimensions) measurements and thicker interventricular walls 
during contraction and are supportive of previous findings, which reported cell-
mediated restraint of LV dilatation. Consistent with low-dose cell therapy, PV 
relationships also reported similar trends in cell-mediated improvements in other 
parameters of cardiac function (Table 6). 
However, ultrasound echocardiography assessments show that high-dose CLC-
therapy may confer superior benefits of global systolic activities with respect to high-
dose MSC-therapy. Consistent trends were observed in contractility measurements 
obtained via PV catheterization. To obtain contractility indices, the inferior vena cava 
was depressed lightly with a cotton swab for a few seconds in each rat. The pressure 
volume loops depicted in Figure 37 were obtained from representative rats in each 
treatment group. The blue line shows robust end-systolic PV relationships in a healthy 
rat, as represented by its steep gradient. These were severely compromised following 
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a myocardial infarction, as observed by the flatter gradient in the red line (Figure 38 
i). Figure 38 shows that cell therapy significantly enhanced end-systolic PV 
relationships. However, CLC-treated rats mediated a more enhanced recovery of 
ESPVR (Figure 38 ii). More remarkably, CLC-therapy restored myocardial systolic 
performance, as ejection fraction and end-systolic pressure-volume relationships in 
CLC-treated rats reverted to baseline levels in normal rats (Figure 38 iii).  
Consistent trends were observed with preload independent contractility indices such 
as maximum dP/dt-EDV, ESPVR and PRSW as CLC-treated rats demonstrated 
superior systolic activities with respect to both control and in particular, MSC-treated 
rats (Table 5). These persistent trends in ultrasound echocardiography assessments 
and PV relationships show that CLC-therapy was more effective in improving 
myocardial systolic activities with respect to MSC-therapy. More importantly, 
contractility studies further show that CLC-therapy restored myocardial systolic 
performance to healthy levels.  
In contrast, Figure 39 shows that preload-independent contractility measurements in 
MSC-treated rats were not significantly different from control animals, although 
MSC-treated rats demonstrated a trend towards enhanced contractility. Consistent 
with previous findings, this may be reflective of the possibility that MSC-mediated 
cardiac repair is of a passive nature. These indices are discussed further in Chapter 4 
of this thesis. Nevertheless, MSC-treated rats showed a trend towards enhanced 
contractility with respect to control rats (Figure 38-39). 
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Figure 37. Pressure-Volume loops of a representative normal and 
(serum-free) medium injected control rat post myocardial 
infarction (post-MI) respectively.  
The rightward shift of the pressure-volume loops shows that cardiac 
volumes were significantly increased from baseline levels following a 
myocardial infarction. This trend was consistent in all infarcted 
control rats.  
 
Table 5.Contractility measurements obtained via real-time occlusion of the inferior vena cava 
at 6 weeks post-therapy in the high-dose therapy groups.  

















ESPVR 2.69 ± 1.13 0.77 ± 0.23* 1.36 ± 0.40# 2.10 ± 0.89#,† 
*p < 0.02 vs. 
baseline 
#p ≤ 0.001 
vs. control 
†p < 0.05 vs. 
MSC-therapy 




133.3 ± 44.5 53.4 ± 16.6* 83.4 ± 31.8* 121.0 ± 31.3#,† 
*p < 0.01 vs. 
baseline 
#p < 0.05 vs. 
control 
†p < 0.05 vs. 
MSC-therapy 
Maximum 
dP/dt - EDV 
147.7 ± 53.5 44.0 ± 33.8* 77.2 ± 23.9* 120.0 ± 65.4# 
*p < 0.02 vs. 
baseline 
#p ≤ 0.001 
vs. control 
Emax 3.71 ± 1.49 1.47 ± 0.48* 2.04 ± 0.57 2.59 ± 1.08# 
*p < 0.05 vs. 
baseline 
#p < 0.05 vs. 
control 






Figure 38. Pressure volume relationships of a representative healthy rat vs. a sham- operated rat.  
The top-leftmost points of a single pressure-volume loop represent end-systole in a single cardiac cycle, and the gradient of the line connecting all the 
top-leftmost points of each PV loop represents the end systolic pressure-volume relationships (ESPVR) and is a measure of myocardial systolic 
contractility. The steep gradient of the blue line is consistent with a robust contractility that is typical of a healthy myocardium, while the flatter 
gradient in the red line indicates a decrease in contractility in control rats as the PV loops shift towards the right. Figure 38ii shows increasingly 
steeper gradients with cell-treated rats with respect to control rats. (iii.) However, CLC-treated rats demonstrated superior myocardial systolic 
performance to MSC-treated rats as CLC-treated rats exhibited significantly enhanced ESPVR than MSC-treated rats.  








Figure 39. CLCs persistently mediated superior enhancement of preload independent contractility indices with respect to control rats. 
Similar trends were observed in preload-independent contractility indices such as (i) the preload recruitable stroke work and the (ii.) maximum dP/dt – 
EDV and the (iii.) maximum time-varying elastance. CLC-treated rats showed persistently better systolic activities than MSC-treated rats in other 
measures of systolic performance, including the preload-independent contractility indices such as the preload recruitable stroke work and the 
maximum dP/dt – EDV. 
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3.5.4 Dose-dependent effects of cell therapy on cardiac function 
Low-dose cell-therapy was unable to detect significant improvements in regional 
myocardial contractility via 2D ultrasound echocardiography assessment. Moreover, 
low engraftment frequencies obscured insights into in vivo cell-mediated repair 
mechanisms.    
A comparative study was thus conducted to compare the dose-dependent effects of 
cell therapies on cardiac function. To conduct multiple pairwise comparisons between 
the high- and low- dose therapy groups, control animals for the respective treatments 
were combined to form a single control group. Figure 30 documents the number of 
rats in the respective low- and high- dose cell therapy groups that survived each 
analytical/ experimental time point. The relatively high experimental attrition 
observed in post-therapy cardiac assessments was not surprising in a survival model 
and was further intensified by a learning curve associated with unfamiliarity with 
relatively novel experimental techniques in pressure-volume relationships at the point 
of investigation. 
Consistent trends in improving cardiac function were observed in high- and low- dose 
cell therapy. Functional assessments via ultrasound echocardiography and PV 
catheterization showed that cell therapy was generally more effective when 
administered in higher doses as evidenced by significantly smaller LV internal 
diameters and persistently better improvements in ejection fraction, cardiac output, 
stroke volume and stroke work with respect to control animals (Table 6 and Figure 
40).  
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However, trends in echocardiography and pressure-volume relationships persistently 
showed that CLC-therapy mediated superior improvements in cardiac repair with 
respect to MSC-therapy. Regional wall assessments via 2D M-mode 
echocardiography showed that high-dose CLC-therapy mediated a negative change in 
LVIDes following cell transplantation (Figure 36 vii). This suggests smaller internal 
diameters post therapy from the previous echocardiographical assessment post-
ligation. Consistently, post-therapy LVIDed measurements were also smaller with 
respect to the post- LAD ligation time point. Overall, these trends suggest smaller 
cardiac volumes with respect to control rats, which combined with a general 
preservation of cardiac geometry would translate into enhanced contractile 
efficiencies. Indeed, PV relationships show that high-dose CLC-therapy trended 
towards the largest improvements with respect to control animals. Additionally, rats 
treated with a high dose of CLCs were the only ones to exhibit statistically significant 
improvements in maximum dP/dt levels (Figure 36 iii).  
Comparatively, MSC-therapy improved cardiac function with respect to control. 
However, unlike CLC-therapy, MSC-therapy appeared only to play passive roles in 
vivo. Despite the increase in dosage, MSC-treated rats demonstrated no discernible 
changes in ejection fraction, following transplantation therapy (Table 6 and Figure 41 
iv). Thus, MSC-therapy appears only to prevent further deterioration in contractile 
function (Figure 36 xii-xv). Notwithstanding, MSC-treated rats consistently exhibited 
thicker interventricular septum walls and correspondingly smaller LV internal 
diameters, which are in turn indicative of possible attenuation in remodeling effects. 
Thus, MSC-therapy does not contribute actively to contractile performance but 
appears only to partake in preventing progressive wall thinning.   
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Table 6. Ultrasound echocardiography assessment of rats treated with high- and low-dose cell therapy. 
Measurements obtained via 2D ultrasound echocardiographical assessments show that high-dose cell therapies were more generally more effective than 
low-dose cell therapy with respect to control rats. The low- and high-dose therapy groups were conducted at different time points. The respective control 
groups for the respective low- and high- therapy groups were combined to form a single control group. Experimental attrition was responsible for the 





Analysis of cell-mediated changes in cardiac function by Ultrasound 
echocardiography assessments (Mean ± SD) 
Medium-
injected control 
n = 25 
MSC-Therapy 
(1 million cells) 
n = 8 
MSC-Therapy 
(5 million cells) 
n = 20 
CLC-therapy 
(1 million cells) 
n = 9 
CLC-therapy 
(5 million cells) 
n = 19 
p-value 
% changes in:       
Heart Rate  -7.64 ± 6.78 -1.41 ± 13.69 -1.82 ±13.03 -6.68 ± 11.51 -5.02 ± 11.35 NS 
IVSes  -0.73 ± 27.50 14.66 ± 33.38 7.12 ±14.31 12.7 ± 18.71 13.17 ± 12.53 NS 
IVSed  -1.97 ± 13.5 6.61 ±17.81 3.3 ± 7.13 2.68 ± 9.59 9.49 ± 7.45* 
*p = 0.008 vs. control 
(Tukey‟s HSD) 
LVIDes  21.98 ± 22.29 16.09 ± 35.44 4.56 ± 13.46# 9.49 ± 20.60 -3.39 ± 11.41* 
#p = 0.034 vs. control 
*p = 0.001 vs. control 
(Tukey‟s HSD) 
LVIDed 12.60 ± 10.57 12.23 ± 15.79 3.49 ± 7.74# 10.00 ± 13.18 2.69 ± 7.81* 
#p = 0.033 vs., control 




29.79 ± 116.27 43.30 ± 86.19 15.19 ± 39.11 48.88 ± 71.77 17.85 ± 42.97* NS 
Ejection 
Fraction 
-8.72 ± 14.74 0.76 ± 28.99 -0.76 ± 7.09 5.87 ± 21.71 7.14 ± 8.39* 




-10.25 ± 16.85 -333.9 ± 502.2 -0.11 ± 10.12 8.51 ± 24.33 9.88 ± 12.08 NS 
Mid-Anterior 
Wall Velocity 
-1.85 ± 111.68 28.18 ± 87.60 29.53 ± 24.72 53.82 ± 99.87 25.95 ± 40.67 NS 
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Figure 40. 2D M-mode echocardiography assessments show that high dose cell therapy led to significantly LV small internal 
diameters.  
However, only CLC-treated rats mediated the highest improvement in ejection fraction relative to control animals. Control animals in the 
respective treatment groups were combined to form a single control group, to conduct multiple pairwise comparisons between the high- and 
low- dose therapy groups.  
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Assessment of dose-dependent effects of cell-therapy on cardiac function by real-
time pressure-volume catheterization 
 
…continued next page 












Figure 41. Cell therapy is generally more effective when administered in a higher dosage as high-dose therapy effected 
persistently better improvements in cardiac function.  
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Table 7. Steady state hemodynamic measurements via real-time in vivo pressure-volume cathetherization showing trends in diastolic activities.  
Control rats showed diastolic dysfunction with respect to normal rats. In general, cell-therapy trended towards improved diastolic activities. However, of 
the 4 different therapies employed, rat treated with high dose MSC-therapy trended towards the highest EDP, and lowest minimum dP/dt and maximum 
dV/dt levels, and thus mediated the worst improvements in diastolic activities as compared to both control as well as the other cell treated rats. A similar 
trend was observed with the preload-independent Tau (weiss) relaxation index as high dose MSC-therapy mediated the worst improvement in relaxation 
properties with respect to the other cell-therapies. However, unlike the load-sensitive indices, the Tau (weiss) relaxation index in cell-treated rats 













(n= 23 rats) 
Low dose 
MSC-therapy 









(n= 15 rats) 
p-value 
Load-dependent indices (Mean  SD) 
Heart Rate 
(bpm) 




11.03  2.92 12.33  17.34 11.18  9.39 13.96  8.34   8.50  1.94  11.72  2.98 NS 
End-Diastolic 
Volume (uL) 
115.58  23.92 192.55  58.90  148.93  49.02 146.79  28.93  139.11  45.17 145.79  28.34 NS 
Minimum dP/dt 
(mmHg/s) 
12151  3679 7859  3694 11118  4744 9340  3361  10160  2839 10611  2544 NS 
Maximum 
dV/dt (uL/s) 
3670  1202 3634  1714 5101  2473 4516  2251  5694  3675 5842  2547 NS 




9.26  1.68 13.62  6.40 12.11  3.57 12.49  3.89  10.13  1.43 11.47  2.55  NS 
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3.5.5 Cell-mediated Cardiac Repair Mechanisms In vivo.  
3.5.5.1 Donor cell engraftment and survival 
It is imperative that the transplanted cell types integrate with the host myocardium in 
order to mediate synchronized contractility and avoid potentially lethal variations in 
the electrical conductance of the heart
133
. Immunofluorescence stainings show that 
both cell types engrafted in the host myocardium. Green fluorescence in Figure 42A 
denotes the presence of MSCs, while red fluorescence in Figure 42B depicts the 
presence of engrafted CLCs in vivo. MSCs were further verified with a specific 
antibody (green fluorescence) towards fluorescein (CFDA), while the presence of 
CLCs were further affirmed with the use of a specific anti-human nuclei antibody. 
MSCs did not stain positive for human nuclei. The absence of human genetic material 
strongly suggests that MSCs did not survive well after their initial engraftment into 
the host myocardium, although a residual presence of the fluorescein label used to 
track the donor MSCs in vivo could still be detected in the host myocardium and 
vasculature. Collectively, these observations suggest the immunocompromised host 
myocardium may have retained the green fluorescent labels reminiscent of these cells 
following their mortality in vivo. Nonetheless, the remaining green fluorescence was 
useful in identifying the last sites of MSC engraftment before their subsequent 
demise. In contrast, CLC-treated myocardium appeared to show higher incidences of 
red fluorescence in vivo that were coincident with human nuclei. This in turn strongly 
suggests that CLCs may have a more robust survival rate as compared to MSCs.  
3.5.5.2 CLCs but not MSCs enhanced cardiac contractility via myocyte-
replacement 
CLCs exhibited mature cross-striated fibers in vivo that aligned with and were 
indistinguishable from native cardiac myofibers in the myocardium, as depicted by 
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the respective cross-striating I-band and A-band of cardiac -actinin and -myosin 
heavy chain, troponin-I and troponin-T (Figure 43). A 3-dimensional representation 
of an engrafted CM-DiI labeled CLC in the host myocardium further shows that the 
cross striations, exemplified by cardiac -actinin, were indistinguishable from the 
host myocardium (Figure 44). More importantly, positive connexin 43 stainings in the 
viable myocardium adjacent to engrafted CLCs indicate the formation of gap 
junctions between the transplanted cells and the host myocardium (Figure 45). This 
strongly suggests that CLCs may become cardiomyocytes that can couple electrically 
with host cardiomyocytes, and are thus likely to contribute actively towards 
contractile performance in the infarcted myocardium. This phenomenon was visibly 
absent in the MSC-treated myocardium (Figure 43A-B, 44-45), and is consistent with 
earlier functional analyzes via ultrasound echocardiography and PV catheterization, 
which show that CLCs are more effective than undifferentiated MSCs in enhancing 
myocardial systolic performance.  
Immunofluorescence microscopy of the MSC-treated myocardium showed an 
apparent alignment of green fluorescence with native cardiac myofibers, some of 
which were encased by red fluorescence denoting positive myocyte stains (Figure 
42B). These observations suggest that some CFDA-labeled MSCs may have engrafted 
in alignment with cardiac myocytes in the MSC-treated myocardium. However, only 
a minority population of CFDA-labeled MSCs was found engrafted in the 
myocardium (Figure 43B). Of the cells that successfully engrafted in the myocardium, 
MSC populations exhibiting a singular green fluorescent staining were visibly 
prevalent in the collagen I-enriched domains of the compromised myocardium. 
Notwithstanding, these staining patterns appeared to assume a vascular-like 
appearance (Figures 42-43 and 45). These observations accentuate the lack of 
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coincident myocyte staining patterns that were contiguous with the engrafted cells. 
This in turn suggests that most of the donor MSCs did not integrate with the resident 
myocardium upon their initial engraftment and may have remained quiescent in vivo 
following cell injection into the peri-infarct borders of the myocardium. 
Consequently, the MSC-treated rats demonstrated unremarkable frequencies of actual 
integration as functional cardiomyocytes (Figure 43), as compared to CLC-treated 
animals. Furthermore, MSCs did not engraft at sites that were proximal to connexin 
43 (Figure 45). This suggests that MSCs did not form gap junctions with resident 
cardiomyocytes and were most likely electrically isolated from the host myocardium. 
These findings are consistent with MSCs‟ significantly diminished capacity to 
enhance myocardial contractile performance in relation to CLCs. Nonetheless, 
functional assessments via echocardiography and PV catheteriazation have shown that 
MSC-therapy conferred some benefits with respect to control rats, as exemplified by 
significantly enhanced global contractility with respect to control myocardium that 
received serum-free media. These results are consistent with current literature which 
reports that MSCs do not survive well in the myocardium
49, 50
 and actual bone marrow 
stem cell-derived cardiomyocyte engraftment is rare and an inefficient process
59
. Also 
consistent with current postulations, MSCs may contribute towards overall 
contractility via passive paracrine-mediated non-myogenic mechanisms.  






Figure 42. Engraftment of the respective cells types in a representative rat in each respective high-dose therapy 
group.  
Green fluorescence in (A) denotes the presence of MSCs, while red fluorescence depicts the presence of engrafted 
CLCs in vivo. CFDA-labeled MSCs were verified with the use of an anti-fluorescein antibody that recognized the 
fluorescein conjugate that was used to label MSCs, while donor derived CLCs in (B) were verified with the use of a 
specific human-nuclei antibody (green).  
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Figure 43. Cell fate and development of donor MSCs vs. CLCs in the injured myocardium.  
Representative micrographs of CLC-treated and MSC-treated rats illustrate the respective developmental fates of 
engrafted cells in the infarcted myocardium.           
            …continued next page 
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Figure 43. Cell fate and development of MSCs vs. CLCs in the injured myocardium (continued) 
A. The prevailing MSC populations are physically isolated from the myocardium. B. A minority of engrafted MSCs exhibited 
an intense staining of the myocardium immediately surrounding the engrafted cells (middle panel). However, these regions did 
not exhibit any distinctive cross-striating patterns that were typical cardiac myocytes. C. In contrast, red-fluorescence labeled 
CLCs demonstrated well-defined cross striations consistent with a developed myocardial phenotype in vivo.  









Figure 44. A 3-dimensional model of an engrafted CM-DiI labeled CLC cell in 
the rat myocardium.  
Constructed from Z-sections and observed at different perspectives, three-dimensional 
rendering of a z-stack of an engrafted CLC showed that cross striations denoting the I-band of 
cardiac a-actinin (green) were indistinguishable from host -actinin fibers.  
 







Figure 45. CLCs integrated in sites proximal to connexin 43 while MSCs did not.  
This suggests that the myogenic CLCs can couple electrically with the host myocardium via the formation of gap junctions 
between the engrafted cells and the resident cardiomyocytes. In contrast, MSCs were not electrically coupled with the 
myocardium. 
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3.5.5.3 Cell therapy mediates cardiac repair via alternative non-myogenic 
mechansims in the infarcted myocardium 
Immunofluorescence examinations showed regular incidences of green fluorescence 
tracking label reminiscent of MSCs in vascular structures in vivo. Figure 46 illustrates 
the colocalization of fluorescein (CFDA) with the von-Willebrand factor and smooth 
muscle actin. In contrast, CLCs did not integrate with any mature vascular structures 
despite their occasional engraftment in sites proximal to the vascular system (Figure 
46). Despite a seemingly rare incidence in the myocardium, MSC-therapy 
significantly enhanced myocardial angiogenesis in the infarcted myocardium with 
respect to control myocardium (Figure 48). However, there was no distinct evidence 
of extended MSC-differentiation into endothelial cells in the myocardium, although 
MSC-treated rats demonstrated a significantly larger number of small arterioles (6.69 
± 0.53 vessels/mm
2
 myocardial tissue, p<0.01) in the myocardium as compared to 
CLC- treated (4.48 ± 1.28 vessels/mm
2
, p<0.05) and control (2.44 ± 1.74 
vessels/mm
2
) rats (Figure 48). It is important to note that the cell-treated myocardium 
also trended toward greater vascular expansion into mid-and large-sized arterioles 
although these trends did not achieve statistical significance with respect to control 
rats. In turn, these increases in the number of arterioles in the MSC-treated 
myocardium may lead to significantly enhanced myocardial perfusion of the MSC-
treated heart. Taken together, these findings strongly indicate that MSC-therapy may 
act to benefit cardiac function via alternative non-myogenic mechanisms.  
Although CLCs were not integrated within vascular structures in the myocardium, the 
CLC-treated myocardium stained positive for the von Willebrand factor (vWF) in 
focal regions that were proximal to the site of cell engraftment. However, these cells 
did not stain positive for the mature blood vessel marker, smooth muscle actin 
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(SMA). Figure 47A shows the colocalization of green fluorescence depicting vWF 
expression with CM-Dil labeled CLCs in vivo (yellow arrowheads). This suggests an 
alternative non-myogenic differentiation pathway in CLCs, as the engrafted cells may 
have differentiated to become endothelial cells in vivo. This is consistent with in vitro 
characterization studies showing an inherent propensity for endothelial differentiation 
in CLCs. Importantly, multiple singular green fluorescent stains (white arrowheads) 
in the immediate vicinity of the engrafted CLCs strongly indicate the expression of 
vWF expression in resident host cells (Figure 47A). Thus, the engrafted CLCs may 
have stimulated the nascent development of resident endothelial cells, which may in 
turn lead to subsequent vasculogenesis. Consistently, the CLC-treated myocardium 
showed a trend towards higher counts of arterioles per mm
2
 of myocardial tissue 
section (Figure 48) with respect to control heart sections, although this did not 
achieve statistical significance. 
Subsequent staining on sequential tissue cryosections also showed positive expression 
of the cell proliferation marker, PCNA, in the myocardial interstices proximal to 
engraftment sites (Figure 47B). PCNA expression was similarly augmented in the 
same vWF-enriched locale of CLC-engraftment in the cell-treated myocardium. The 
colocalization of green and red fluorescence representative of CM-DiI labeled CLCs 
(yellow arrowheads) in Figure 47B suggests that these CLCs survived well and 
proliferated in the treated myocardium. Subsequent immunofluorescent stainings on 
sequential tissue sections showed the absence of distinct cardiac myofibrillar protein 
expression in the vicinity of these proliferating cell types. Given the focused vWF-
enriched locale of CLC-engraftment (discussed in the following paragraph) as well as 
an enhanced vWF expression in the engrafted CLCs, it is likely that the PCNA-
positive CLCs differentiated to become proliferating endothelial cells in vivo. 
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Singular green fluorescent PCNA stains encasing the nuclei (white arrow heads) of 
host cells in the immediate vicinity of CLC- engraftment indicate the presence of 
proliferating endogenous resident cells in the treated myocardium. Thus, the engrafted 
CLCs may have stimulated an uncharacteristically active proliferation in terminally 
differentiated host cells in vivo (Figure 47B). Given the spatial localization of these 
proliferative cells in the interstitial spaces between host muscle cells and the relatively 
absent myocyte expression in these PCNA-positive cells, it is highly unlikely that the 
proliferating endogenous cell types were resident cardiac myocytes. The lack of 
(obvious) mature vascular structures and an absent smooth muscle actin expression in 
the focal regions surrounding the site of CLC-engraftment also precluded the 
possibility that these cells were endogenous pericytes or mature blood vessels. On the 
contrary, these observations collectively suggest the nascent development of SMA- 
vWF+ endothelial cells in the synthetic phase of mitosis in the CLC-treated 
myocardium. Thus, CLCs can promote the nascent development of endogenous host 
cells in the locale of CLC engraftment into actively proliferating endothelial cells. 
Consistently, the CLC-treated myocardium also demonstrated consistent trends in 
higher counts of arterioles per mm
2
 of myocardial tissue section (Figure 42) with 
respect to control heart sections, although this did not achieve statistical significance. 
This highlights the possibility that CLC-therapy may mediate alternative non-
myogenic cardiac repair mechanisms such as neoangiogenesis in the infarcted 
myocardium.  Importantly, the active proliferation of donor CLCs and endogenous 
resident cells underscore the likely possibility that engrafted CLCs may secrete 
cardioprotective paracrine factors like cytokines into the milieu of CLC-engraftment. 
These elements may in turn exert a protective effect on the compromised 
myocardium. For example, paracrine factors may improve myocardial perfusion in 
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the infarcted myocardium by increasing the number of functionally viable arterioles, 
albeit to a lesser extent with respect to MSC-therapy. This observation is not 
surprising given that a large number of CLCs have been committed to a cardiac 
myogenic lineage in vitro before cell transplantation so that CLCs‟ primary 
contribution to cardiac repair is likely through myocyte replacement. Cardioprotective 
cytokines may also alleviate adverse remodeling effects, thus enhancing regional 
myocardial activities and contributing indirectly towards the recovery of global 
cardiac functions via this non-myogenic repair mechanism. 






Figure 46. Engrafted MSCs persistently colocalized with the von Willebrand factor and SMA in vivo.  
This suggests that MSCs may have integrated as immature blood vassals, and thus may promote angiogenesis in the host 
myocardium. In contrast, although CLCs may have engrafted in sites proximal to blood vessels, they did not integrate as 
mature blood vessels in the treated myocardium.  
 




Figure 47. Engrafted CLCs mediated cardioprotective paracrine effects, which stimulated extended endothelial 
differentiation and endogenous cellular proliferation. 
A. The CLC-treated myocardium promoted expression of the von Willebrand factor in the focal regions proximal to the site 
of cell engraftment. B. Subsequent staining for vascular structures on sequential section positive expression of the 
proliferating cell nuclear antigen, PCNA in regions proximal to the site of engraftment. The juxtaposition of red (CLCs) and 
green (PCNA) fluorescence encasing some nuclei (yellow arrow heads) identifies proliferating CLCs in vivo. Thus, engrafted 
CLCs survived well and demonstrated sustained proliferation in vivo. Similarly, singular green fluorescent stains enclosing 
other nuclei (white arrow heads) in the interstitial spaces between muscle cells suggest that the endogenous resident cells in 
treated myocardium underwent proliferation that was uncharacteristic of terminally differentiated cells.  






Figure 48. MSC-treated rats show significantly higher numbers of small arterioles (<20um) in the myocardium with 
respect to CLC-treated and control rats.  
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3.5.6 The role of collagen in the cell fate and development of CLCs in 
vivo  
CLCs demonstrated preferential engraftment in collagen V-expressing myofibers in 
the peri-infarct borders. Figure 49 shows extensive fibrosis and active remodeling of 
the myocardial extracellular matrix in the anterior wall of the left ventricle of a 
control rat, following suture-ligation of left anterior descending coronary artery. 
Collagen type I ECM was the predominant subtype in the subendocardium of 
transmural infarcts, while endogenous collagen type I colocalized with collagen type 
III expression in the pericardium and the subepicardium that extended into the 
infarcted myocardium. More specifically, collagen types –I were mainly localized to 
the perimysium that enwrapped large cardiac muscle bundles in the viable regions of 
the infarcted myocardium (Figure 49). In contrast, predominant endogenous collagen 
V expression was persistently observed in the endomysium surrounding viable 
myofibers in the peri-infarct zones of the infarcted myocardium (Figure 49).  
Immunofluorescent cell tracking showed the persistent engraftment of CLCs (arrows) 
in the collagen V enriched endomysial space proximal to viable myofibers in the peri-
infarcted region of myocardium (Figure 50). These cells were often intimately 
integrated with -actinin-, MHC- and troponin T- positive myofibers of the host 
myocardium (Figure 43), and were also electrically connected to the resident 
myofibers via the formation of gap junctions in the myocardium (Figures 45). As 
previously established, these intimately integrated CLCs demonstrated distinct cross-
striations that were indistinguishable from the native myofibers. Consistent with in 
vitro findings, endogenous myocardial collagen V matrices supported the distinct 
cardiomyogenic phenotype of CLCs in vivo. At the same time, a minority population 
of CLCs also engrafted within the characteristically collagen I-enriched interstitial 
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spaces bordering the infarcted areas in the myocardium. These cells did not show 
distinct myogenic actinin striations and were physically isolated from the main 
muscle bundles in the myocardium (Figure 51.1-51.2). This observation is consistent 
with in vitro studies showing that collagen I ECM does not support a cardiac-like 
phenotype in CLCs. It remains unclear if the observed localization of CLCs in the 
interstitial tissues enriched in collagen -I extracellular matrices prevented their 
engraftment into the host myofibrillar architecture. Nonetheless, these observations 
highlight the possibility that a collagen V -directed response may be essential to 
lineage differentiation and functional integration of CLCs within the cardiac 
syncytium 
In contrast, transplanted MSCs mostly engrafted in collagen I-enriched perimysial 
tissues or infarcts that were electrically isolated from the native muscle. These stem 
cells were absent of cardiac myofilaments, even as neighboring native cardiac 
muscles demonstrated an ubiquitous expression of myofibrillar proteins (Figure 43). 
Collectively, these findings suggest that myocardial collagen ECMs may play pivotal 
roles in cell fate and development of in the infarcted myocardium
134, 135
 




Figure 49. Spatial expression of endogenous collagen V in the peri-infarcted regions of the myocardium.  
Severe thinning of the infarcted left ventricular anterior wall (yellow box) 6 weeks post ligation of left anterior descending coronary artery. 
Magnification of the boxed area showing sub-endocardial expression of collagen I and sub-epicardial expression of both collagen I and collagen III in 
the transmural infarcts. Collagen V was detected in the peri-infarcted myocardium with occasional co-localization with collagen III in the infarcted 
myocardium. Focal expression of collagen V was detected in the endomysial tissues that surround viable myofibers  (boxed ) on the order of the 
infarct. Expression of collagen I and III was co-localized in the infarcted areas. 




Figure 50. CLCs (yellow arrowheads) 
primarily engrafted in the collagen V-
enriched endomysium that enwraps 





Figure 51. CLCs engrafted in collagenous domains in the myocardium.  
CLCs that engrafted in the collagen I-enriched (1) interstices or (2) myofibers in the 
myocardium did not exhibit positive -actinin stainings. 3. In contrast, CLCs that 
engrafted in the collagen V-enriched endomysium sheath that encapsulates viable 
myofibers showed cross striations indistinguishable from host cardiomyocytes. As 
shown in Figure 43, these cells were often intimately integrated with host -actinin, 
MHC- and troponin I- positive myofibers, and were also electrically connected to 
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3.5.7 Key findings 
1. Bone marrow mesenchymal stem cells (MSCs) can be differentiated into 
cardiomyocyte-like cells (CLCs) via the concomitant use of myogenic-
differentiating medium and collagen V matrices in vitro. 
2. CLCs expanded more than 30-fold within 2 weeks while still retaining their 
distinct cardiac-like phenotype.  
3. CLCs interacted preferentially on collagen V extracellular matrices.  
4. The v3 and 21 integrins are involved in initial CLC attachment and cardiac 
transdifferentiation.  
5. Pre-differentiating MSCs into CLCs ex vivo prior to cell transplantation therapy, 
commits these multipotent cells to a stable cardiac-like lineage.  
6. Cell-based therapies enhanced global contractile function in the infarcted 
myocardium by restraining progressive LV dilation and attenuating LV 
remodeling. It is likely that the presence of cells in an otherwise non-compliant 
tissue „softens‟ the infarct area, which in turn retains myocardial tissue 
compliance and indirectly improves overall tissue contractility.  
7. Transplanted CLCs appeared to demonstrate enhanced survival rates in host 
myocardium as compared to MSCs. 
8. Rats treated with CLCs demonstrated superior systolic function to rats 
administered with undifferentiated MSCs.  
9. CLCs actively confer added mechanical benefit by actively restoring myocardial 
systolic performance.  
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10. CLCs often engrafted in the collagen V-enriched peri-infarct domains of the 
myocardium that were relatively more viable.  
11. These CLCs demonstrated cross-striations that were indistinguishable from host 
cardiomyocytes in vivo. 
12. CLCs that were localized to collagen I-enriched interstitial domains in the scar 
areas of the myocardium did not achieve terminal myocyte differentiation. 
13. However, CLCs that were localized in the collagen I-enriched interstices 
expressed the proliferating cell nuclear antigen, and were thus actively 
proliferative. These cells also expressed the von-Willebrand factor and were thus 
angiogenic. 
14. These cells also promoted neoangiogenesis within the locale of CLC-engraftment.  
15. Transplanted MSCs did not survive well in the host myocardium.  
16. MSCs contributed passively towards improved global contractility via alternative 
non-myogenic repair mechanisms. 
17. Robust angiogenesis in the infarcted and peri-infarcted areas of the MSC-treated 
myocardium strongly suggests cardiac improvements via paracrine effects. 
18. Predifferentiating MSCs into CLCs ex vivo before transplantation is more 
efficacious than current undifferentiated bone marrow stem cell therapy for the 
treatment of chronic heart failure. However, CLCs‟ beneficial effects may be 
conditional on engraftment in relatively more viable areas in the infarcted 
myocardium.    
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Chapter 4: Discussion 
4.1 In vitro characterization studies 
4.1.1 MSC commitment to a distinct cardiac lineage before cell transplantation 
ES-derived cardiomyocytes have huge potential in clinical cell therapy for heart 
failure. These differentiated cells are also more efficacious than undifferentiated 
BM stem cells in restoring cardiac contractile function
136
. Similar to benefits of 
committing pluripotent ES cells to a stable and distinct cardiac phenotype for 
cell therapy, predifferentiating autologous multipotent BM stem cells into 
cardiomyocytes before cell transplantation may significantly increase the 
frequency of myogenic replacement in vivo to confer enhanced regional and 
global contractile performance in the failing heart. In this study, patient-derived 
MSCs were found to transiently express some cardiac gene transcripts such as 
GATA4, Nkx2.5, troponin C and MLC2a. Committing these MSCs into CLCs 
stabilizes the cardiac-like phenotype in vitro and maximizes their survival and 
extended differentiation in vivo. 
4.1.2 Cardiac differentiation of MSCs into CLCs 
Cardiac differentiated MSCs have also been reported to demonstrate active 
cardiac-like action potentials
137
, inward rectifying potassium currents
135
 and 
rhythmic calcium transient currents
55
 when placed in appropriate and conducive 
microenvironments. These methods are unlikely to be clinically applicable 
given their low reproducibilities and 5-azacytidine‟s potentially toxic 
consequences on a systemic level. This study extends from an earlier work 
which reported the development of a simple and non-toxic myogenic 
development medium, MDM
118
. This medium is essentially free of cytotoxic 
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, which are known to promote cardiac myogenesis in MSCs 
and embryonic stem cells. A preliminary study comparing the respective 
differentiation efficacies of MDM vs. azacytidine and butyric acid showed an 
enhanced and sustained cardiac troponin -C and -T expression in MDM-treated 
MSCs (Figure 8).  
4.1.3 Expression profiling of CLCs .   
In this study, primitive and unsorted sternum-derived mesenchymal stem cells 
(MSCs) were successfully differentiated with MDM into cardiomyocyte-like 
cells (CLCs) with a distinct myogenic phenotype
118
. These CLCs retained some 
characteristics of primitive and untreated MSCs, such as adherent-dependent 
expansion and a fibroblastic morphology.  
In contrast to the reportedly limited cardiomyogenic potential of MSCs
140
, 
CLCs exhibited distinctive cardiac-like characteristics that remained stable in 
prolonged cultures, as was evident by the persistent gene and protein expression 
of multiple cardiac-specific proteins including the Nkx2, GATA and MEF2 
family of cardiac transcription factors, cardiac calcium channels including 
IP3R2 and the voltage gated L-type calcium channel and sarcomeric 
myofilaments such as troponin T and cardiac  actin throughout 11 culture 
passages. More than 95% of the cardiac differentiated CLC cultures stained 
positive for sarcomeric -actin, sarcomeric-actinin, tropomyosin, the cardiac 
troponins -I, -C and -T, the myosin light chains 1/2 and titin. Furthermore, the 
appearance of nascent Z-lines rich in sarcomeric -actinin in 15-20% of MDM-
treated MSC cultures substantiated a developing contractile phenotype.  
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However, the diffused spatial distribution of the other cardiac sarcomeric 
proteins in the cytoplasm and the apparent lack of spontaneous contractions in 
CLC cultures suggest that these cells only attained partial differentiated 
phenotype in vitro.   
In this study, bone marrow stem cells were derived from cardiac patients with a 
mean age of 58.9 ± 11.4 years. Although successfully committed to a stable 
cardiac phenotype with Z-bands, CLCs did not exhibit more mature A-, and I- 
bands in vitro.  Furthermore, the absence of spontaneous beatings in patient-
derived CLC- cultures underscore the strong possibility that the bone marrow 
MSCs derived from relatively old patients may not possess optimal 
differentiation or cardiomyogenic developmental potential. Lin- cKit+ MSCs 
have been reported to undergo cardiac transdifferentiation with a higher 
efficiency in vitro as compared to primitive and unsorted bone marrow MSC 
progenitor cells, although no reports of spontaneously beating Lin- cKit+ MSC 
cultures in vitro have been documented. Nonetheless, isolating Lin- cKit+ 
MSCs from patient-derived bone marrow stem cells before their induction with 
MDM may further enhance the cardiomyogenic potential
126, 141, 142
 of these 
MSCs.  
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4.1.4 Golgi-localization of GATA4 and -MHC in patient-derived MSCs and 
CLCs.  
Interestingly, patient-derived MSCs and CLCs exhibited a persistent Golgi-
localization of GATA4 and MHC. However, the golgi-localization of GATA4 
remains to be verified with further studies since the colocalization of GATA4 
with Golgin97, a resident golgi protein in the trans Golgi network (TGN), were 
only observed with immunohistochemical but not immunofluorescent 
examinations. In contrast, golgi-localization of cardiac MHC has been 
consistently shown in patient-derived MSCs and CLCs by 3 different cardiac 
MHC- specific antibodies. More importantly, this unexpected accumulation of 
MHC within the juxta-nuclear TGN complexes assumed a coincident swollen 
appearance upon monensin disruption of the golgi apparatus
143
. This strongly 
suggests that MHC‟s association with the golgi apparatus was not fortuitious. 
However, this remains to be verified with stringent coimmunoprecipitation 
experimentation with resident golgi proteins. Alternatively, golgi fractions 
obtained via ultracentrifugation in a sucrose density gradity may be probed with 
a GATA4 and MHC-specific antibodies.  Notwithstanding, golgi retention of 
GATA4 and MHC did not appear to affect normal cellular function as 
exemplified by CLCs‟ robust proliferation (Figure 10) and stable cardiac gene 
expression (Figure 13).  
Golgi complex encompasses
 
an actin-based filament system in which 
nonmuscle actin and many of its binding partners including myosin are 
implicated in Golgi complex-mediated trafficking. In particular, the myosins 
that are associated with Golgi apparatus are the non-conventional myosins such 
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as the nonmuscle myosin II and myosin VI, which are not involved in 
contractility but are implicated in vesicular transport of secretory/membrane 
proteins
144, 145
 or in the maintenance of structural morphology of the Golgi 
Apparatus
146
. Therefore, it remains to be determined if MHC has an alternative 
nonmuscle isoform which play similar developmental roles in Golgi dynamics.  
The in vitro characterization studies in this thesis strongly suggest that the 
persistent golgi-localization of the cardiac MHC may be a property of 
undifferentiated state, rather than an aberration of MHC development since 
MSCs can be induced to increase protein transport into the proper cellular 
compartments upon cellular differentiation into CLCs.   
Interestingly, GATA4 expression is critical for downstream MHC 
expression
147
. The golgi-localization of both GATA4 and the myosin heavy 
chain implicates the Golgi apparatus in playing an important role in the 
developmental regulation of myofibrillogenesis of MHC in quiescent MSCs. 
Therefore, it is more likely that the complete maturation of the cardiac MHC 
may be dependent on a protein/factors that is expressed later in the cells‟ 
differentiation/ development. Consistently, MSC-derived conditioned medium 
has been shown to upregulate the expression levels of beta-myosin heavy chain 
(MHC) in cardiac progenitor cells
148
. More investigations are warranted in 
elucidating the association between Golgi dynamics and MHC participation in 
myofibrillogenesis.  
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4.1.5 CLCs’ contractile apparatus resemble primitive premyofibrils in early 
myofibrillogenesis 
The golgi-localization of cardiac HMC underscores the strong possibility that 
MHC did not attain terminal maturation as a functional contractile protein in 
CLCs. In addition, its insertion into nascent myofibrils was independent of -
actinin. Similarly, although other sarcomeric proteins such as myomesin and 
titin were expressed, they were not also inserted into the distinct cross striations 
of sarcomeres. This diffused (spatial) expression of other sarcomeric proteins 
such as titin and myosin is coincident with the distinctive -actinin striations in 
CLCs, and can be explained with Sanger et al‟s theory that myosin insertion 
into mature myofibrils occurs later in myocyte development, after the formation 
of the premyofibrils which are in turn characterized by Z-bodies enriched in -
actinin
29
. This observation is also consistent with Schultheiss et al‟s postulation 
that thin and thick filaments assemble independently on stress fibre-like 
structures during early myofibrillogenesis
12
. Taken together, in vitro 
characterization studies strongly suggest that CLCs resemble immature 
premyofibrils
28
 during early myofibrillogenesis. Importantly, patient-derived 
CLCs are similar to ventricular heart cells, which retain the expression of the 
cardiac MHC and also do not exhibit spontaneous beatings or contractions. 
However, ventricular heart cells reportedly limit negative LV remodeling and 
preserve systolic function when
 
implanted into an injured region
149. Thus, we 
expect that CLCs, being a mesenchyme derivative, would confer similar if not 
more enhanced improvement in post-infarct LV function. 
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4.1.6 Effect of ECM in vitro on CLCs 
This thesis reports that Collagen V significantly enhanced the initial cellular 
adhesion and subsequent attachment-dependent expansion of CLCs as 
compared to MSCs. Cellular interaction with collagens is predominantly 
mediated via the engagement of the 11, 21 and V3 heterodimeric 
integrins
104
. The augmented adhesion may likely be attributed to relatively 
higher expression levels of the 21 and V3 integrins in CLCs as compared to 
MSCs. Consistently, the single 1 integrin subunit is known to mediate cellular 
adhesion and proliferation of bone marrow stromal cells
104
. Similarly, the V3 
integrin heterodimer has been implicated in cellular attachment of muscle 
precursor cells on ECM
150
. The commercial unavailability of the 11 integrin 
antibody precluded a detailed examination of its role in mediating cellular 
attachment to collagen -I and -V matrices in this study. Notwithstanding, the 
11 integrin is believed to play relatively minor roles as compared to 21 
integrin in binding the  helical chains of collagen V 151. More specifically, 
11 integrin reportedly binds native collagen V, while 21 and v3 integrins 
interact with collagen V via unmasked Arg-Gly-Asp (RGD) sequences of 
denatured collagen V
151-153
 that was used in the current study. 
The augmented cellular adhesion on collagen V substratum may possibly be 
attributed to relatively higher expression levels of the 21 and V3 integrins in 
CLCs as compared to MSCs. Consistently, the single 1 integrin subunit is 
known to mediate cellular adhesion and proliferation of bone marrow stromal 
cells 
104
. Similarly, the V3 integrin heterodimer has been implicated in cellular 
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attachment of muscle precursor cells on ECM
150
. Notwithstanding, the 11 
integrin is believed to play relatively minor roles as compared to 21 integrin 
in binding the  helical chains of collagen V151. The integrin inhibition assays 
conducted in this study indicated that CLC adhesion on collagen -I and -V 
matrices may be predominantly mediated via the engagement of the 1 integrin. 
In contrast, v integrin may only play a secondary role in CLC adhesion on 
collagen V as compared to collagen I.  However, it remains to be determined if 
differential integrin signaling events were responsible for the enhanced 
adhesion and proliferation of CLCs as a consequence of their preferential 
interaction with collagen V matrix.  
Importantly, the v3 integrin heterodimers are implicated in cardiac 
development. The expression levels of the v3 integrin heterodimers are 
upregulated 1-3 weeks post myocardial infarction while the modulated spatial 
distribution of v integrin and upregulation of 3 integrin is correlated with the 
growth and survival of 1 integrin knock out cardiac pacemaker-like cells 
during early cardiac development. However, v and 3 integrins cannot 
compensate the loss of 1 integrin function during the terminal differentiation of 
cardiac cells, thus implicating specific 1 integrin -induced cardiac 
specialization in cardiomyocytes
154
. Consistently, this study shows the 
modulated expression of the GATA4, a cardiac transcription factor involved in 
early cardiac development, upon functional v3 integrin inhibition.  
This study shows that V3 integrin neutralization resulted in a muted response 
of cardiac specific genes such as Troponin T, skeletal muscle  actin and 
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ryanodine receptor 2. These observations strongly indicate that collagen V may 
exert a pro-cardiogenic effect via the engagement of the V3 integrin 
heterodimer in CLCs. It is important to note that the myogenic development 
medium used to differentiate MSCs into CLCs contains insulin, while blocking 
ligand occupancy of the v3 integrin have been shown to inhibit insulin growth 
factor 1 signaling
155. The v3 integrins interact with collagen V via unmasked 
Arg-Gly-Asp (RGD) sequences of denatured collagen V
151-153
. Thereafter, v3 
integrin clustering is induced at a focal adhesion point which subsequently 
activates insulin growth factor 1 signaling that may in turn be responsible for 
cardiac gene expression in CLCs. Expression of GATA4 and Nkx2.5 
transcription factors is associated with extracellular regulated kinase 1/2 (ERK 
1/2)
156, 157




Moreover, the V3 integrin has been reported to enhance cardiac 
differentiation of P1 embryonic carcinoma cells
159
. PDGF- mediated signaling, 
which reportedly influence cardiac differentiation in MSCs
118, 160
 is similarly 
implicated with V3 integrin heterodimerization
161
. More importantly, the V3 
integrin reportedly blocked matrix contraction of collagen V but not collagen I 
gels 
128
. The results of the in vitro characterization study conducted in this study 
suggest that the V3 integrin may be a dominant effector of cardiac 
differentiation in CLCs as a collagen V-centric response. However, it is 
important to note that functional blocking of the relevant integrins in CLCs 
cultured on collagen V only demonstrated a selective attenuation of troponin T, 
sarcomeric -actin and RyR2 gene expression. This strongly implicates an 
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alternative or compensatory collagen V –centric response on cardiac 
differentiation in CLCs that is independent of the relevant integrins, especially 
since collagen V is a multi specific ligand for other receptors such as 
thrombospondin
162
  and heparan sulphate
163
 among other receptors. 
Alternatively, this suggests that insulin growth factor 1 may directly influence 
the expression of these cardiac genes in MDM-derived CLCs. Unexpectedly, 
the results in this study showed that neutralization of either v3 did not affect 
GATA4 expression in CLCs. This would imply that GATA4 expression was 
independent of V3 integrin mediated signaling. However, GATA4 expression 
was assessed after 7 days of the second V3 integrin inhibition. Being a 
transcription factor that is involved in early cardiac development, it is possible 
that the effect of functional V3 integrin neutralization may be almost 
immediate or earlier than 7 days. A quantitative assessment of GATA4 
expression a few seconds to a day after integrin neutralization may provide 
some insights into the role of V3 integrin on GATA4 expression.  
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4.2 In vivo functional studies 
Bone marrow-derived stem cell therapy presents as a promising therapeutic modality 
for myocardial infarction (MI)
78, 82, 164, 165
. However, there are inconsistencies in this 
approach as recent clinical studies have not been able to readily reproduce the 
findings of preclinical investigations and early clinical studies
84, 89, 166-169
. In addition 
to these discrepancies, the fate and development of the stem cells in the injured 
myocardium is also controversial
170-177
. Contrary to in vitro findings, which show that 
MSCs can differentiate into cardiomyocytes, endothelial cells and smooth muscle 
cells
55, 118, 160, 178, 179
, other groups have suggested that the significant benefits of cell 
transplantation therapy may be attributed to a more potent cardioprotective paracrine 
effect as compared to direct myocyte replacement via extended stem cell 
differentiation in vivo
180-183
. However, most of these clinical trials have employed the 
use of primitive, undifferentiated bone marrow stem cells, which may be less efficient 
than cardiac-differentiated cells in recovering contractile performance in the infarcted 
myocardium. 
4.2.1 Optimal time for cell transplantation 
Injecting the right cell type at the right time and in the right place is crucial in 
maximizing cardiac repair. Cells that were transplanted into the compromised 
myocardium 7 days following LAD-ligation as myocardial infarcts were only 
clearly visible from echocardiography assessments from the 4
th
 day of ligation. 
Furthermore, a second operative procedure proved to be too traumatic for the 
immunocompromised rats in this survival model, which had been injected daily 
with cyclosporine from the 3
rd
 day of ligation. Preliminary investigative efforts 
strongly suggested that rats which had received a second operation before the 
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5
th
 day of ligation usually died mid-procedure or of post-operative 
complications such as pneumonia; while rats that were subjected to a second 
operation more than a week following LAD-ligation resulted in massive scarred 
tissues that were often adhered to the chest wall. Thus, hearts were not easily 
accessible via mid-or left thoracotomy for cell transplantation.  
Furthermore, MSCs have been reported to exhibit poor survival rates when 
transplanted into the myocardium 4 days after LAD-ligation
184
, as only 0.44% 
of the total MSC population injected were found to survive the transplantation 
procedure. In contrast, MSC transplantation reportedly received the best 
functional recovery in terms of global myocardial contractility, anti-apoptosis 
and angiogenesis 1 week after myocardium infarction
185
. 
4.2.2 Dose dependent contribution of cell therapy 
4.2.2.1 Donor cell survival 
None of the MSCs were detected in frozen rat cryosections, while only trace 
number of CLCs was detected via histological approaches in the low dose 
therapy groups. In contrast, high-dose therapy appeared to exhibit a larger 
donor cell presence in vivo. However, the fluorescent label used to track MSCs 
in vivo did not colocalize with human nuclei although the myocardial or 
interstitial tissues in the immediate locale of initial cell engraftment may have 
retained the fluorescent label remnants of MSCs and can therefore still be 
detected via immunofluorescence examination. This underscores a limitation 
in current techniques in long-term cell tracking. Given that resident cells may 
uptake or take a longer time to degrade the cell labels, it is important to verify 
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the identity of donor cells via the presence of human-specific markers or 
genes. 
It is likely that MSCs did not survive well in the myocardium following cell 
transplantation. The absence of BrdU-labelled MSCs in the low-dose therapy 
group as well as the trace presence of fluorescein in rat myocardium treated 
with a high dose of MSCs strongly suggests a low survival rate in vivo. These 
observations are consistent with current literature findings which report poor 
donor MSC engraftment and survival following injection into the myocardium 
regardless of dose and time of application
184, 186
. Specifically, MSC presence 
reportedly decreased from 34-80% to only 0.3-3.5% of the total MSC 
population injected 6 weeks post transplantation
186
.  
In contrast, the CLC-treated myocardium showed a relatively larger presence 
of CM-DiI labeled CLCs, which also stained positive for human nuclei. This 
strongly implies that the CLCs that engrafted in the infarcted myocardium 
may be more resilient than MSCs in surviving the traumatic process of direct 
syringe injection into the myocardium and/or the harsh ischemic 
microenvironment of an infarcted myocardium, thereby exhibiting a more 
robust survival rate in vivo. Thus, predifferentiating MSCs into CLCs ex vivo 
prior to cell transplantation therapy may enhance the donor cell survival rates 
in vivo. However, these observations remain to be vindicated with a 
quantitative flow cytometry analysis or fluorescence activated cell sorting 
(FACS) comparing the survival of MSCs and CLCs in the infarcted 
myocardium. Future experimentation should also include tracing the 
fluorescence-labeled MSCs and CLCs 1, 2, 4, 6 and 8 weeks post 
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transplantation in order to gain some insight into their cell fate and 
development, including survival and integration, in vivo.    
4.2.2.2 Postulated role of myocardial ECM on donor cell survival 
A typical type I collagen fibril comprises of a core of collagen V encapsulated 
by polymerized collagen -I and -III
93, 95
. The ubiquitous collagens types I-III 
confers mechanical strength onto the collagen fibril, while the core collagen V 
fibrils contribute towards overall fibril morphology and therefore tissue- 
specificity. Besides conferring structural support and integrity, collagens 
reportedly promote the cellular adhesion and expansion of as well as 
differentiation in stem cells
187-189
 For instance, the myocardial extracellular 
matrices have been reported to influence embryonic differentiation towards 
cardiomyocytes
190
. Collagen I represents the major components of 
extracellular matrices in the myocardium while collagen V is a minor subclass 
of collagens that regulates matrix assembly and possibly matrix stiffness
191, 192
.  
Cellular adhesion to denatured and native collagen V ECM is mediated by 
distinct sets of RGD-dependent and RGD-independent receptors. Importantly, 
the interstitial collagen I also interacts with collagen V in the same way, so 
that when included in the triple-helical conformation of collagens, RGD 
sequences in collagen V are either not accessible to cells or exhibit specific 
conformations recognized by different integrins
152
. 
Active ECM remodeling following a myocardial infarction alters the local 
collagen composition as well as the integrins that constitute the interface 
between myocytes and the myocardial matrix
193
. This study reports an 
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enriched collagen V deposition in the focal regions in the relatively more 
viable peri-infarct borders in relation to the scar tissues of the CLC-treated 
myocardium. As discussed in the preceding paragraphs, collagen V forms the 
core of type I collagen fibrils. It is not surprising therefore that it is often 
shielded by other more dominant collagen types in the myocardial 
extracellular matrix
128, 152
. It is possible that the RGD sequences usually 
„hidden‟ within the triple helices of collagen fibrils may be unmasked in this 
process, so that these RGD sequences are now available for interaction with 
donor cells or interstitial collagen I molecules, which are significantly over-
expressed in the infarcted myocardium. Consistent with their preferential 
affinity in vitro, the persistent localization of CLCs to collagen V- 
encapsulated endomysial space of viable myofibers strongly suggests a 
specific interaction between the engrafted CLCs and the myocardial matrix 
components.  
This favorable „tethering‟ of CLCs to the relatively more viable domains of 
the myocardium that is characterized by elevated collagen V deposition may 
provide a conducive microenvironment that is imperative for donor cell 
survival and proliferation
194
. This may in turn explain CLCs‟ relatively 
enhanced survival in the myocardium as compared to MSCs. In contrast, 
MSCs that were localized to collagen I-enriched domains within the 
myocardial interstices of the infarcted myocardium were physically isolated 
from the resident cardiomyocytes. Just as donor cells cannot survive, grow or 
proliferate in the absence of physical tethers to functional myocardial 
components or matrix elements, so the physical isolation of MSCs from 
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resident myocytes may have been responsible for diminished survival after 
myocardial transplantation.  
Additionally, collagen V supports a robust migration of cells belonging to a 
mesenchymal lineage in vivo
195, 196
. Given that CLCs are essentially derived 
from the mesenchymal lineage, their distinctive spatial distribution within 
myofibrillar structures may be a migratory response to collagen V. Collagen 
V-mediated response may be essential to lineage commitment and functional 
integration of transplanted CLCs within the cardiac syncytium since intimate 
cell-cell contacts are known to induce stem cells to undergo cardiac 
differentiation
134, 135
. However, it remains to be elucidated if the occasional 
localization of CLCs to the collagen-I enriched interstitial tissues as 
demonstrated in this study, prevented their engraftment into the host 
myofibrillar structure and thereby integration with resident cardiomyocytes in 
the myocardium.  
4.2.2.3 Cell mediated attenuation of adverse LV remodeling 
Stem cells have been reported to play significant roles in alleviating the 
adverse effects of ventricular remodeling
197, 198
. This study shows that these 
beneficial effects were indiscriminate of differentiation status as both MSCs 
and CLCs significantly ameliorated ventricular dilatation and prevented 
progressive wall thinning.  
This cell-mediated attenuation of adverse LV remodeling was already evident 
at low-dose cell therapy as exemplified by significantly smaller end-systolic 
and end-diastolic volumes (Figure 32i-ii) in the cell-treated myocardium as 
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compared to control myocardium. Nonetheless, high-dose cell therapy 
significantly reversed negative remodeling effects as myocardium treated with 
high-dose cell therapy demonstrated significantly smaller LV dimensions, 
such as significantly reduced LV internal diameters (Figure 36 i-ii) and LV 
ESV and EDV (i.e ESV and EDV in Figure 36 i-ii), in relation to myocardium 
treated with low-dose cell therapies. This is consistent with Menasche et al‟s 
observation that LV volumes and consequently negative LV remodeling 
effects were significantly reduced with a high-dose administration of skeletal 
myoblasts as compared to the placebo group in the MAGIC trial
62
. 
ECM dysregulation in the failing heart is a primary cause of adverse LV 
remodeling and myocardial fibrosis leading to impaired cardiac dysfunction. 
The extracellular cardiac microenvironment in the myocardium comprises 
primarily of collagen matrices. Following a myocardial infarction, cell-matrix 
components are disrupted and there is extensive collagen turnover as a result 
of maladaptive remodeling. Subsequently, collagen degradation in the 
myocardial ECM reportedly interferes with both systolic performance
199
 and 
relaxation properties of the ventricle
200
 and eventually leads to contractile 
dysfunction. Villari et al also reports that the total collagen volume/mass, its 
distribution as well as fiber organization collectively influence the LV 
myocardial elasticity
201
 and therefore compliance. Thus, ECM remodeling 
during the progression of heart failure is responsible for the maladaptive 
reorganization of cardiac size and geometry so that collagen degradation leads 
to chamber dilatation. 
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Both high- and low-dose cell-therapy demonstrated a significant amelioration 
of adverse ventricular modeling effects. It is possible that physical presence of 
cells may confer an added degree of compliance in collagen- enriched domains 
in the infarct and peri-infarct borders of myocardium. This may in turn 
increase tissue elasticity of the increasingly stiff scar or fibrotic tissues. This 
may preserve regional myocardial tissue compliance in the locale of cell 
engraftment. Consistently, stem cell transplantation has been reported to 
improve cardiac function by modulating collagen structure in vivo that may 
reduce tissue stiffness in border infarct zones of the scar tissue 
202, 203
.  
The insignificant number of surviving MSCs as well as CLCs in the treated 
myocardium 6 weeks post transplantation in the low-dose cell therapy groups 
strongly indicates that cell-mediated attenuation of adverse LV remodeling 
was not dependent on sustained cell survival or integration in the myocardium. 
Conversely, this underscores the likely possibility that the limitation of 
negative LV remodeling may have been attributed to cell-mediated paracrine 
effects. This is not surprising since bone marrow stem cell transplantation 
therapy has been reported to prevent the progression of adverse LV 
remodeling in the ischemic heart by secreting pro-survival cytokines with anti-
apoptotic and myoangiogenic differentiation stimulatory (discussed in 
subsequent paragraphs in this chapter) properties into the myocardium even 
after the disappearance of donor MSCs in vivo
204
. This cardioprotective 
cytokines such as the vascular endothelial growth factor (VEGF), the basic 
fibroblast growth factor (bFGF), insulin-like growth factor (IGF) and the 
stromal cell-derived factor (SDF), are in turn implicated in protecting the 
resident cardiomyocytes in the early phase of MI
205
. Both high- and low-dose 
  158 
cell-therapy demonstrated consistent trends in a significant cell-mediated 
amelioration of adverse ventricular modeling effects. Given the high death 
rates in the low-dose therapy groups, it is likely that cell-mediated cardiac 
repair mechanisms may be attributed to the release of paracrine factors. It is 
possible that physical presence of donor cells may confer a certain degree of 
compliance in the proximal regions of collagen- enriched domains in the 
infarcted and peri-infarct borders of an increasingly fibrotic myocardium, thus 
„softening‟ the increasingly overwhelming stiffness with their inherent 
elasticity in the collagen I-enriched scar or fibrotic tissues along the anterior 
wall or interventricular septum. This in turn confers a certain degrees of 
compliance thus preventing progressive systolic wall thinning. Thus, donor 
cell engraftment may preserve regional myocardial tissue compliance and may 
prevent the progression of myocardial dyskinesia, in turn a secondary factor 
that directly influences global contractility. Donor cell-induced paracrine 
effects may also include the recruitment of native cardiac progenitor cells to 
the site of injury. These cells may differentiate into functional cardiomyocytes 
in the peri-infarct domains of the myocardium, thus decreasing the number of 
„stiff‟ domains within the infarcted myocardium and enhancing overall 
myocardial compliance as well as contractility.  
More relevant to limiting negative LV remodeling, stem cell transplantation 
has been reported to improve cardiac function by modulating collagen 
architecture in vivo that may reduce tissue stiffness in border infarct zones of 
the scar tissue
202, 203
. Consistently, MSCs has been shown to express the 
antifibrotic factor adrenomedullin, which can inhibit the post-infarction 
proliferation of cardiac fibroblasts as well as attenuate the expression of 
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collagens –I and –III mRNA206. This limits if not prevents the development of 
scar tissue which would otherwise confer a degree of stiffness and result in a 
noncompliant myocardium that ultimately deteriorates overall contractility.  
4.2.2.4 Dose-dependent contribution of cell therapy towards myocardial 
contractility 
PV catheterization studies show that low-dose cell therapy improved global 
myocardial contractility with respect to the control group. However, there 
were no discernible differences between MSC- and CLC- therapies. At the 
same time, echocardiography assessments showed that CLC-therapy 
consistently improved LV dimensions and global contractilities such as EF, FS 
and regional mid-anterior wall contractility, in relation to MSC therapy. 
However, these trends did not achieve statistical significance.  This is not 
surprising given such a low incidence of cellular engraftment observed in the 
low-dose therapy groups. Nevertheless, the small in vivo CLC presence in the 
low-dose cell therapy group showed sign of CLC-mediated myogenic 
replacement whereby engrafted CLCs demonstrated cross-striations that were 
indistinguishable from host cardiomyocytes. Furthermore, CLCs that survived 
in the host myocardium 6 week post-therapy engrafted as myocytes that were 
electrically coupled with the resident cardiomyocytes (Figure 43-45). In 
contrast, the cell fate and development of MSCs could not be studied in rats 
treated with a low-dose cell therapy. Nonetheless, results from 
echocardiography and pressure-volume catheterization strongly suggest that 
MSCs may play a passive role towards improving overall contractile 
performance.   
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The lack of discernible differences between low-dose MSC- and CLC- 
therapies may be attributed to an incomplete CLC-mediated repair mechanism 
in the rat myocardium 6 weeks post transplantation therapy. In contrast, the in 
vivo functional data (immunofluorescent examinations of microvessels in the 
MSC-treated myocardium) indicated that the MSC-therapy may mediate 
cardiac repair via angiogenesis. However, these paracrine-mediated 
mechanisms may decline over time with a diminishing MSC presence. In 
contrast, low dose CLC-therapy showed enhanced myocardial contractility via 
myogenic and neoangiogenic mechanisms. Thus, a discernible difference 
between low-dose MSC- and CLC- therapies may only be observed with a 
longer follow-up assessment of cardiac function.    
Cell dose can exert a significant influence on cell-mediated cardiac relief. 
Although no significant improvements were observed with cardiac contractile 
function such as EF in the MAGIC trial, the high-dose therapy mediated a 
more significant attenuation of adverse LV remodeling and chamber 
dilatation
62
. There are currently no reports comparing a dose-dependent effect 
of cardiomyocyte transplantation on postinfarction cardiac function. However, 
Menasche et al reported that both skeletal myoblast and fetal cardiomyocyte 
transplantation resulted in equivalent efficacies for improving postinfarction 
LV function
207
. Notwithstanding, it has been established that skeletal 
myoblasts do not express the gap junction protein, connexin 43
149
 and will not 
contract synchronously with the heart, thus resulting in ventricular 
arrhythmias. Importantly, cardiomyocyte transplantation offered the best 
functional improvement in a functional study comparing the therapeutic 
efficacies of 3 different fetal cell types such as cardiomyocytes, smooth 
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muscles and fibroblasts
208
. Taken together, we expect that cardiomyocyte 
transplantation would be more effective than skeletal myoblast transplantation 
for the functional recovery of contractile performance in the infarcted heart. 
Thus, high-dose cardiomyocyte therapy may mediate more significant 
improvements in cardiac function than current transplantation treatments 
involving the use of other myocyte derivatives. 
BOOST trial which used 2.5 x 10
9
 undifferentiated BM stem cells resulted in a 
higher improvement in EF as compared to the ASTAMI trial which employed 
7x10
7
 BM stem cells (Table 1). Although both trials led to insignificant 
improvements in global contractility with respect to their placebo groups, it is 
believed that high-dose cell therapy would enhance the probability of cellular 
survival and engraftment in the myocardium and may therefore provide a 
clearer insight into the direct cellular effects on myocardial contractility. This 
postulation was verified by a relatively larger cell presence in tissue sections 
of myocardium administered with high-dose cell therapy as compared to those 
who have received a low-dose of MSCs or CLCs.  
In vivo functional studies showed that high-dose cell therapy was generally 
more effective than low-dose cell therapy as dose-dependent assessments of 
cell therapy showed that high-dose cell-therapy mediated statistically 
significant improvements in LV dimensions (Figure 40i-ii), ESV, EDV and 
ejection fraction (Figures 41i-ii, iv-vii). Thus, high-dose cell therapy mediated 
larger improvements in restraining chamber dilatation and systolic activities as 
compared to low-dose cell therapy. This may be attributed to a significantly 
low cellular engraftment and integration of the respective cell types in the low-
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dose therapy groups. Notwithstanding, some significant improvements in EDV 
could already be observed in rats administered with low-dose CLC-therapy 
with respect to control rats, while low-dose MSC-therapy did not mediate any 
statistically significant information. Although low-dose cell therapy also 
attenuated negative LV remodeling and improved global contractility, as 
observed by smaller cardiac volumes (Figure 32i-ii) and enhanced minimum 
dP/dt (Figures 32iii), and cardiac output (Figure 32 v) respectively, these 
improvements were statistically insignificant relative to high-dose cell 
therapy.  
High-dose MSC therapy improved cardiac function by appearing to prevent 
progressive worsening of cardiac function, which was observed with control 
animals in both the high- and low-dose therapy groups. However, 
echocardiography assessments showed that on the average, high-dose MSC-
therapy mediated a -0.11 to 1.6% improvement in the HR-dependent and -
independent contractility indices. These observations underlie the possibility 
that MSCs contribute passively to overall contractility. In contrast, CLCs 
showed ~7-13% improvement in the same parameters, and thus contributed 
actively towards contractile performance. In contrast, echocardiography 
analysis of global contractility low-dose therapy group did not show any 
significant differences between MSC-treated and control rats, although PV 
catheterization showed consistent improvements in LV function in both high- 
and low- dose MSC therapy.  Notwithstanding, high-dose MSC therapy was 
the more effective therapy as improvements due to the low-dose MSC therapy 
was statistically insignificant as compared to high-dose cell therapy (Figure 
40-41). 
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More importantly, discernible functional differences in EF, FS and MPI were 
also observed between high-dose MSC- and CLC-therapy (Figure 36xii-xv). 
Furthermore, differences in myocardial systolic activities were uncovered with 
the assessment of load-insensitive contractility measures observed with rats 
treated with a high-dose cell therapy. However, among the 4 therapy groups 
compared, high-dose CLC therapy mediated the best improvements in global 
systolic activities as observed by the highest maximum dP/dt (Figure 41 iii) 
and the best improvement in LVEF (Figure 40iii) with respect to control 
animals. 
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4.3 Relative therapeutic efficacies of CLCs vs. MSCs 
4.3.1 Assessment of myocardial systolic activities 
4.3.1.1 Echocardiography assessments 
Echocardiography assessment of LV function was derived primarily from 
the parasternal short axis view, which in turn assesses the contraction of 
the circumferential fibers that gives rise to radial contractility. As 
discussed in the previous section, echocardiography assessments show no 
significant differences in these measures of contractility between rats in 
the low-dose therapy groups. Although there were no significant 
differences in heart rate between the respective therapy groups, the heart 
rate of rats studied ranged between 300-400bpm. It is possible that the 
relative rapid heart rate in rodents may have obscured accurate analysis of 
ventricular contractility between treatment groups via current diagnostic 
techniques. In retrospect, sedating the rats further on a higher but safe 
percentage of isoflurane to further depress the heart rate may provide 
further insight into true contractility measures in rats in the respective 
treatment groups. Notwithstanding, rats treated with a high-dose of CLCs 
demonstrated significantly superior improvements in heart-rate dependent 
global contractility indices including ejection fraction and fractional 
shortening with respect to those treated with a high-dose of MSCs, in spite 
of the rapid heart rate. This may be attributed to a relatively higher 
frequency of CLC-derived myogenic replacement in vivo as compared to 
that arising from MSCs (Figure 43).    
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HR-independent measures of cardiac contractility such as the myocardial 
velocities of circumferential fiber shortening (Vcfc) were also obtained to 
verify that cell-mediated enhancement in contractile function was not a 
consequence of rapid heart rates. Notwithstanding, rats treated with a high 
dose of CLCs showed higher improvements in Vcfc as compared to 
animals administered with high-dose MSCs.   
It is possible that the differences observed with these conventional 
measures may be an inadvertent consequence of loading conditions
209
 
rather than actual global systolic function. This is because derivations of 
the load-sensitive contractility measures rely on the assessment of radial 
or circumferential fiber contractions, which in the presence of the most 
common cardiac condition of left ventricular hypertrophy (LVH) may 
overestimate cardiac contractility. The contraction of excess sarcomeres 
may mask impaired cardiomyocyte function by preserving normal wall 
contractions. In addition, radial or circumferential fiber function is 
preserved in LVH but the adverse effects of subendocardial ischemia may 
lead to longitudinal fiber function that is otherwise obscured in 
conventional load-sensitive contractility indicators. 
Echocardiography assessments persistently showed that cell therapy 
persistently attenuated left ventricular remodeling and dilatation, a benefit 
that was already readily observed in rats administered with a low-dose of 
cell therapy. However, high-dose cell therapy provided a clearer insight 
into the direct cellular effects on myocardial contractility. In particular, 
echocardiography showed significant CLC-mediated improvements in 
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systolic activities that were not confounded by the rapid heart rate, as can 
be seen by the HR-independent contractility indices, such as Vcfc and the 
Tei index.  
4.3.1.2 Real-time pressure-volume catheterization 
4.3.1.2.1 Load-sensitive hemodynamic measurements 
In contrast to echocardiography measurements, PV loops derived 
indices are better able to separate ventricular function into primary 
systolic, diastolic and ventricular loading properties
209
.  
Consistently, PV measurements show similar trends in cell-
mediated attenuation of chamber dilatation and myocardial wall 
thinning. However, high-dose cell therapy resulted in smaller 
cardiac volumes as compared to those observed with low-dose cell 
therapy. Rats treated with high-dose cell therapy also showed 
superior enhancement of global contractility indices such as EF, 
SW, CO and SV in relation to those administered with low-dose 
cell therapy. Consistent with HR-independent echocardiography 
contractility measures, high-dose CLC therapy mediated the 
largest improvement in systolic activities as can be seen by 
significantly elevated increase in maximum dP/dt.  
4.3.1.2.2 Load-insensitive contractility measures 
The biomechanical performance of cardiac muscle is influenced by 
acute changes in the resting fibre length (preload) and alterations 
in wall stress during ventricular ejection (afterload)
132
. It is 
therefore important to distinguish between haemodynamic 
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performance due to mechanical lesions from that due to depressed 
myocardial function. The hemodynamic performance of the 
ventricle is not an accurate measure of actual myocardial 
contractile state if these 2 parameters are not held constant. A 
major limitation in detecting acute contractility changes arises 
when the determinants of performance other than the inotropic 
state are altered by an intervention so as to change performance in 




Conventional assessments of systolic activity by echocardiography 
such as ejection fraction and fractional shortening are highly 
reliant on load-sensitive measures
209
. In certain compensated 
disease states such as LV hypertrophy (LVH), it is not surprising 
that additional sarcomeres are developed so that normal cardiac 
performance is sustained per unit circumference in the basal state 
by maintaining seemingly normal wall shortening and thickening 
values, thus obscuring actual defective cardiomyocyte function. 
Furthermore, radial and circumferential fiber contractility may be 
preserved in LVH, while longitudinal fibres in the 
subendocardium are reportedly reduced
132, 209
. 
Thus, functional determinants of left ventricular (LV) contractility 
should ideally be linear and load-independent while still sensitive 
to changes in inotropic state. Although no measure of contractility 
is absolutely load-independent, various contractility indices such 
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as PRSW, ESPVR and maximum dP/dt-EDV
210
 have been 
reported to remain relatively unaffected by various loading 
conditions in both animal and human studies
211
, and have since 
been widely accepted as load-insensitive indices of myocardial 
contractility that are better reflections of true or absolute 
contractility at the cardiomyocyte level.  
Preload reduction allowed for load-insensitive systolic and 
diastolic function to be examined and was achieved via a transient 
depression of the inferior vena cava. The results of this study show 
consistent trends in cell-mediated contractility. Both cell therapy 
mediated enhanced systolic activities as compared to control rats 
as can be seen by an enhanced ESPVR. However, CLC-therapy 
resulted in a superior recovery of systolic performance as can be 
observed by the restoration of ESPVR to baseline levels. However, 
the ESPVR index is limited by its dependence of mass and heart 
size
209
. Consistent with other reports, we also observed that the 
ESPVR curve is curvilinear with increasing IVC depression. It was 
also a technical challenge to derive ESPVR slopes in the over 
similar ESP ranges as suggested by Kass et al in order to reduce 
the nonlinearity of this curve
212
 as depression of the IVC could 
displace the catheter from its steady state position, sometimes 
displacing the topmost pressure sensor entirely out of the chamber 
as was verified visually by echocardiography. In other cases, the 
displacement of the catheter often led to an interference signal 
between the pressure and sometimes volume sensors and the 
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ventricular walls, causing a spike or complete distortion in the top 
left corner of several PV loops so that interpretation of results 
were rendered impossible. A few rats were excluded in this study 
because no interpretable load-insensitive contractility data could 
be derived from them.  
The PRSW and dP/dt-EDV measures are 2 alternative load-
insensitive measures of systolic function. PRSW is reportedly 
independent of ventricular size and mass but is sensitive to 
changes in cardiac contractility, while dP-dt-EDV is another 
sensitive indicator of myocardial contractility but is relatively 
more pre-load sensitive as compared to PRSW
209
. Both measures 
demonstrated similar improvement to the ESPVR although CLC-
therapy did not lead to restoration to baseline levels. As with 
ESPVR, the MSC-treated myocardium trended towards enhanced 
systolic performance, but only the CLC-treated myocardium 
demonstrated a superior improvement in systolic performance with 
respect to control myocardium.  
4.3.1.3 CLCs contribute actively towards myocardial contractile 
performance via myocyte replacement 
Collectively, trends in in vivo functional studies strongly indicated that 
CLCs improved systolic performance without compromising end-diastolic 
pressures in the infarcted myocardium. As discussed in the preceding 
sections, CLCs may facilitate a synergistic recovery of cardiac function by 
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attenuating LV remodeling and limiting chamber dilatation, thereby 
preserving regional tissue compliance in the collagen V-enriched peri-
infarct borders. This leads ultimately to an enhancement of regional 
contractility that may contribute indirectly towards overall myocardial 
contractile performance. CLCs predominantly engrafted in the collagen 
V- endomysial lined viable muscle fibers and demonstrated well-
developed Z-bands and A-bands that were indistinguishable from host 
cardiac myocytes. Thus, CLCs confer actual mechanical benefit via 
myocyte replacement, which contributes regional and global myocardial 
contractile performance in the treated myocardium. 
4.3.1.4 MSCs contribute passively to myocardial systolic activities 
Echocardiography assessments as well as PV catheterization show that 
MSC-treated rats exhibited a relatively diminished contractile 
performance as compared to CLC-treated rats. MSCs may play a passive 
role towards enhancing contractile performance in the myocardium. 
Consistently, immunofluorescent examinations showed that transplanted 
MSCs were absent of cross striations that are consistent with 
cardiomyocytes. Furthermore, MSCs appeared to be predominantly 
localized to the collagen I-enriched interstitial spaces that were physically 
isolated from the myocardium. This strongly suggests that most of the 
engrafted MSCs remained quiescent following cell injection into the peri-
infarct borders of the myocardium. Thus, unlike CLCs, MSCs did not 
integrate as functional cardiomyocytes (Figure 43) in the infarcted 
myocardium.  
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Notwithstanding, both high- and low-dose MSC led to significant 
improvements in global systolic activities as compared to the control. 
These observations are consistent with the results of current MSC 
transplantation therapies, which reported improvements in global 
contractile performance as shown by enhanced EF. Given the seemingly 
low survival rates of MSCs in vivo and the coincident increase in small 
sized blood vessels in the MSC-treated myocardium, it is possible that 
MSC-mediated improvements in systolic activities such as EF, FS and the 
load-insensitive indices such as ESPVR, PRSW and maximum dP-
dt/EDV may be largely attributed to paracrine effects as MSCs may 
secrete angiogenic growth factors into the microenvironment within the 
locale of cell engraftment as an inadvertent consequence of paracrine 
mediated effects. Alternatively, the apparent improvements in the MSC-
treated myocardium may be reflective of a possible compensatory 
contractile mechanism as a passive consequence of scar stiffening in the 
MSC-treated myocardium. Afterall, MSC transplantation induced systolic 
wall thickening,
 
which prevented dyskinesis, in turn a secondary factor 
that directly influences systolic contractility
213
. If true, high-dose MSC-
therapy may result in a deterioration of cardiac contractile function in the 
long run. However, whether MSC-mediated enhancement of systolic 
activities is really a compensatory mechanism can only be determined 
with a longer follow-up assessment of contractile performance following 
cell transplantation.   
MSC transplantation has also been reported to modulate the ECM 
architecture in the infarcted regions of the failing heart by decreasing the 
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levels of collagen -I and -III fractions in vivo
206, 214
. However, this study 
showed an extremely high death rate especially in the high-dose therapy 
group, which may lead to massive inflammation at the site of cell death. 
This release of inflammatory cytokines can induce subsequent myocardial 
fibrosis, which may inadvertently lead to subnormal ventricular relaxation 
and negate MSC’s initial positive effect on decreasing collagen levels in 
vivo (seen in the low-dose therapy group). Taken together, high-dose 
MSC-therapy may be counterproductive in the treatment of heart failure. 
Notwithstanding, this postulation can only be affirmed with a quantitative 
measure of the collagen levels in the myocardium in respective high- and 
low-dose MSC therapy groups.  
Alternatively, MSC-mediated improvements in systolic function may be 
attributed to paracrine mechanisms more than myocyte replacement in the 
MSC-treated heart. Recent studies have shown that donor MSC 
engraftment and survival in the infarcted myocardium decreased rapidly 
from 34-80% from the time of injection to 0.3-3.5% 6 weeks post therapy 
regardless of dose and application time
186
. These numbers are too low to 
exert a direct influence on organ function and thus may be therapeutically 
irrelevant. In addition, bone marrow stem cells reportedly confer acute 
improvements in cardiac function less than 72 h after MI. This precludes 
extended differentiation in vivo it is not likely that MSCs can differentiate 
into cardiomyocytes within 3 days to regenerate the infarcted 
myocardium. Most importantly, in vitro and in vivo animal studies have 
revealed that much of the functional improvement and attenuation of 
injury afforded by stem cells can be replicated by cell free, conditioned 
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media derived from stem cells. Taken together, these findings strongly 
suggest that MSCs confer cardiac relief via complex paracrine 
mechanisms, which ultimately preserve or enhance global contractile 
performance with respect to control myocardium. 
4.3.2 Assessment of myocardial diastolic activities  
4.3.2.1 Echocardiography assessments 
An in-depth analysis of diastolic function using tissue Doppler Imaging 
techniques could not be performed as the rapid heart rates in rodents 
resulted in the fusion of the E and A waves in almost every ECG cycle.  
As such, echocardiography examinations could not adequately assess 
diastolic activities/ dysfunction in the myocardial infarction rat models. 
The Tei index however provides an insight into global myocardial 
contractile performance as a summation of both systolic and diastolic 
activities. It remains debatable however if this measure of contractility is 
independent of heart rate
209
 or preload conditions
215
. For this study, the 
Tei index was significantly decreased in rats treated with a high-dose of 
CLCs. Although not significantly different from control rats, MSC-treated 
rats consistently demonstrated no nett change in this relatively HR-
independent global contractility index. 
4.3.2.2 Conductance catheterization 
The results of this study show that low-dose cell therapy improved 
systolic performance with lower end-diastolic pressures (EDP) as 
compared to control animals. However, CLC-therapy resulted in a 
relatively lower EDP as compared to MSC-therapy. Furthermore, 
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increasing dose of MSCs in particular resulted in a compromised diastolic 
function (Table 7). Consistently, of the 4 cell therapy groups, rats treated 
with high-dose MSC-therapy demonstrated the lowest minimum dP/dt and 
the slowest passive filling rate as depicted by the smallest maximum 
dV/dt value.   
At the same time, similar trends were observed with the loafd-insensitive 
measure of isovolumetric relaxation, Tau (Weiss). High-dose MSC-
therapy consistently gave rise to the highest Tau (Weiss) value and thus 
demonstrated the worst isovolumetric relaxation among of the 4 cell 
therapy groups. However, high-dose MSC-therapy negative effect on 
diastolic performance may have been confounded by alterations in loading 
conditions. Given that these trends are not statistically significant, more 
investigations are necessary to draw a firm conclusion in the effect of 
high-dose MSC-therapy on possible diastolic impairment.  
Taken together, these results suggests that sustenance of systolic activities 
in rats treated with a high dose of MSCs may be a compensatory 
mechanism in which end-diastolic pressures were correspondingly 
elevated. This may not be beneficial in the long run, as chamber dilatation 
may be inadvertent to offset the increased cardiac pressures within the left 




It is important to stress that these mechanisms are dynamic and relatively 
higher collagen levels and compromised diastolic activities can occur 
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concurrently with an apparent improvement of systolic function and 
attenuation of LV remodeling in the MSC-treated myocardium at 6 weeks 
post transplantation therapy. These trends may be more apparent with a 
larger sample size and a longer follow-up assessment period i.e 6-12 
months post therapy. More investigations are warranted before a 
definitive conclusion on the effects of high-dose MSC-therapy on 
myocardial diastolic activities, collagen remodeling and overall cardiac 
contractile function can be derived.  
Systolic function in rats appears to look more significant than that of diastolic 
activities in this study. However, it is important to realize that current 
techniques in assessing diastolic activities are not well optimized and need to 
be further refined so as to attain a more accurate measure of diastolic indices. 
One way to better study diastolic activities via echocardiography assessments 
may be to decrease heart rates significantly within the 100-200 bpm range so 
as to better segregate the E and A waves. However, this technique remains to 
be optimized a safe and nonhazardous levels for rats to survive the otherwise 
toxic effects of anesthetics at higher levels. In addition, some EDPVR data 
obtained with PV catheterization were excluded as they did not yield any 
discernible information. A way to overcome the large variations that existed in 
this study would be to recruit more rats into this study so that the sample size 
of rats approximates a normal distribution. More investigation evaluating 
diastolic indices are warranted before a conclusion on relative cell-mediated 
diastolic activities can be reached. 
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4.4 Cell-mediated paracrine effects 
4.4.1 MSC-mediated neovascularization in the infarcted myocardium 
Transplanted MSCs were localized to immature blood vessels, while CLCs 
often engrafted in sites proximal to blood vessels. This strongly suggests that 
MSCs may play significant roles in vasculogenesis. This observation further 
reinforces the merits of committing MSCs to a cardiac-like phenotype ex vivo 
before transplantation to enhance contractile performance via myocyte 
replacement in the infarcted myocardium. Consistently, MSC-treated 
myocardium demonstrated enhanced myocardial angiogenesis in the peri-
infarct and infarcted borders. Embryonic stem cells expressing VEGFR2 have 
been reported to differentiate into endothelial and smooth muscle cells 
217, 218
. 
Although patient derived MSCs expressed KDR/ VEGFR2 in vitro, it 
remained to be determined if MSCs underwent extended vascular 
differentiation following cell transplantation. Nevertheless, intramyocardial 
angiogenesis may have contributed indirectly towards overall contractile 
function in the MSC transplanted animals by enhancing myocardial perfusion. 
Consistently, MSCs have been reported to secrete cytokines which lead to 
ultimate improvements in myocardial performance
182
.  
4.4.2 CLCs also elicit alternative non-myogenic mechanisms of cardiac repair 
Notwithstanding, the seemingly elevated CLC presence in rats treated with a 
high dose of CLCs was still disproportionate to the remarkably restoration of 
myocardial systolic performance to baseline levels. Such inconsistencies 
underscores the unlikely possibility of cell-mediated myocyte replacement 
alone was being the primary reason for such recovery of global cardiac 
function. Instead, the results of both high- and low- dose CLC therapy groups 
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consistently hint at possible cell-mediated non-myogenic cardioprotective 
paracrine effects. A subset of transplanted CLCs that engrafted in the collagen 
I enriched interstitial spaces between adjacent viable myofibers did not exhibit 
sarcomeric cross striations.  In contrast to MSCs, CLCs also did not integrate 
as immature vessels. However, the CLC-treated myocardium showed a 
significant increase in neoangiogenesis with respect to control myocardium. 
At the same time, in vivo functional studies showed an alternate minority 
population of CLCs that engrafted in the collagen I enriched interstitial spaces 
between adjacent viable myofibers. These CLCs did not exhibit distinct cross 
striations consistent with sarcomeric structures. However, these cells 
demonstrated a coincident expression of the proliferating cell nuclear antigen 
(PCNA) and the von-Willebrand factor (vWf). This strongly suggests that the 
CLCs engrafted as proliferating endothelial cells in the myocardial interstices. 
Additionally, resident cells in the immediate locale of CLC-engraftment in the 
interstitial tissues also exhibit a coincident expression of PCNA and vWf. 
Thus, CLC-therapy promoted endogenous and donor cell-derived endothelial 
proliferation in the treated myocardium possibly via the secretion of relevant 
cytokines such as VEGFR2. This is consistent with in vitro characterization 
studies of CLCs, which show that these cardiogenic cell types simultaneously 
expressed endothelial markers such as VEGFR2 and smooth muscle actin. 
Thus, CLCs may also possess an inherent propensity for endothelial 
differentiation in addition to myogenic differentiation. 
Collectively, these results strongly suggest that CLC may also mediate 
cardioprotective benefits via paracrine signaling. Thus, the combined action of 
an enhanced cell-mediated regional contractility due to myogenic replacement, 
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attenuated negative LV remodeling and paracrine cardioprotection may confer 
to a synergistic improvement in overall cardiac function in the CLC-treated 
myocardium.  
In vivo findings suggest that MSCs may contribute passively towards functional 
improvement by preventing the progressive deterioration of cardiac activities. 
However, MSC-mediated improvements in cardiac function as well as a 
coincident increase in blood vessels in the MSC-treated myocardium despite the 
absence of human nuclei in infarcted myocardium strongly suggest possible 
paracrine effects that may promote angiogenesis post transplantation. This is 
consistent with current literature, which reports that MSC-mediated 
improvements are may be attributed to paracrine mediated
205, 206
.  
Similarly, the CLC-treated myocardium demonstrated enhanced endothelial cell 
proliferation in vivo, which implicates CLCs in playing significant roles in 
neoangigenesis, an inadvertent consequence of paracrine effects. Future 
investigations should include an analysis of secretory angiogenic growth factors, 
such as VEGFR2, in the microenvironment in the vicinity of cell engraftment via 
an ELISA assay or flow cytometry as a quantitative measurement would provide 
a more conclusive insight into the relative paracrine contribution of either cell 
type.   
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4.5 Postulated role of myocardial ECM on in vivo cell fate and 
development 
The effect of post-infarct remodeling of myocardial extracellular matrix on in situ 
stem cell differentiation remains to be determined. The developmental potential 
of MSCs is reportedly regulated by underlying substrate elasticity in vitro
219
. 
Collagen I may impart heightened tension and mechanical stress within the cell, 
leading to an overwhelming stiffness that is unfavorable towards 
cardiomyogenic-like phenotype of CLCs. Consistently, MSCs have been reported 
to undergo osteogenic differentiation on collagen I surfaces. In contrast, collagen 
V ECM may present a more pliable environment that favors the differentiation of 
CLCs. These physical forces may similarly induce appropriate cascades of 
stimulatory intracellular signals that are favorable for survival, proliferation and 
cardiac transdifferentiation in CLCs in vivo. Consistent with in vitro studies, 
MSCs and CLCs that engrafted in the collagen I-enriched interstices in the 
myocardium bordering the scar areas of the infarcted myocardium did not exhibit 
expression of cardiac-specific myofibrillar proteins. In contrast, CLCs that 
engrafted in the collagen V-enriched endomyosium lining viable myofibers 
demonstrated well-developed Z-bands and A-bands that were indistinguishable 
from host cardiac myocytes.  
Transplantation of terminally differentiated fetal and adult cardiomyocytes have 
reportedly led to the preservation of systolic activities and overall contractile 
performance and a significant attenuation of LV remodeling and dilatation in the 
infarcted myocardium. However, it is not easy to isolate cardiomyocytes from 
cardiac tissue biopsies in large quantities. CLCs are partially differentiated but 
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committed to cardiac lineage. Importantly, large numbers of CLCs can be derived 
in vitro before transplantation. These cells bear a resemblance to fetal 
cardiomyocytes and can survive well in the myocardium. Like fetal 
cardiomyocytes, CLCs also significantly enhanced contractile performance, 
limited negative LV remodeling and dilatation and promoted angiogenesis in the 
infarcted myocardium. However, being partially differentiated, CLCs may not 
undergo extended myocyte differentiation and may thus remain quiescent in vivo, 
especially if they were engrafted in a collagen I-enriched domain in the infarcted 
regions of the failing heart. 
Notwithstanding, the results of this study show that CLCs mediated superior 
improvements in cardiac function to undifferentiated bone marrow MSC therapy 
in an infarcted rat myocardium. Importantly, CLCs contribute actively towards 
overall contractile performance via myocyte replacement and paracrine mediated 
effects, while playing possible roles in neoangiogenesis. In contrast, 
undifferentiated MSCs mediated functional improvements via a predominant 
cardioprotective paracrine effect. Future directions improvements should be made 
to current techniques in the delivery of viable CLCs to the injured myocardium. 
Culturing of CLCs on an engineered collagen V-based scaffold and applied 
directly onto the infarcted heart may enhance and maximize their survival, 
engraftment and integration with host cardiomyocytes.     
Although clinical trials have reported mixed outcomes, some patients have 
undeniably benefited from undifferentiated bone marrow stem cell therapy. CLCs 
are expected to confer equal if not superior cardiac relief in patients and present 
as a promising autologous cell-based therapy for the treatment of CVD. However, 
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further preclinical investigations should be conducted before CLCs are applied in 
clinical trials. For example, the beneficial effects CLC therapy should be further 
investigated in large animal models with follow up assessments of cardiac 
function over a period of time. It is also important to determine if CLCs 
demonstrate a stable cardiomyogenic profile in vivo, and if CLC-mediated 
paracrine effects excluded deleterious consequences such as fibrosis and 
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Chapter 5: Conclusion 
This study supports the concept of pre-differentiating bone marrow mesenchymal 
stem cells into cardiomyocyte-like cells in vitro before cell transplantation therapy. 
These differentiating cells exhibit distinct Z-band cross striations in vitro that is 
consistent with a developing contractile phenotype. Importantly, this distinct cardiac-
like phenotype is stable in prolonged cultures. A large-scale expansion of these 
cardiomyogenic cell types was further achieved via preferential interaction with 
collagen V extracellular matrices.  
Figure  52 summarizes the possible distinct myogenic and non-myogenic mechanisms 
of cardiac repair mediated by CLCs as compared to MSCs. Importantly, cell therapy 
significantly improves the efficiency of myocardial repair as human bone-marrow 
derived stem cells act to enhance the elasticity of the infarct area, thus preventing 
deleterious LV-remodeling and ventricular dilatation. Cell therapy also confers 
cardioprotection on resident host cells via the release of paracrine factors. More 
specifically, cell therapy promotes robust angiogenesis with respect to control 
myocardium, as exemplified by increased vessel counts in cell-treated myocardium. 
This improves myocardial perfusion, which may in turn prevent extensive apoptosis 
of the surviving resident cardiomyocytes.  
In particular, CLCs present as a more efficacious therapy to MSC-treatment as CLCs 
contribute actively towards overall contractility via cell-derived myocyte replacement 
besides promoting neoangiogenesis in the infarcted myocardium. More remarkably, 
high- dose CLC therapy specifically confer added mechanical benefit by restoring 
myocardial systolic performance in the treated myocardium. Thus, CLC-treated rats 
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demonstrated superior contractile performance to rats administered with 
undifferentiated MSCs.  
Infarcted myocardium demonstrated elevated collagen I deposition in the peri-infarct 
borders and especially in the scar tissue. MSCs injected directly into the collagen I-
enriched interstices in the myocardium bordering the scar areas of the infarcted 
myocardium did not exhibit expression of cardiac-specific myofibrillar proteins. In 
contrast, CLCs that engrafted in the collagen V-enriched endomyosial space of viable 
myofibers demonstrated well-developed Z-and A-bands indistinguishable from host 
cardiac myocytes.  
Predifferentiating mesenchymal stem cells into cardiomyocyte-like cells ex vivo 
before transplantation is more efficacious than mesenchymal stem cells for the 
treatment of chronic heart failure. CLCs may present an added value to current 









Figure 52. Possible MSC- and CLC- mediated repair mechanisms in the compromised myocardium. 
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